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Genetic alterations defining human primary melanoma and mechanisms
of immune evasion
The somatic mutations found in melanomas reflect the biological processes that govern
tumour development. They also help shape how tumours evolve and escape immune regu-
lation. Studying these changes can therefore help to refine our understanding of melanoma
progression with the added potential to offer new perspectives for disease management.
Most prior melanoma sequencing studies have focused on advanced disease. Thus, so-
matic alterations that influence the behaviour of early-stage tumours have not been fully
explored. Consequently, in this thesis I study a collection of 524 primary melanomas on
which extensive clinical data have been collected for almost two decades. I describe the
mutational landscape of these tumours including driver genes, new recurrent variants, mu-
tually exclusive genetic interactions and copy number alterations. I discuss and associate
these features with aspects of tumour pathology, sun exposure, immunogenicity and patient
outcomes. To identify genes required for melanoma survival, I intersect my genomic anal-
ysis with a dataset of CRISPR-Cas9 dropout screens and discover a melanoma-associated
genetic vulnerability mediated by Interferon Regulatory Factor 4 (IRF4). I then begin to
experimentally validate and explore the biological pathway by which IRF4 may function in
the context of melanoma.
Checkpoint inhibitors have revolutionised melanoma care, yet only a minority of pa-
tients respond to these treatments and our comprehension of the mechanisms governing
PD-L1 expression on melanoma cells is still limited. In the second part of this thesis, I
examine the regulation of the key checkpoint receptor PD-L1, which is often upregulated
in melanoma to facilitate tumour escape. To improve our understanding of the processes
controlling PD-L1 expression, and how the PD-1/PD-L1 axis can be targeted to overcome
immune evasion, I employ a genome-wide CRISPR-Cas9 screening approach. I identify
genes which elicit downregulation of PD-L1 when disrupted in melanoma cells, capturing
several central processes including basal transcription, N-linked glycosylation and intracel-
vi
lular transport. A second extensive screen in eight cancer cell lines of melanoma, bladder
and lung cancer origin validate these findings and link novel candidate genes, including
Sphingolipid Transporter 1 (SPNS1), to the control of PD-L1 cell surface expression.
Additional work is required to further validate and understand the regulation of PD-L1
through SPNS1, as well as its contribution to immune surveillance.
In summary, I present the first comprehensive evaluation into the somatic alteration
landscape of primary melanomas, gaining insight into the molecular architecture of these
tumours. Additionally, I introduce novel genes and processes regulating PD-L1 gene tran-
scription, processing and presentation on the cell surface. Collectively, these results improve
our understanding of the genetic processes that govern primary melanomas, as well as pro-
viding valuable insights into the mechanism of PD-L1 regulation.
Sofia Yixin Chen
Till min familj för all er kärlek, omtanke och stöd.
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1.1 The origin and epidemiology of melanoma
Melanoma, the deadliest form of skin cancer, is the fifth most commonly diagnosed cancer
in the UK [1] and US [2], and accounts for 1.6% of all newly diagnosed cancers worldwide
[3]. The incidence of melanoma in fair-skinned individuals is among the most rapidly in-
creasing cancer types (Fig. 1.1). However, the survival rates have almost doubled in the
past 40 years [1], possibly owing to earlier detection and successful clinical interventions.
Early stage melanomas often have a good prognosis, but the five-year survival rate declines
rapidly if the tumour has metastasised [4, 5].
UV exposure is one of the most important environmental risk factors for the development
of melanoma [6–10], where total sun exposure, sunburns and sun exposure patterns have
been linked to melanoma susceptibility. Other established risk factors include phenotypic
characteristics [11, 12], such as freckles, fair skin, pigmentation and naevi count, a history
of other cancers [13] and genetic factors driving hereditary melanoma [14, 15].
Melanoma arises from melanocytes [16–18], a slow-proliferating, melanin pigment-
producing cell present on body sites including the skin, eye, sinonasal, genital tract and
mucosal surfaces. Melanin synthesis is responsible for pigmentation, a process where TYR
and MC1R are critical components. However, it is also important in protecting against UV
damage [19–22]. The melanocyte lineage is overseen by the master regulator MITF, with
SOX10, PAX3 and KIT being other key genes in melanocyte development [19]. Interestingly,
the reactivation of such melanocyte-linage-associated genes have been found to increase the
aggressiveness and metastatic propensity of melanoma cells [23, 24].
The transformation of a melanocyte into melanoma is proposed to follow one of the
following two trajectories: either they arise de novo or from a pre-existing naevus [25–28].
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Figure 1.1: Incidence rates of melanoma. Top panel: Melanoma incidence rates, shown
worldwide with 2018 statistics. Bottom panel, left figure: Melanoma incidence rates over
time for selected countries (data for males shown, a similar trend was observed for fe-
males). Bottom panel, right figure: Number of melanoma cases per 100,000 persons by
race/ethnicity (data for males shown, a similar trend was observed for females). All data
shown are age-adjusted. Data extracted from GLOBOSCAN 2018 or SEER, graphs adap-
ted from IARC (http://gco.iarc.fr/) and [2].
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The early Clark model (Fig. 1.2), describes the process of malignant transformation through
a series of events including the formation of a naevus, and has historically been seen as the
standard model depicting melanoma development [29]. This model of melanoma devel-
opment illustrates specific histopathological characteristics with each stage of progression.
It starts with the proliferation of melanocytes to form a benign naevus lesion, followed
by irregular growth causing structural abnormalities. In the following phases, cells begin
to spread, first intraepidermally, and then vertically into the dermis, until finally acquiring
metastatic properties to advance to other organs. In terms of the genetic components link-
ing to the Clark model, the initiating event is credited to MAPK activation mainly through
a BRAF V600E mutation, and a large proportion of benign moles also harbour activating
BRAF mutations [30, 31]. The majority of moles do however not progress into melanoma,
as oncogene-induced senescence needs to be overcome to facilitate melanoma development
[32–34]. This can be achieved through inactivation of CDKN2A and associated cell cycle
regulatory checkpoints. In the final stages, additional processes include overcoming rep-
licative senescence through activation of the oncogene TERT [35], alteration of signalling
pathways involving chromatin remodelling, cell adhesion or migration, or inactivation of
other important cell growth and survival regulators may occur.
However, it is now known that the majority of melanomas form spontaneously rather
than from a mole [26, 28, 37]. Both models share the fundamental basis that the acquisition
of genetic alterations provide the tumour cells with favourable tumourigenic traits. Such
traits include those associated with the hallmarks of cancer [38–40], such as increased cell
proliferation and evasion of apoptosis. The proposed order of events, do however differ
slightly. In support of the de novo hypothesis, the BRAF V600E mutation identified as a
founder event in the Clark model does not show complete penetrance amongst melanocytic
naevi [30, 41, 42], suggesting moles form through other processes. Furthermore, subclones
within a naevus have been found to comprise of a mix of BRAF-mutant and wild-type (WT)
cells [43], an observation which challenges the traditional Clark model which describes
clonal expansion of BRAF-mutant cells. The two models do however agree in the necessity
of losing apoptosis and cell cycle regulatory mechanisms, most notably through CDKN2A
loss, as a step towards melanoma development. Whether this event would take place prior
to, simultaneously or following Mitogen-activated protein kinase (MAPK) pathway activ-
ation remains a debate [44–46]. The final steps towards melanoma progression involving
escape of the hayflick limit and acquisition of additional pro-tumourigenic properties remain
concordant between both the Clark and the de novo models.
Recent work by Bastian and colleagues, support the sequential procurement of somatic
4 Introduction
Figure 1.2: The Clark model of melanoma development. In this model, melanoma de-
velopment begins with the formation of a benign naevus. This is followed by the dysplastic
naevus stage, the radial-growth phase, the vertical-growth phase and finally the melanoma
becoming metastatic. Each stage is represented by specific biological and molecular events.
Reproduced with permission from [36], Copyright Massachusetts Medical Society.
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alterations during melanoma evolution. This involves early activation of the MAPK pathway
and upregulation of telomerase activity, followed by additional modifications targeting cell
cycle regulation and epigenetic modifications in the transition to invasive melanoma [47,
48]. The later stages were also shown to be associated with inactivation of key tumour
suppressors PTEN and TP53, as well as the presence of increased genomic instability with
multiple activating mutations in key melanoma pathways.
The proposed models of melanoma development, progressing through an intermediate
melanocytic naevus or not, might reflect heterogeneity in melanoma as a disease. Tumours
harbouring BRAF V600E mutations are more likely to originate from a mole [18, 49]. Such
tumours are also more frequently found on body sites with intermittent sun exposure and
in younger patients [50–52]. In contrast, de novo arising melanomas are more frequently
associated with tumours found on body sites heavily exposed to UV radiation [45, 53, 54].
This indicates that different progression models of melanoma could reflect distinct differ-
ences in melanoma biology [47]. These differences extend also to histopathological sub-
types (discussed in Section 1.2), where the coexistence of nevoid cells is more common in
the superficial spreading subtype of melanoma (although the majority still arise de novo)
[28, 49, 55]. This is in contrast to much lower frequencies of nevoid cells found in for ex-
ample lentigo maligna or acral lentiginous melanomas. Thus, melanomas cover a diverse
range of characteristics, whereby the different roads leading to malignancy are shaped by
genetic and environmental factors, which also contribute to its histopathological features.
1.2 Melanoma classification
1.2.1 Histopathological subtypes
Cutaneous melanomas, originating from the skin, are commonly classified into subtypes
based on histopathological features [56–60]. The major four subtypes comprise superficial
spreading melanoma (SSM), nodular melanoma (NM), lentigo maligna melanoma (LMM)
and acral lentiginous melanoma (ALM) (Fig. 1.3). Approximately 70% of all melanomas in
patients of European descent are diagnosed as SSM, making it the most prevalent subtype.
Most often, it arises on intermittently sun-exposed skin, and is characterised by a growth
pattern of horizontal spread [61–63]. The more rapidly growing NM subtype, which makes
up 5-25% of reported melanoma cases, spreads vertically rather than horizontally, and often
show a raised and symmetric appearance [56, 61]. LMM (10%) originates from a slow-
growing lentigo maligna precursor lesion, is often flat and gradually spreads horizontally
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Figure 1.3: The major histopathological melanoma subtypes. Superficial spreading
melanoma (SSM) is characterised by a growth pattern of horizontal spread. Nodular melan-
oma (NM) often show a raised and symmetric appearance. Lentigo maligna melanoma
(LMM) is often flat and gradually spreads intraepidermally. Acral lentiginous melanoma
(ALM) is commonly found on palms, soles and under the nails. SSM, NM and LMM fig-
ures reprinted with permission from [67], under © Crown copyright, and ALM from [68],
under the Creative Commons Attribution License.
before becoming invasive [64]. This type of melanoma is more commonly associated with
older age and high UV exposure. ALM is characteristically found on palms, soles and under
the nails, and also shows an initial horizontal growth, similar to the SSM and LMM subtypes
[65]. This subtype is rare in people of European descent; however, it is the most common
type of melanoma affecting people with darker skin [66].
Besides these four major subtypes, a whole range of rarer histopathological subtypes
exist including amelanotic, desmoplastic and spitzoid tumours, each with unique histopath-
ological characteristics [60, 62]. Occasionally, melanoma can also arise from melanocytes
residing on surfaces other than the skin, such as the eye (ocular/uveal melanoma) or mucosal
membranes (mucosal melanoma) [69–72]. Recently, adaptations to these histopathological
subtypes have been proposed, as several components including naevi count, UV exposure
and genetic alterations have been shown to provide distinct characteristics to melanomas
[54, 63, 73]. This has resulted in the World Health Organisation (WHO) incorporating a
new classification system in 2018 taking into account epidemiological, clinical, histopatho-
logical and genomic attributes for the stratification of melanoma [62].
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1.2.2 Prognostic classification
An alternative way of classifying melanomas, which is routinely used in clinical practice, is
by prognostic factors which can be assessed from the primary tumour. Breslow thickness is
an estimate of the tumour depth of invasion, measured vertically from the skin surface down
to the deepest invasive cell [74]. A thicker tumour is associated with worse prognosis. A
tumour showing signs of ulceration, where the epidermis covering the melanoma has been
compromised, is another important factor contributing to a worse patient outlook [75, 76].
Breslow thickness and ulceration status makes up the T category of the widely adopted
American Joint Committee on Cancer (AJCC) staging system [77]. In the previous edi-
tion, mitotic rate, defined as the number of mitoses per mm2, was also part of the T stage
classification [76], but in the newest 8th edition, mitotic rate was excluded due to lack of
prognostic power in their multivariate model [5]. However, they argue it might still be an
important factor in specific cases such as thin melanomas, supported also by other studies
[78–80], and should therefore not be completely disregarded. Furthermore, the AJCC sta-
ging system also incorporates measures of metastasis, where the N stage corresponds to the
presence of regional lymph node spread, and the M category illustrates if distant metastasis
has occurred. Together, the T, N and M stages are jointly combined into main prognostic
stages ranging from I-IV, with associated substages ranging from A-D (Table 1.1).
1.3 Genetics of melanoma
Genetic factors influence the susceptibility and pathogenicity of all cancers [81]. Cutaneous
melanomas are particularly affected by genetic aberrations as a result of UV exposure, lead-
ing to excessively high mutation burdens often dominated by C>T transitions [82–86]. To-
gether with the dysregulation of DNA damage repair genes [87, 88], these changes contrib-
ute to the genomic instability often found in melanoma and other cancers [89, 90]. These
instabilities further provoke the acquisition of additional changes, paving way for diverse
and opportunistic clones to manifest. This heterogeneity and multitude of genetic altera-
tions will pose a great challenge in our attempts to unravel the important biological changes
in melanoma as a disease.
As melanomas progress, they adapt and modulate key biological pathways in their fa-
vour (Fig. 1.4). This has resulted in the implementation of molecular subtypes in melanoma,
categorising patients based on tumour alterations in key driver genes [73, 85, 91–93]. These
subtypes describe the key genetic events driving melanoma progression in different tumours,
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Table 1.1: AJCC 8th edition pathologic staging groups for melanoma of the skin. The
prognostic AJCC staging system according to respective T, N and M stages. 5-year survival
rates refer to melanoma-specific survival. Adapted and reprinted with permission from [57]
and [5].
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highlighting the importance of genetics. Since the first discovery of the highly oncogenic
BRAF V600E mutation [94], this event has emerged as one of the most important genetic
alterations in melanoma, causing up to 700x increase in MAPK pathway activity. The BRAF
gene is mutated in approximately half of all patients with sporadic melanoma [73], and is
the predominant RAF isoform altered in melanoma and other cancers. This could be be-
cause it is the most efficient isoform in activating downstream MAPK components, while
ARAF and CRAF are only found mutated in rare cases [95].
RAS genes are also frequently mutated in sporadic cases of melanoma and other cancers
[96], where amino acid substitutions in codon 12, 13 and 61 are the most common onco-
genic events resulting in a constitutively active form of the protein [97]. NRAS is altered in
approximately 30% of melanoma cases [73, 85], whereas HRAS and KRAS mutations are
less common. RAS proteins are critical for signal transduction through the MAPK pathway;
however, they also control the Phosphoinositide 3-kinase (PI3K)/AKT pathway, another es-
sential pathway in melanoma progression [98–100].
1.3.1 The MAPK pathway
The MAPK pathways are integral in signal transduction control, regulating essential bio-
logical functions including cellular proliferation, differentiation and apoptosis [101–103].
Multiple MAPK families exist: in mammalian cells the most well-characterised involve the
ERK (also known as the classical MAPK), JNK and p38 pathways [102]. Throughout this
thesis, the definition of the MAPK pathway will refer to the ERK-associated MAPK path-
way. The MAPK cascade is initiated through the binding of external stimuli to receptor
tyrosine kinases (RTKs), causing receptor dimerisation and intracellular autophosphoryla-
tion events [101, 104]. This in turn leads to the recruitment of GRB2 and SOS1, causing
activation of small GTPase RAS proteins (HRAS, KRAS or NRAS) through the conversion
of GDP to GTP. The active GTP-bound form of RAS is then capable of binding to RAF
kinases (ARAF, BRAF or CRAF), causing conformational changes to occur which stim-
ulate its activity [105]. Activated RAF then exerts its kinase function by phosphorylating
MEK, which in turn phosphorylates ERK, leading to its translocation to the nucleus and the
subsequent activation of various transcription factors [106]. The MAPK pathway is upregu-
lated in up to 90% of all melanomas [92, 107], emphasising the central role of this signalling
pathway in melanoma pathogenesis.
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Figure 1.4: Key signalling pathways in melanoma. An overview of the three main
signalling pathways dysregulated in melanomas: the Mitogen-activated protein kinase
(MAPK) pathway, the Phosphoinositide 3-kinase (PI3K)/AKT pathway and the CDKN2A-
associated pathways. Figure adapted and reprinted with permission from the publisher [92].
1.3.2 The PI3K/AKT pathway
Similar to the MAPK pathway, the PI3K/AKT pathway can be activated through stimulation
of RTKs and activated RAS proteins. Different classes and isoforms of PI3Ks exist and
might play different roles depending on tissue- and disease context [108].
Most relevant for human cancers are the heterodimeric class I PI3Ks for which PIK3CA,
PIK3CB, PIK3CD or PIK3CG genes encode the catalytic domain (p110), whilst PIK3R1,
PIK3R2 and PIK3R3 translate into the regulatory subunit (p85). When activated, PI3Ks
phosphorylate phosphatidylinositols (PIPs, also sometimes referred to as PtdIns) into phos-
phatidylinositol triphosphate (PIP3). PIP3 in turn regulates various signalling molecules,
such as AKTs, which are activated through phosphorylation by PDK1 (sometimes referred
to as PDPK1) [109] and mTORC2 [110]. AKT is a protein kinase (also called Protein
Kinase B), encoded by AKT1, AKT2 and AKT3, which has a wide range of targets includ-
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ing TSC2 [111–113], BAD [114] and FOXO proteins [115, 116]. It is therefore involved
in regulating a range of cellular processes that are hijacked to promote tumour develop-
ment [112, 117, 118]. Other targets of AKT phosphorylation have been identified which
impact important hallmark pathways in promoting cancer progression. Such targets include
MDM2, which has a direct impact on p53 degradation [119, 120], and GSK3 [121]. When
phosphorylated by AKT, GSK3 returns to its inactive form, which promotes activation of
downstream effectors part of the WNT/b-catenin pathway [122], such as b-catenin [123],
c-myc [124] and cyclin D1 [125].
As the PI3K/AKT signalling pathway has such important biological functions, there are
also several control mechanisms in place, which could partly explain the great difficulties
encountered in the development of single agent drugs to inhibit this signalling cascade [126,
127]. In the context of melanoma, the most important negative regulator of the PI3K/AKT
pathway is PTEN [128–132]. The role of PTEN is to convert PIP3 back to PIP2, thereby
terminating the signalling cascade. However, as PTEN is a tumour suppressor gene which is
commonly silenced, this alteration would lead to increased activity through the PI3K/AKT
pathway.
1.3.3 CDKN2A-associated regulatory pathways
Inherited germline variants in genes such as CDKN2A and CDK4 have been found to play
a significant role in the development of familial melanoma [133–135]. However, somatic
alterations in these genes are also important contributors to sporadic melanoma [73, 136],
where CDKN2A is one of the most frequently silenced genes. CDKN2A encodes two pro-
tein products: p14ARF and p16INK4A. p16INK4A is involved in the regulation of cell
cycle progression and replicative senescence [137], through negative regulation of CDK4
and CDK6, thus preventing complex formation with Cyclin D (CCND1) and subsequent
phosphorylation of retinoblastoma protein (RB1) [138]. p14ARF, the alternative protein
produced by CDKN2A, has tumour-suppressive properties through its activation of TP53
directly or through inhibition of MDM2 [139–143]. Direct silencing of TP53 is less common
in melanoma compared to other cancers [144–146], suggesting compensatory mechanisms
such as the ones mentioned above are substituting for the lack of such changes.
1.3.4 Additional important pathways
TERT is essential for telomere maintenance, and is another frequently altered gene found
both in hereditary and sporadic cases of melanoma [147, 148]. Oncogenic activation of
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TERT has been indicated as a critical event in the cellular progression towards malignancy,
by mediating escape of the hayflick limit [35]. Frequencies of TERT mutations are higher
in metastatic melanoma compared to primaries [73, 148–150], and mostly clusters in the
promoter region where the mutation creates an E26 transformation-specific or E-twenty-six
(ETS) transcription factor binding motif, resulting in increased gene expression [148, 151].
Finally, genetic alterations targeting other biological processes and pathways are also
found in melanoma. Wnt signalling might play a role in melanoma progression [152–154],
epigenetic modulators such as ARID2 have been implicated as driver genes [85, 155], and
the impact of genetic alterations on controlling immune regulation is emerging as an inter-
esting area to study [156, 157].
1.3.5 Advantage of large-scale genome profiling
With the rapid advancement of next-generation sequencing technologies over the past two
decades, it quickly became feasible to utilise this powerful method to aid cancer research.
It is now possible to rapidly and comprehensively analyse DNA from tiny tumours, at an
affordable price. This impressive development has led to the establishment of large col-
laborations such as the cancer genome atlas (TCGA) [96, 158], the cancer genome project
(CGP) [159] and the international cancer genome consortium (ICGC) [160], which are con-
tinuously providing the research community with invaluable knowledge through character-
ising the genomic landscape of various human cancers. These and other large-scale genome
profiling studies have made essential findings in the field of melanoma research, with the
discovery of novel melanoma genes, identification of genomic subclasses of melanoma with
potential prognostic value, and further insights into the molecular processes dysregulated in
melanoma [73, 85, 91, 161]. Yet, there is still much to learn, especially in the context of
primary melanoma where only smaller cohorts have been studied to date.
1.4 Melanoma management
1.4.1 Diagnosis
Suspicious melanoma lesions are often initially evaluated based on the ABCDE rule (Fig.
1.5), where A stands for asymmetry, B for border irregularity, C for colour variegation, D
for diameter >6mm and E for evolving (Fig. 1.5).
A combination of these markers [162–164] and other features such as the “ugly duck-
ling” sign [165], could indicate the presence of an early melanoma. However, a biopsy
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Figure 1.5: The ABCDE rule of melanoma diagnosis. A: Asymmetry, B: Border, C: Col-
our, D: Diameter >6 mm, E: Evolving. Reproduced from [57], under a Creative Commons
CC BY-NC 4.0 license.
is needed for in-depth pathological assessment for accurate diagnostic and prognostic pur-
poses [166]. The early detection of melanoma is crucial as early stage melanomas have an
exceptionally good prognosis, while the survival rate declines rapidly with advancement of
tumour stage [2, 77]. As such, many efforts to raise awareness, educate the general public
on skin self-examination, as well as the initiation of mass screenings have been undertaken
over the past decades [167–175].
Many newly diagnosed melanoma patients with intermediate to thick primaries also un-
dergo a sentinel lymph node biopsy to exclude the possibility of nodal spread [176–178].
Additionally, if the presence of tumour cells is found in the biopsy, complete lymph node
dissection usually follows. However, recent data suggest the excision of all remaining re-
gional lymph nodes might be excessive, as melanoma-specific survival is not improved with
this strategy [179].
1.4.2 Therapy for melanoma
Tumour characteristics from biopsy of the primary melanoma are used to classify tumours
according to prognostic factors such as AJCC stage, and are informative in therapy de-
cisions. Patients with early stage melanomas, where the tumour is confined to a localised
region only, are mostly treated surgically, where complete excision of the primary can be
curative [25, 166, 180]. In cases where removal of the primary tumour is considered insuf-
ficient or the tumour is deemed high-risk, such as when loco-regional spread has occurred,
adjuvant therapy can be offered to lower the risk of recurrence [25, 181–183]. However,
limited effects on survival have been observed and there is no established standard of care
[184, 185]. For stage IV melanomas, where distant metastases are found, surgical resection
is performed where possible [186]. However, chemotherapy, radiotherapy, targeted therapy
and immunotherapy have historically also been considered treatment options [182, 187].
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Figure 1.6: Timeline showing selected key melanoma FDA approvals since 1974. FDA-
approved drugs from 1974 to 2018.
There have been dramatic improvements in non-surgical interventions for melanoma
treatment over the past decades (Fig. 1.6). For a long time, palliative care using Dacar-
bazine, was the predominant option to treat inoperable advanced melanoma [188, 189].
Complete response on Dacarbazine was rare (5%) and the median response rate was lim-
ited to 5-6 months [190–192]. Therefore, several Dacarbazine-combination regimes have
been attempted in clinical trials, unfortunately with limited improvement of survival rates
[193–199].
In the late 1990s, three early immunotherapy drugs (interferon a-2b, interleukin-2, and
ontak) gained FDA approval, showing slight survival benefit in subgroups of melanoma
patients [200–202], such as those with ulcerated tumours [203]. The first breakthrough
however, came almost a decade later, when the BRAF V600E mutation was discovered as
a key genetic alteration in melanoma patients [94]. This finding led to the development of
selective BRAF inhibitors, with Vemurafenib showing significant improvement compared
to standard of care in terms of response and survival [204–207]. In 2011, it became the first
approved mutation-dependent targeted therapy in melanoma, with many others to follow in
the subsequent years [208–210]. In conjunction with this progress, the genetic component
of melanoma became a hot topic, and molecular testing to determine the presence of not
only BRAF-mutations are now routine in clinical practice [182, 211]. Unfortunately, despite
an initial tumour regression, resistance to targeted therapy tend to occur. This is likely due to
reactivation of the MAPK pathway and other key cell proliferation and survival-regulatory
pathways [212, 213]. Intensive research into combating resistance is ongoing, where dual
targeting of MAPK pathway components is a promising approach [185, 214–217].
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Figure 1.7: Immune checkpoint blockade targeting PD-1/PD-L1 or CTLA-4 signalling.
In the priming phase, blockade of CTLA-4 restores T cell activation. In the effector phase,
blockade of the PD-1/PD-L1 interaction restores effector T cell function. Reproduced with
permission from [227], Copyright Massachusetts Medical Society.
2011 was a landmark year for melanoma, but not only due to the FDA approval of the
first BRAF inhibitor. The same year, Ipilimumab, an immune checkpoint blockade antibody
targeting Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), was also approved for use
in melanoma [218]. Additionally, evasion of the immune system was added as a hallmark
of cancer, recognising the importance of immune surveillance in mounting an anti-tumour
response [38]. As cancer cells evolve, the genetic alterations they acquire distinguishes
them from a normal cell. Each mutation increases the risk of neoantigen presentation on
the cell surface to signal to immune cells for destruction [219, 220]. With a functional
immune system, the tumour should be identified as foreign and destroyed. Therefore, the
development of a tumour indicates impairment of host protection capabilities [221–224]. A
common mechanism involves the dominance of inhibitory signals in the tumour microen-
vironment, leading to immune cell exhaustion and reduced anti-tumour activity [225, 226].
Immunotherapy using immune checkpoint inhibitors work by blocking these inhibitory sig-
nals sent to immune cells, thereby awakening the force of previously tumour-suppressed
cells to attack the tumour (Fig. 1.7).
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To activate a naive T cell, a major histocompatibility complex (MHC)-bound peptide
must interact with the T cell receptor, followed by a second T cell activation signal provided
by the binding of CD28 to its ligands CD80 (also known as B7.1) and CD86 (also known
as B7.2) [228]. In an activated T cell, the expression of CTLA-4 is upregulated, a feedback
mechanism to control the immune response. The inhibitory receptor CTLA-4 then com-
petes with the co-stimulatory receptor CD28 for binding to CD80 and CD86, but CTLA-4
has a higher affinity for its ligand, causing a dampened T cell response [228–230]. High
expression of inhibitory receptors such as CTLA-4 is a marker of T cell exhaustion, indicat-
ing hampered T cell function, commonly found in a suppressive tumour microenvironment
[231, 232]. By blocking CTLA-4 using antibodies like Ipilimumab, this suppressive signal
is removed, and T cell activity is restored. Additional anti-tumour mechanisms linked to
anti-CTLA-4 antibodies have also been proposed, including depletion of intratumoural reg-
ulatory T cells [233–235] and blocking of trans-endocytosis of B7 molecules on dendritic
cells [236].
Another major inhibitory signal in the tumour microenvironment results from the inter-
action between the programmed cell death protein 1 (PD-1) receptor on immune cells and
its ligand programmed death-ligand 1 (PD-L1) (Fig. 1.7) [231, 237]. PD-1 is mainly ex-
pressed on activated T cells, B cells and myeloid cells [228, 238, 239], and the expression is
maintained as a consequence of continuous antigen exposure, causing immune cell exhaus-
tion. PD-1 binds PD-L1 and PD-L2. PD-L1 expression is more widespread than PD-L2 and
has been shown to be upregulated in melanoma and other cancers [226, 240–242]. While
blocking CTLA-4 impacts T cell activation, inhibition of the PD-1/PD-L1 axis modulates
T cell effector functions (Fig. 1.7). Blocking the interaction between PD-1 and PD-L1
therefore reverses the exhausted state of effector immune cells, facilitating T cell mediated
tumour killing. Just a few years after Ipilimumab was approved, Pembrolizumab and Ni-
volumab, two anti-PD-1 antibodies were also granted FDA approval [243–246]. Immune
checkpoint inhibitors have since been quickly making their way into standard clinical prac-
tice [185, 247, 248]. Furthermore, several anti-PD-L1 antibodies have now been approved
[208, 249–251], and combination strategies targeting both CTLA-4 and PD-1/PD-L1 show
success in melanoma and other cancers [252–254].
1.4.3 Future outlook
Targeted therapy and the newer immunotherapies have revolutionised melanoma care. While
the standard treatment a decade ago did not improve patient survival [195], current phase
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3 clinical trial data of combined Nivolumab (anti-PD-1 treatment) and Ipilimumab (anti-
CTLA-4 treatment) show an impressive 58% overall survival after 3 years [253, 254]. Ad-
ditionally, reports indicate these newer strategies demonstrate durable responses, with the
potential of achieving long-term remission in a subset of patients [214, 255, 256]. This
emphasises the power of firstly utilising genetic information to target important signalling
pathways, and secondly modulating immunological mechanisms to achieve an effective host
anti-tumour response. But unfortunately these newer therapies have not been completely
successful, as complications including resistance to targeted therapy [257–260] and severe
adverse events with immunotherapy [252, 253, 261] can occur. Therefore, immunother-
apy might not be a good option in particular for frail, elderly or patients with an abnormal
immune function. In addition, targeted therapy can only be administered to a subgroup of
patients showing a certain mutation profile. Consequently, much work is still needed to ad-
dress the limitations with current treatment regimens. These include understanding intrinsic
and acquired resistance, research into designing effective treatments to patients currently not
eligible for targeted or immunotherapy, as well as understanding how to improve outcome
by patient stratification. In late 2017, the MSK-IMPACT panel used to profile tumours to
identify genetic alterations was approved by the FDA [262], and will likely pave the way
for personalised discovery of clinically actionable targets. Additionally, recent work has
suggested biomarkers such as PD-L1 tumour expression, tumour mutational load and in-
creased markers of cytolytic activity might help identify patients more likely to respond to
immunotherapy [220, 263–270]. The important research leading to the development of im-
mune checkpoint inhibitors was recognised by the 2018 Nobel prize in medicine which was
awarded to the two immunologists James Allison and Tasuku Honjo for their discovery of
CTLA-4 and PD-1 [271]. We are just on the forefront of exploring genetics and immuno-
logy to combat melanoma, with many interesting and important discoveries lying ahead of
us.
1.5 Regulation of PD-L1 expression to treat melanoma
PD-L1, also known as B7-H1, encoded by CD274, was discovered in 1999 and is a member
of the B7 family of immune-regulatory cell surface membrane receptors [272]. It is con-
stitutively expressed on a mRNA level by a wide range of tissues [272]; however, protein
expression is mostly confined to the eyes, placenta, endothelial cells and activated immune
cells [226, 238, 273]. Additionally, PD-L1 expression can be induced by pro-inflammatory
molecules, most importantly IFN-g [274].
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Figure 1.8: T cell response to acute or chronic antigen exposure. During an acute in-
fection, antigen is cleared rapidly, therefore leading to a functional T cell response. These
T cells have high proliferative capability, effector functions and are capable of forming
memory T cells. During a chronic infection, the antigen exposure persists leading to T cell
exhaustion. These T cells have an increased expression of inhibitory receptors such as PD-1,
decreased effector functions and impaired capability of forming functional memory T cells.
PD-L1 expression on tumours during a chronic infection can be triggered by IFN-g in the
tumour microenvironment.
1.5.1 PD-L1 biology
PD-L1 can bind to PD-1, which is induced on activated T cells, and this interaction mediates
an inhibitory signal to suppress T cell proliferation, cytokine production and cytotoxicity
[273, 275]. PD-L1 therefore functions as a control mechanism to regulate excessive im-
mune responses, and in maintaining tolerance against self-antigens. Its expression patterns
indicate it might play an important role in foetal-maternal tolerance and in restricting T cell
reactivity to maintain the immune privileged status of the eye [276–278]. However, in the
context of chronic infection or cancer, persistent antigen exposure and inflammation causes
a state of T cell exhaustion [237]. This constant pro-inflammatory condition causes failure
to generate memory T cells, loss of proliferative capability, impaired effector functions and
an abundant expression of inhibitory receptors (Fig. 1.8).
In cancer, PD-L1 expression is often upregulated in the tumour microenvironment by
both cancer cells and immune cells [226], which promotes tumourigenesis and facilitates tu-
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mour escape [279]. Physical blockade of the PD-1/PD-L1 interaction has proven successful
in reversing T cell exhaustion and restoring normal immune cell function [280, 281]. These
therapies are therefore now routinely used to treat patients with melanoma, non-small cell
lung cancer, bladder cancer and many other cancer types [282, 283].
In addition to PD-1, PD-L1 can also interact with CD80, which produces another in-
hibitory signal to T cells, stalling their activation, proliferation and cytokine production
[284, 285]. This interaction has been proposed to function in the induction and maintenance
of T cell tolerance [286]. Therefore, blocking PD-L1 rather than PD-1 might provide an
additional advantage. Animal studies have shown that blockade with a dual-specific anti-
PD-L1 antibody creates superior T cell responses in chronically infected mice compared to
anti-PD-1 blockade [280]. Furthermore, PD-1 also has a second interaction partner: PD-
L2, which has a more conserved expression pattern than PD-L1. PD-L2 is only inducibly
expressed on dendritic cells, macrophages and bone-derived mast cells [284], and its expres-
sion is regulated by different factors compared to PD-L1 [287]. Contrary to PD-L1, PD-L2
expression on melanoma cells is only found in a small subset of samples, and its expres-
sion in the tumour microenvironment is mostly confined to stromal or immune cell subsets
[288, 289]. Moreover, some studies suggest PD-L2 might also act as a co-stimulatory lig-
and [290], possibly through a PD-1-independent mechanism [291, 292]. This suggests a
context-dependent role of PD-L2 interactions [293, 294]. Taken together, blocking PD-L1
expression rather than PD-1 might therefore be advantageous.
1.5.2 Processes controlling PD-L1 expression
The production of IFN-g in the tumour microenvironment has multiple consequences on im-
mune cell activity. On one hand, secretion of IFN-g promotes a pro-inflammatory immune
response by activating macrophages, T cells, B cells and NK cells, upregulating expression
of MHC molecules, as well as mediating direct anti-tumour effects [228, 295–299]. On the
other hand, through the process of adaptive immune resistance, melanoma cells escape im-
mune destruction by upregulating expression of PD-L1 as a response to IFN-g produced by
tumour-infiltrating immune cells [248, 300]. Because of this, high expression of PD-L1 on
tumours could both indicate an active ongoing immune response [301] and a dysfunctional
state of immune cell exhaustion [237]. It is therefore not surprising to find contradictory
reports on how PD-L1 tumour expression influences patient prognosis [300, 302–308].
Although IFN-g is the strongest inducer of PD-L1 expression, other cytokines and ex-
trinsic factors can also alter PD-L1 expression (Fig. 1.9) [309–312]. PD-L1 expression can
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Figure 1.9: Overview of mechanisms controlling PD-L1 expression. In a simple model,
PD-L1 expression can be regulated on multiple levels: through stimulation with cytokines,
intrinsic signal transduction pathways, microRNAs and genetic alterations. Reprinted with
permission from [323].
be modulated on an epigenetic level, by promoter methylation [313, 314], hypoxia [315],
bromodomain or histone deacetylase regulation [316–319], or by microRNAs [313, 320–
322]. Furthermore, tumour PD-L1 expression can also be induced by intrinsic factors as
well as external stimuli.
By acquiring genetic alterations that would render tumours less immunogenic or confer
resistance to immunotherapy, cancer cells learn to adapt and survive. Genetic alterations
targeting CD274 (PD-L1) have been found in various cancers, with cases of mutations [324],
amplifications [325–329], 3’-UTR disruption [330] and genomic rearrangements [331, 332]
being reported. Several oncogenic pathways can play a role in modulating the anti-tumour
immune response [156, 248, 332–334], with some exerting their effect through altering PD-
L1 tumour expression [335, 336].
The MAPK pathway is overactive in the vast majority of melanomas [73, 92, 107]. Sev-
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eral reports have shown that oncogenic activation of this pathway contributes to immune es-
cape [337]. Cells which acquire resistance to BRAF inhibitors show upregulation of PD-L1,
possibly through transcriptional regulation by c-Jun and STAT3 [338]. Subsequently, using
knock-down experiments or drugs targeting components of the MAPK pathway, PD-L1 ex-
pression could be reduced [312, 339–341]. Furthermore, patients treated with BRAF inhib-
itors have been shown to have an increase in immune cell infiltrate to the tumour [342, 343],
improved T cell recognition [344, 345] and effector T cell functions [345]. Co-treatment
using BRAF inhibitors with immunomodulatory regimens show a favourable anti-tumour
response in several preclinical models [337, 346–348], and similar combinations are now
being tested in clinical trials [349, 350].
Oncogenic RAS signalling, targeting both the MAPK and PI3K/AKT pathways, have
also been shown to upregulate PD-L1 expression, through a mechanism of reduced tristet-
raprolin activity causing stabilisation of PD-L1 mRNA transcripts [351]. Loss of PTEN is
a frequent event activating the PI3K/AKT pathway in melanoma, and this event has been
linked to increased PD-L1 expression, hampered immune responses and resistance to im-
munotherapy [156, 335, 352]. Aberrant PD-L1 expression as a result of regulating other
members of the PI3K/AKT pathway has also been reported [338, 353–355]. Furthermore,
additional genetic alterations could also impact PD-L1 expression, as exemplified by EGFR
mutations [356], CDK5 disruption [357], altered Hippo pathway activity mediated by YAP1
or TAZ activation [358, 359], and transcriptional regulation by amplified MYC oncogene
expression [360]. It is important to note, many studies have mainly looked at the effect on
PD-L1 expression on a gene level, and such changes might not always translate to a similar
change in protein expression [226, 361, 362].
Research on PD-L1 is a rapidly expanding field, with emerging data from just the past
few years uncovering important mechanisms of PD-L1 post-translational regulation. Some
of these mechanisms causing abundant PD-L1 protein expression include targeting glyc-
osylation through GSK3b [363], deubiquitination-associated stabilisation via CSN5 [364],
cyclin D/CDK4-dependent proteasomal degradation [365] and protection versus induction
of lysosomal degradation by CMTM6 [366, 367] and HIP1R [368], respectively. Regulation
of PD-L1 expression on a protein level could provide valuable insights into the mechanisms
that may constitute future therapeutic targets.
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1.6 CRISPR-Cas9 screening approaches to identify regu-
lators of cell surface proteins
The concept of genomic engineering, enabling precise modifications of DNA in living or-
ganisms, reached a new era with the discovery of the clustered regularly interspaced short
palindromic repeats (CRISPR)-CRISPR-associated (Cas) system [369–371]. Originally
found functioning as part of the adaptive immune system in prokaryotes [371–373], re-
searchers have over the past 20 years learned to utilise this process in creating targeted
alterations in the genome of living cells [374–376]. The CRISPR locus is defined by short
conserved DNA repeats scattered across the genome, separated by non-repetitive and unique
sequences of a similar length [370]. Three major CRISPR-Cas systems exist, where the type
II CRISPR-Cas9 system is the most widely utilised today [377].
1.6.1 The CRISPR-Cas9 mechanism
The CRISPR-Cas9 system works in three steps (Fig. 1.10). In the first adaptation (also
known as spacer acquisition) stage, a short segment of foreign DNA is integrated into the
CRISPR locus [373, 378]. This is followed by the interference (also known as the CRISPR
RNA (crRNA) biogenesis) phase where the CRISPR locus is transcribed and processed to
generate the crRNA [379]. The crRNA functions as a targeting motif, and is comprised of
the unique foreign sequence, followed by a repeat protospacer adjacent motif (PAM). In
the final interference step, crRNA forms a complex with trans-encoded RNA (tracrRNA),
a highly abundant endogenous non-coding sequence showing part complementarity to the
repeat region of the crRNA [380]. This fusion generates the guide RNA (gRNA) which then
directs Cas9 proteins to the DNA site showing complementarity to the gRNA sequence. This
is finally followed by the Cas9 protein exerting its function by recognising and cleaving the
double-stranded DNA at a site-specific position upstream of the PAM motif [376].
In the context of prokaryotic immunity, this process leads to degradation of the foreign
DNA and also provides the host with a genetic memory, protecting against future encoun-
ters with viruses containing the same recognised sequence. However, this mechanism can
be designed to target any position in the human genome located three base pairs adjacent
to a PAM sequence using a customised synthetic gRNA together with expression of Cas9
[376, 381, 382]. In mammalian cells, the double-stranded DNA breaks introduced by the
CRISPR-Cas9 machinery will subsequently be repaired through two main processes: non-
homologous end joining (NHEJ) or homology-directed repair (HDR) [383]. NHEJ is an
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Figure 1.10: An overview of the CRISPR-Cas9 mechanism. DNA is delivered through
viral infection, whereby the DNA is integrated into the CRISPR locus (adaptation or spacer
acquisition phase). This is followed by the interference (or crRNA biogenesis) phase where
the CRISPR locus is transcribed and processed. Finally, in the target degradation stage, the
target is degraded by Cas9 proteins. In mammalian cells, DNA damage repair pathways
generate gene modifications through non-homologous end joining or homology-directed
repair. Adapted from [375] and printed with permission.
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error-prone mechanism which generates insertions or deletions when repairing the cut, and
is the dominating pathway when a repair template is absent. The mutations created with
NHEJ could render the targeted gene dysfunctional, thereby creating a gene knock-out.
HDR is much more precise and could be used to generate targeted modifications by using a
customised repair template. The repair template is specifically designed to contain the de-
sired alteration such as point mutations or sequence insertions, which would be integrated
into the genome through this process. The CRISPR-Cas9 technology can therefore be used
to create specific modifications to alter gene function in cells or living animals.
The field of CRISPR-Cas9 research is rapidly advancing [384], with continuous im-
provements including increased target specificity or efficacy [385–387], new applications
such as transcriptional activation, manipulation of epigenetic marks or chromatin, inducible
in vivo CRISPR systems and combined approaches with single-cell sequencing technology
[388–392].
1.6.2 The pooled CRISPR-Cas9 screening approach
The discovery that a synthetic gRNA could be designed to alter almost any gene in the
genome, led to the rapid development of optimised CRISPR components and computa-
tional tools to enhance specificity and efficacy of genome engineering [376, 381, 393–396].
Furthermore, libraries containing a pool of gRNAs with different specificities, were found
successful in the application of forward genetic screens [381, 397, 398]. The first imple-
mentations of genome-wide screens utilising the CRISPR-Cas9 approach in human cells
were published five years ago [399, 400], and is now widely used to study pan-genome loss
of function perturbations. This approach is superior to older techniques such as RNA inter-
ference because it is capable of stable and permanent gene silencing, in addition to being
highly versatile and specific [374, 401]. In a pooled genome-wide CRISPR-Cas9 screen,
first a library of gRNAs needs to be designed, synthesised and cloned into plasmids (Fig.
1.11). These libraries can be custom-made using various gRNA design tools [402, 403];
however, several well-designed and frequently used gRNA libraries are also available for
purchase [403–408]. The plasmid library can be packaged into lentivirus, to allow delivery
of the gRNA library into the Cas9-expressing target cells. Finally, a selection pressure is
applied whereby the desired phenotype can be studied by sampling the evolving cell popu-
lation and comparing the gRNAs present at each stage.
Three main types of screening approaches are commonly used to identify the genes re-
sponding to the perturbation of interest [409, 410]. In a dropout screen (also known as neg-
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ative selection), the majority of cells are expected to survive the selection pressure, whereas
the minority of cells showing increased cell death upon treatment could provide clues as to
what genes cause the decreased viability [411–413]. In an enrichment screen (also known
as positive selection), the increased survival is instead measured, where the vast majority of
cells are expected to die upon treatment. In the few surviving cells, this allows for identific-
ation of the genes overcoming the effects of the selection pressure such as drug resistance
[400, 406, 414]. The third screening approach, is not viability or proliferation based, but in-
stead looks at a phenotypic signal such as the expression of cell surface markers [415–417].
A potential readout would then be the consequence of gene knock-out on the expression of
the marker of interest, which can be measured by comparing a control cell population with
one subjected to fluorescence activated cell sorting (FACS).
Essential for all screening approaches is the subsequent sequencing of the various cell
populations, to identify the gRNAs giving rise to the desired phenotype upon treatment with
the selection pressure. Finally, several bioinformatic packages exist to aid the selection and
ranking of hits from the screen [418, 419].
A phenotypic marker-based screening approach could be particularly interesting in un-
derstanding how important cell-surface proteins are regulated, and will be covered in Chapter
5 of my thesis to study regulation of tumour PD-L1 expression. The target of interest could
be a fluorescently labelled protein or an endogenous cell surface protein which could be
labelled with antibodies coupled to a fluorescent tag. The change in expression level of
this target could then be measured by FACS or related strategies, whereby the genetic per-
turbations causing this alteration could be examined. It is possible to study either or both
genetic perturbations causing a downregulation or upregulation of the target expression.
These types of screens have proven successful in identifying regulators of key signalling
processes, including genes controlling the host response to pathogens through assessing the
LPS-mediated induction of TNF [415], or regulators of Hedgehog [420] and Wnt signalling
pathways [421]. A caveat with this approach however, is the time-consuming nature of the
FACS methodology, limiting the possible size of the screen. Yet, it holds a major advantage
compared to the viability or proliferation-associated screens, in the possibility to examine
a non-binary readout. Rather than studying death or survival, varying degrees of marker
expression could be assessed separately, as well as simultaneously identifying regulators
which mediate an increase or decrease in the expression of the target of interest. In conclu-
sion, this marker-based CRISPR-Cas9 screening approach has been and will continue to be
a useful strategy in identifying regulators of cell-surface proteins.
An interesting function-based approach of CRISPR-Cas9 screens has also emerged re-
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Figure 1.11: A simple overview of a pooled CRISPR-Cas9 screening approach. The
first step is to create a library of gRNAs, which is cloned into plasmids and packaged into
lentivirus. The targets cells are then transduced with this library, generating a heterogenous
population with varying genetic perturbations. A selection pressure is applied and after-
wards the desired phenotype can be studied. Printed with permission from [375].
cently, which has proven particularly useful in the field of immuno-oncology. These ap-
proaches typically use in vivo or co-culture systems of tumour and immune cells, whereby
genes or mechanisms enhancing tumour cell killing [422], conferring protection to immune
cell cytotoxicity [423–425], or facilitating tumour escape [333, 426] could be identified.
The advent of CRISPR-Cas9 technology has revolutionised the field of genome engineer-
ing, and its rapid advancement will certainly continue to transform the way research is being
conducted in ways beyond imagination.
1.7 Outline of my thesis
My thesis comprises two separate projects, both united under the scope of melanoma re-
search, with one focusing on melanoma genetics and the other on immune evasion. There-
fore, my thesis will be structured into two main parts reflecting the respective projects I
have worked on. Part I will contain the three chapters that constitute my melanoma genetics
project: the genetic landscape of human primary melanoma. The first results chapter will
describe the sequencing methods and quality control of the data, followed by two results
chapters where I describe the key genetic alterations and dysregulated biological pathways
in human primary melanoma. Part II, will outline through one extensive chapter: the design,
set up, performance and initial validation of a CRISPR-Cas9 screen identifying regulators
of PD-L1 tumour expression. Finally, the last chapter will bring together and conclude my
thesis as a whole.
The overarching goal of Part I is to understand how genetic alterations shape melanoma as a
disease. The genetic composition of melanomas holds the key to understanding melanoma
development, such as the genes or signalling pathways which might play a large role in
tumourigenesis, and the interplay between these components. Due to the significant het-
erogeneity found across melanomas, it is also important to outline the genetic differences
between different subgroups of melanomas, which can be distinguished by histopathologi-
cal subtype, sun exposure, mutational or pathway alterations. Ultimately, genetic changes
could also have a prognostic impact, which is important to explore. Overall, with this project
I hope to visualise how the successful application of large-scale sequencing of human pri-
mary melanoma can provide valuable insights into melanoma development, progression and
patient prognosis.
Part I





Sequencing methods and QC
2.1 Introduction
In this chapter, I will introduce the human primary melanoma dataset (Leeds melanoma co-
hort) I have generated sequencing data for and worked on for part I of my thesis (Section
C.2). I describe the cohort characteristics and sequencing methods, including the key para-
meters that makes this dataset remarkable and unique compared to all previous studies. Like
any project dealing with extensive sequencing data, it is essential to perform comprehensive
quality control prior to analysis. Therefore, I have utilised a broad range of tools to assess
and ensure the trustworthiness of the data used for this project.
Details of any software tools including specific parameters can be found in Section C.1.
2.1.1 Chapter aims
The aim of Chapter 2 is to describe the sequencing methods and confirm that the quality of
the sequencing data is sufficient for downstream analyses by:
• Ensuring the low amounts of DNA from primary melanomas will provide enough
coverage to assess the driver gene landscape
• Assessing the consequences of FFPE preservation on the data quality
• Ensuring the choice of method used for variant calling will provide the highest accur-
acy and is best suited for my dataset
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2.2 Sequencing of human primary melanomas
2.2.1 Cohort description
In an effort to thoroughly examine the genetic landscape of primary melanoma, I have util-
ised one of the largest cohorts of primary melanomas to date, the Leeds melanoma cohort
(Section. C.2). This cohort consists of over 2000 patients from the Northern UK region
[427], recruited shortly after melanoma diagnosis. These patients have thereafter been
followed-up in the clinic for over 15 years. A major advantage of this cohort is not only
the length of follow-up, but also the additional extensive clinical, pathological and lifestyle
data that have been gathered, see Table 2.1 for some key characteristics. Further variables
such as evidence of regression in the primary tumour, smoking, sun exposure, tanning and
sun sensitivity scores, history of other illnesses such as autoimmune disorders, diabetes or
other cancers are also possible to study in conjunction with the sequencing data. The pa-
tients’ primary tumours were biopsied shortly after recruitment, and where sufficient DNA
could be obtained, data generated from these samples were used in my project. Targeted
therapy and immunotherapy were not developed until the later stages of this study, therefore
97% of the patients in this cohort can be considered treatment-naive, as they have not re-
ceived any such treatments. As such, the genetic alterations studied with this project reflect
the innate genetic state of each patient, a trait most other studies does not benefit from.
2.2.2 Targeted capture bait design
To study genetic alterations in the primary melanoma cohort, I custom-designed an Agilent
SureSelectXT library, summarised in Table 2.2. More details can be found in Table A.2
and Section B.1. Rather than using exome sequencing, I elected to tailor the design for my
specific project. This not only cuts down sequencing costs by limiting the sequencing to only
capture genes of particular interest, but also allowed me to capture non-coding regions and
positions important for copy number calling and human leukocyte antigen (HLA) typing.
The bait library was designed to capture genes or genomic locations potentially altered
in melanoma. Probe group 1 consists of probes targeting coding regions and untranslated
regions (UTRs) of 551 genes. This list includes melanoma driver genes [73, 91], signific-
antly mutated genes from TCGA [428], melanoma driver genes identified using a dN/dS
model [429, 430] and genes in the Intogen database mutated in more than 3% of melanoma
samples. Additionally, 254 genes associated with solid cancers, designed by Dr. Ultan Mc-
Dermott (Section C.1), were also included in this group to allow discovery of new genes
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Table 2.1: Leeds melanoma cohort patient clinical characteristics. The key clinical
characteristics of patients in the Leeds melanoma cohort, which had their primary tumours
sequenced as part of my project. The patients are split by the overall cohort or the current
survival status of patients. Data originated from patient clinical records.
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Table 2.2: Targeted capture bait design. The bait design for the probe groups included in
my targeted capture panel. More details can be found in Table A.2 and B.1.
potentially important in melanoma development. Finally, this group also includes genes of
the IFN-g pathway [431], to make it possible to study genetic alterations influencing im-
mune regulation. My baits were shared with an adnexal cancer (henceforth referred to as
spiradenocarcinoma) project, hence I included 39 genes in this probe group because of their
potential role in the development of this cancer type.
Probe group 2 was designed to extract coding regions of 6 additional genes: BNC2,
CASP1, NUP107, PSIP1, SETDB1 and TERT. These genes or locations of these genes have
been found to be amplified or deleted in melanoma [432].
Probe group 3 was designed by Dr. Ultan McDermott and has 1934 probes against 960
reference Single Nucleotide Polymorphisms (SNPs), allowing a low resolution genome-
wide analysis of copy number alterations.
Probe group 4 allows more detailed copy number estimation of 28 genes, where probes
were tiled spanning 80-100 heterozygous SNPs per gene (designed by Dr. Vivek Iyer, Sec-
tion C.1). Positions with SNPs with a Minor Allele Frequency (MAF) between 0.45-0.55
were selected. Where the number of SNPs found in these regions were below 80, the region
flanking the gene was expanded until sufficient number of SNPs were captured.
Probe group 5 was designated to promoter mutations, with a total of 330 probes span-
ning 5 genomic locations for TERT, 3 genomic locations each for SDHD and DPH3 and 1
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genomic location for NDUFB9 and NFKBIE each.
Probe group 6 focuses on gene fusions, designed by Dr. Ultan McDermott (Section C.1),
where introns adjacent to exons known to be part of a gene fusion were targeted.
Probe group 7 captures HLA genes [433], to allow haplotyping for subsequent neoanti-
gen prediction.
Probe group 8 was designed to capture SNPs for the spiradenocarcinoma project.
2.2.3 Sample preparation and sequencing
All sample preparation from sampling to DNA extraction were done by collaborators in
Prof. Julia Newton-Bishop’s group at the University of Leeds (Section C.1). Informed
consent was obtained under the Multicentre Research Ethics Committee (UK): 01/3/57.
Following recruitment, patient primary tumours were excised and Formalin-Fixed Paraffin-
Embedded (FFPE). These blocks were then sampled using a Tissue Microarray (TMA)
needle to allow 0.8 x 0.2 mm cores to be extracted. Horizontal sections were taken from the
part of the tumour deemed to contain the least stroma and adjacent tissue. Average tumour
purity was estimated to be approximately 70%, measured visually [434], using RandomSpot
[435] and ESTIMATE [436]. Blood samples were also collected from the patients. DNA
and RNA were simultaneously extracted using Qiagen AllPrep DNA/RNA FFPE kit. RNA
was used for transcriptome sequencing using Illumina WG-DASL HT arrays, performed at
University of Leeds; and not part of my project.
DNA from 544 tumours and 487 germline blood normal (henceforth referred to as nor-
mal) samples were sent from collaborators at University of Leeds. All samples were sub-
jected to in-house DNA pull-down using the targeted capture custom design described in
Section 2.2.2, with the Agilent SureSelectXT baits diluted 1/24. In short, DNA was sheared
to obtain shorter fragments, followed by indexing and 8-14 cycles of PCR amplification.
Next, DNA libraries were pooled at equimolarity and hybridised with the biotin-tagged
bait library. Finally, bait-hybridised DNA was captured using streptavidin-coated magnetic
beads, followed by purification and 13 cycles of PCR amplification.
Sequencing was done using the Illumina HiSeq4000 platform, using 75 base pairs (bp)
Paired End (PE) sequencing, at 24 samples per lane to yield 2 Gb of sequence reads per
sample. Reads were mapped to the human reference genome assembly GRCh37d5 using
BWA-mem version 0.7.15 [437] and duplicates marked using biobambam bamsormadup
version 2.0.72 [438]. All steps from library preparation, including sequencing and align-
ment were performed by the Wellcome Sanger Institute (henceforth referred to as Sanger)
pipelines teams.
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2.2.4 Variant calling
Single Nucleotide Variant (SNV) mutation calling was performed using Caveman v.1.11.2
[439], with Vagrent to annotate the variants. 59 tumours did not have a matched normal, for
which a random normal sample, PD36169b, was used as the normal sample for the somatic
variant calling of these samples. The initial post-processing filters used are specified in
Table A.3, and include removal of variants with insufficient number of reads containing the
variant, high proportion of low quality of reads with the variant and presence of the mutation
only on one strand. The Exome Aggregation Consortium (ExAC) release 0.3 was then
used to filter out known polymorphic variants at a population frequency of <0.001. Only
variants falling in the targeted capture region designed for variant calling were considered.
Additional filters to reduce false positive calls were applied as follows: First, variants called
in positions where the coverage was <10x in either tumour or normal sample were excluded.
Next, variants which both had a MAF <0.10 and a coverage <30x in the tumour sample were
excluded. Coverage across the TERT promoter region was lower than average, as this region
is particularly difficult to sequence because of high GC-rich content [440]. Therefore, for
variant calling in known recurrently mutated promoter positions of TERT, the slightly less
stringent criteria of three or more reads with the mutated base was applied instead.
Pindel v.2.2.2 [441] in conjunction with Variant Effect Predictor (VEP) [442] was used
to call and annotate functional consequences of indels. The post-processing filters used
for Pindel are specified in Table A.4. The indel calls were further filtered to exclude calls
with low mapping quality (SUM_MQ < 150 for 1-10 bp indels and SUM_MQ < 100 for
indels of at least 11 bp), coverage <10x or MAF <0.10 in combination with <30x coverage.
Additionally, variants with only one supporting read were filtered out. As recurrent indels
are highly unlikely providing the low frequency of such variants, a sample recurrence filter
was also applied, to remove any identical indel variant being discovered in three or more
samples.
2.2.5 Copy number calling
Copy number calling was done by Dr. Kerstin Haase (Section C.1), using allele-specific
copy number analysis of tumours (ASCAT) [443]. Briefly, alleleCount was run on all
tumour-normal pairs. Based on the 1000 genomes phase 3 SNPs, and using a coverage
threshold of minimum 8 reads, the B allele frequency (BAF) and logR were calculated. The
BAF is the frequency of the non-reference allele, and logR is the read depth ratio between
the tumour and matched normal, subjected to normalisation and log2-transformation. Then
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the samples were subjected to GC correction, followed by removal of SNP positions show-
ing homozygous BAF data for germline samples. Finally, segmentation data was obtained
using the Allele-Specific Piecewise Constant Fitting algorithm and a grid search performed
to retrieve purity, ploidy and copy number data for the samples.
Samples estimated to be 100% pure were removed from the analysis, as such samples
were likely cases of bad fitting of the model. The following filters were then applied to
identify copy number events:
1. Samples showing whole genome duplication were defined at a ploidy cutoff of >2.7.
2. Regions showing homozygous deletion had a total copy number of 0.
3. Regions showing high level amplification were classified as a total copy number   5
for diploid samples and   9 for tetraploid samples.
4. Regions showing loss of heterozygosity had a minor copy number of 0.
Copy number events at a gene level were set using a strict filter: only in cases where the
whole gene was affected by the change was the event assigned on a gene level. Loss of
heterozygosity (LOH) events affecting chromosome X, were removed for all male samples.
2.3 Assessment of data quality
All quality control values were generated for reads mapping to the target region, excluding
genes in the HLA typing panel (probe group 7). Samtools stats was used to generate in-
formation about PCR duplicate rates and samtools bedcov was used to generate coverage
information for unique reads across all positions in the targeted capture design, see Table
A.1 for further details of software parameters used.
2.3.1 PCR duplicate rates
All sequenced samples show an average PCR duplication rate of 28%, irrespective of tumour
or normal origin. Several of the tumour samples had very low amounts of input DNA.
Subsequently, 10 samples failed library preparation and high duplicate rates were observed
for samples with very low DNA amounts (Fig. 2.1A,B). Only 1 of the normal samples had
low DNA input, which yielded 70% duplicate reads. All 24 samples sequenced in library
pool 43 showed a slightly higher duplicate rate than the other samples, potentially reflecting
batch processing effects.
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High duplicate rates are expected of samples with low input DNA, and will have an
impact on sequencing coverage, with lower coverage of such samples being inevitable.
2.3.2 Sequence read coverage
The average coverages, calculated for each sequenced sample across the entire capture re-
gion excluding HLA genes, were 49x for tumours and 68x for normal samples, with tumours
of low input DNA showing lower coverage. 12 tumour samples were excluded from further
analysis due to an average coverage below 10x. No normal samples were excluded, as
all normal samples had an average coverage of 10x or above. Samples of library pool 43
showed a lower than average coverage, probably due to the increased PCR duplicate rate.
All genes in the panel had an average coverage across tumour samples above 10x, including
important melanoma driver genes (Fig. 2.1E). Overall, the genes in the panel show a mean
coverage across tumour samples of 53x, which should be sufficient for mutation calling.
The coverages were lower than the desired coverage, which can be explained by the fol-
lowing reasons: First and foremost, in the bait design, no masking criteria was used for the
melanoma genes (probe group 1), which made up over 90% of the whole region size being
selected in my design. UTRs commonly contain small repetitive regions such as Alu ele-
ments, which comprise over 10% of the human genome [444]. Therefore, including probes
in the design which targets such segments will lead to the sequencing of very scattered
reads across the genome, and loss of bait target coverage. Secondly, many of the tumour
samples had very low amounts of input DNA, as can be expected from tiny primary melan-
omas. This led to an increased number of duplicate reads, and subsequently lower coverage.
Thirdly, the very polymorphic HLA regions were not included when calculating the desired
sequencing coverages. The total genomic size of these genes were 215.5kb; however, the
different probes used to capture these regions amounted to 2Mb of bases. The total size of
the genome targeted by the probes in my design, excluding the HLA probe group, was 6Mb.
Therefore, these probes made up 25% of the total design, rather than 3%. The impact this
has on the sequencing coverage would be approx. 10% loss compared to the original calcu-
lation. Despite these caveats, several early landmark genomic sequencing studies in other
cancer types relied on coverages similar to my study or lower [445–447], with success.
To estimate the impact of the sequencing coverage, ABSOLUTE [448] was used to cal-
culate the power to detect mutations at different subclonality levels with an average coverage
of 49x, see Fig. 2.1F. Dr. Vivek Iyer (Section C.1) adapted the power calculation to fit my
dataset, using inputs of 70% purity and assuming a ploidy of 2n, sequencing error rate of
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Figure 2.1: Assessment of sequence coverage measures. A, B) The PCR duplicate rate
(%) across all sequenced samples of tumour or normal origin. Samples with low amounts
of input DNA is highlighted in red or yellow, and those processed together as part of library
pool 43 are marked in blue. C, D) The average sequencing coverage across the target region
for all tumour and normal samples, respectively. The coverage cutoff of 10x is highlighted
with a dashed line. E) The average sequencing coverage for each gene in the panel design,
with 10x coverage marked with a dashed line. F) The power to detect mutations of varying
allelic fractions at different coverages, with 49x coverage marked with a dotted line.
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1x10 3 and using a defined false positive rate of 5x10 7. With my average coverage, this
results in >80% power to detect variants with an allelic fraction of 10%.
Other researchers have also investigated the impact of sequencing coverage on the pro-
portion of mutations called using a high coverage whole genome sequencing (WGS) dataset
[449]. With downsampling to simulate 50x coverage, 86% of all mutations were identified
in a 100% pure tumour sample. A further 10% of mutations were lost when the tumour
purity dropped to 67%. However, the biggest proportion of mutations lost as a consequence
of sequencing coverage, were at lower allele frequencies. Higher coverages are necessary to
pick up rarer subclonal mutations, but important mutations in driver genes are often clonal.
Hence, although I will inevitably miss a small proportion of mutations, the average tumour
coverage in my dataset will be sufficient for my project purpose.
2.3.3 FFPE artefact estimation
Mutations in sun-exposed melanomas often arise from UV damage, which most frequently
gives rise to C>T mutations. UV damage causes cross-linking of pyrimidine bases, and
when such positions undergo DNA replication, an adenine is incorporated on the opposite
strand, causing a C>T base change [450].
The process of preserving tumour tissue though FFPE processing, inevitably results in
minor DNA damage such as formaldehyde-induced crosslinks, deamination of cytosine mo-
lecules and the creation of abasic sites [451–453]. When subjected to PCR amplification,
such damage results in erroneous nucleotides, in particular adenine, being incorporated op-
posite the damaged base [454, 455]. The resulting DNA would therefore have an artificial
C>T mutation after sequencing, which would be difficult to distinguish from UV-induced
C>T mutations.
Because of this, FFPE samples are more prone to sequencing errors than fresh tumour
tissues. However, most errors will be random, and is not expected to repeatedly target
the same position of all DNA molecules. Therefore, variants found in several samples are
not likely caused by FFPE artefacts. Similarly, FFPE artefacts most often arise as C>T
mutations at low MAFs, in particular at MAFs below 10% [456], of which I have already
excluded much of due to the stringent mutation calling filters. To assess the impact of FFPE
artefacts among the final mutation calls, I looked at the proportion of low allele frequency
C>T mutations. Only 3% of all C>T mutations were at 10% MAF. Additionally, the
percentage of mutations at 10% MAF which were C>T base changes were 51%, compared
to 68% of all mutations being C>T. Therefore, I conclude that the contribution of erroneous
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mutations caused by FFPE damage should be minimal in my dataset.
Distinguishing FFPE artefact variants from true mutations can be a challenge. But as
discussed, using strict filters and focusing on recurrent variants will aid in removing a pro-
portion of such false positives. That being said, any exceptional finding in this cohort should
be treated with care and validated in a separate cohort, preferably from non-FFPE tissue ori-
gins.
2.3.4 Genotype concordance analysis
When dealing with a large sequencing project, there is a small possibility of sample swaps
occurring, and it is general good practice to check for such errors. A mix up of tumour DNA
and normal DNA was deemed highly unlikely, as these samples had been extracted and
handled separately at all times by our collaborators at Leeds University. However, a mix up
among the tumour DNA or among the normal DNA samples, causing an erroneously labeled
tumour-normal pair, could in theory happen. Therefore, I used bcftools gtcheck (Table A.1)
to compare the raw output of all unfiltered SNPs from the Caveman variant caller for all
matched tumour and normal samples. Each tumour sample was compared against all normal
samples, allowing me to identify sample swaps resulting in incorrect tumour-normal pairs
. The error rate, calculated as the number of discordances divided by the number of shared
sites between the samples compared, were used to identify the sample pair with the lowest
dissimilarity. As expected, the tumour-normal pair of the same patient, showed the lowest
error rate for all comparisons (see Fig. 2.2). Therefore, no sample tumour-normal pair were
identified as incorrect.
A subset of the patients in this cohort previously had their normal samples analysed us-
ing a SNP array. Therefore, these data could be used as an additional genotype check. Muta-
tion calling for the normal samples in my cohort was performed using samtools mpileup
followed by bcftools call (Table A.1). I obtained the SNP array data from Leeds Univer-
sity (Section C.1), and filtered for the overlapping regions between the array and my target
region. Unfortunately, a total of only 18 positions were shared between the 2 methods, for
which SNPs were reported in more than 1 sample. In most cases, the comparison of SNP
concordance was based on just one or two positions, which limits the effectiveness of this
assessment.
A total of 226 samples had SNPs in any of the 18 positions. 223 samples (98.7%)
showed the same SNPs analysed with both methods. Only three samples were identified
to have discrepancies between the SNP array and my targeted capture method, and these
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Figure 2.2: Genotype concordance analysis to assess sample swaps affecting tumour-
normal pairs. The error rate calculated for each tumour-normal pair, with tumour samples
on the x axis and normal samples on the y axis. The pair with the darkest blue colour
corresponds to the tumour-normal pair with the lowest error rate.
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discrepancies were investigated. For 2 samples, PD36252b and PD36311b, a variant in 1
of the 18 positions were found in the SNP array data, but not using the targeted capture
method. This position had a high coverage, with no reads supporting the variant, confirmed
by visual inspection using Integrative Genomics Viewer (IGV) [457]. For the third sample,
PD36491b, the SNP array data called a variant in two different positions, whereas in the
same sample, the targeted capture data did not identify this mutation. Absence of the muta-
tion was again confirmed by visual inspection of the regions, which also proved to have
high sequencing coverage and good quality reads. It is therefore unlikely these SNPs exist
in these samples without being picked up using my method. Intriguingly, I did observe the
presence of the two variants in the matched tumour sample from the same patient, rather
than the normal sample. But, as mixups between tumour and normal samples were deemed
impossible, and since the tumour-normal genotype check did not identify any sample swaps,
I think it is highly unlikely the three discrepant samples are results of sample swaps. The
exact same swap would have had to take place for both tumour and normal samples, which
is extremely unlikely. More realistically, these discordances affecting 3 out of 226 samples
would be due to limitations of either assay.
In summary, the genotype concordance analyses using matched tumour-normal pairs and
the Leeds SNP array data showed a high concordance of 100% and 98.7% for respective
analysis. This does suggest the likelihood of any sample swaps having occurred during
sample processing to be extremely unlikely.
2.3.5 Variant calling concordance with patient clinical records of BRAF
and NRAS mutation status
In this project, I identified patients with mutations in the clinically relevant positions BRAF
V600E, NRAS Q61, and NRAS G12/G13. These positions are commonly analysed as part of
routine clinical tests, and as such our collaborators at Leeds University provided me with a
list of patients which had mutations in either of these positions, measured by pyrosequencing
or from clinical records of the patients. I compared this list with the corresponding variants
from my mutation calls and calculated the concordance between our methods to assess the
quality of my mutation calls. 96.5% of samples (384 out of 398) showed the same genotype
for BRAF V600E. For the NRAS positions, codon 61 showed a 97.4% concordance (373 out
of 383 agreed) and codon 12/13 a 100% concordance (352 out of 352 agreed), see Fig. 2.3.
Of the BRAF V600E discordant calls, one was for a patient who had a mutation accord-
ing to my analysis, but was not reported to have this mutation by Leeds University. The
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Figure 2.3: Variant calling concordance with patient clinical records of BRAF and
NRAS mutation status. Comparison between my mutation calls (Sanger) and Leeds Uni-
versity records (Leeds) of BRAF and NRAS hotspot variants.
position was covered by 46 reads, with 24 of them reporting the variant, therefore I believe
the mutation to be accurately called. The remaining 13 discordant calls were cases where the
patient was reported to have a mutation by Leeds University, but not using my analysis. 2 of
the samples had a coverage below 10 for this position, which falls below the filter threshold
for my mutation calling (Section 2.2.4). One of these patients had three reads out of nine
supporting the mutation, and the second patient did not have any of the nine reads support-
ing the mutation. In these two cases the coverage was too low in my analysis to conclude
the presence of the variant, and illustrates either tumour heterogeneity or a limitation of my
analysis. The remaining discordant samples had a coverage between 44-80 for this position,
indicating the coverage is sufficient for mutation calling. For three of these samples, no
reads supporting the variant was present, and for an additional six samples the combination
of low number of alternative reads and stringent mutation calling criteria resulted in not
enough evidence to assign the variant. The last two discordant samples had the mutation
called, but they were filtered out due to the presence of reads supporting the variant in the
germline, suggesting it might not be a somatic variant.
For NRAS codon 61, a total of 10 samples showed discrepant results between the meth-
ods. 4 of the 10 discordant samples had a mutation called using my analysis, whereas the
mutation had not been reported by Leeds University. These 4 samples had a decent number
of supporting reads, 14-24, and a coverage of 50-89 for the variant position. Therefore, I
believe they are rightfully classified as having a mutation. The samples which showed a
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discrepancy where the mutation was not found in my analysis were checked manually using
IGV, for presence of reads containing the variant. For one sample, the variant was filtered
out because the only reads containing the variant had the variant at the end of the reads,
hence it was removed because of the likelihood of it being a sequencing error. The remain-
ing five samples had no or low number of reads supporting the variant, again a consequence
of stringent mutation calling criteria. Upon further investigation by the Leeds team, 5 out
of the 6 samples which were classified as having a NRAS codon 61 mutation by them,
were only classified as positive after repeating the assay, initially being classified as negat-
ive. This suggests that different assay thresholds can account for some of the discrepancies
found between the data. Excluding these 5 samples from the comparison increases the con-
cordance value to 98.7%. NRAS codon 12 and 13 showed 100% concordance between the
two methods.
In conclusion, the few discrepant samples are likely the consequence of different assay
thresholds and sensitivity. An overall high concordance between the methods, confirms that
any errors occurring through sample preparation, sequencing and analysis are limited, and
more importantly provides confidence for my mutation analysis suggesting the coverage
and filters applied, although stringent, are appropriate.
2.3.6 Variant calling concordance with Mutect
A second algorithm was used to evaluate the false positive rate of my mutation calls. A
whole range of variant callers have been developed over the years, and for the comparison
I chose Mutect, because it is one of the most frequently used methods for somatic mutation
calling, and has been shown to be reliable and of good performance [458–461]. Addition-
ally, the fundamental algorithm Mutect is based on is different from Caveman. Instead of
estimating genotype probabilities, Mutect works by estimating the probability of MAFs be-
ing different between the tumour and normal samples. Dr. Rashid Mamunur (Section C.1)
ran the cake pipeline to yield the Mutect calls, which I used for this comparison [462].
With both methods, only nonsynonymous variants were included in the analysis. The
same post-processing filters were applied to both callers: removing positions with low cov-
erage (<10x), and low coverage in combination with low allele frequency (<30x and MAF
<10%). 94% of genes which had a nonsynonymous mutation called using the Caveman
algorithm, also showed the presence of a nonsynonymous mutation using Mutect (Fig. 2.4).
This suggests I have a high rate of robust calls using my method.
When examining where the two methods were discordant, Mutect picked up a lot of
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Figure 2.4: Concordance between mutation calls using Caveman and Mutect. A) The
number of gene level nonsynonymous mutations calls with Mutect compared to Caveman,
and the overlap between both methods. B) The allele fraction distribution of mutations
called for each mutation caller.
mutations which were not found using the stricter Caveman method. However, the vast
majority of the mutations called using Mutect only, were found to be variants of low allele-
frequency (Fig. 2.4B). This is consistent with its algorithm design, with Mutect performing
well in calling subclonal mutations. For our analyses, subclonal mutations are of less im-
portance. While the data suggests Mutect has a higher sensitivity to pick up subclonal
mutations, this comes at the expense of more ’noise’. This is especially prominent in my
dataset, as the power to detect variants reduce drastically with lower allele frequency, in par-
ticular below 10% MAF (Section 2.3.2). I find it better to be strict than to increase my rate
of potential false positives, therefore I conclude Caveman with strict filters applied is the
right mutation calling method to use. Furthermore, as the rate of genes with nonsynonym-
ous mutations confirmed using Mutect were 94%, the false positive calls using my method
is likely to be small.
2.3.7 Samples without matched normal
59 tumours did not have matched normal samples. For these samples, PD36169b was se-
lected randomly to run the mutation calling against. The unmatched tumour samples had a
median nonsynonymous mutational load of 25.3 (range between 4 and 101), compared to
the matched tumour samples which had a median nonsynonymous mutational load of 26.3
(range between 0 and 371). As no bias was found towards either low or high numbers of
mutations called, this suggests the specific germline sample used as matched normal does
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not cause a general over- or underestimation of mutation numbers. Additionally, low cov-
erage of the germline sample could lead to an overestimation of somatic variants called.
The selected normal sample had an average coverage of 76x, which is slightly above the
average for all normal samples (68x). Therefore, an overestimation of somatic mutations as
a consequence of low germline coverage is deemed unlikely.
To ensure important somatic mutations in the unmatched tumours were not missed
due to specific SNPs in the selected normal sample, two approaches were taken. Firstly,
germline mutation calling was performed using mpileup in conjunction with bcftools call
(Table A.1). Only nine nonsynonymous germline mutations were found in the target cap-
ture region. None of these positions were reported to have somatic variants in any of the
tumour samples. Secondly, because a small number of mutant reads in the germline sample
can result in a potential somatic variant being discarded, the Caveman mutation calling was
repeated for the 59 unmatched tumours with 2 additional, randomly selected normals. As a
result, looking across all 59 tumour samples, only 1 out of the total 1235 nonsynonymous
mutations called using the originally selected normal, PD36169b, were not called using any
of the other two normals (see Fig. 2.5). Upon closer inspection, this is a variant in SPTA1,
which in this tumour sample had 9 reads supporting the variant out of 70. In PD36169b all
126 reads show the reference allele, whereas PD36521b and PD36283b each have 1 out of
104 reads supporting the variant. Therefore, this variant is likely filtered out in the latter
cases. Without the actual matched normal samples for these tumours, it is difficult to as-
sess which mutations are true. Nevertheless, this comparison suggest a very low error rate,
considering only 2.4% of all mutations across the 59 unmatched tumour samples were not
jointly called using all 3 normal samples. Additionally, when inspecting the genes with vari-
ants only called using PD36169b, or called exclusively by the other two except PD36169b,
none include well-established melanoma genes and recurrent positions. Therefore, the risk
of erroneous mutation calls using PD36169b as the dedicated matched normal sample for
these 59 samples can be considered fairly small.
2.3.8 ASCAT SNP distribution assessment
Analysis of copy number alterations with ASCAT relies on capturing sufficient SNPs over-
lapping between the sequenced genomic region and the SNP panel used by ASCAT. To
investigate this, I intersected the SNP panel used by ASCAT with the targeted capture re-
gion bed file, and found a total of 170179 SNPs which could be used for copy number
analysis. These SNPs were distributed across the chromosomes as shown in Table 2.3. The
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Figure 2.5: Shared mutations in unmatched tumours called using three normal
samples. Distribution of shared and unique mutations in the 59 samples without matched
normal, comparing mutation calls using 3 different normal samples.
median number of SNPs per gene in my bait panel were 215, and only 10 genes had 10 or
fewer SNPs within the region of the gene. Further information can be found in Section B.2.
However, not all SNPs will be informative in BAF calculations. The number of heterozyg-
ous SNPs per patient tumour-normal pair is individual, and therefore the number of SNPs
used for BAF calculation will be lower than the total and different between samples. In
contrast to BAF estimations, all SNPs can be used to calculate logR, and therefore, I believe
the input to ASCAT is sufficient to call copy number variations in the regions containing the
majority of my genes of interest. Unfortunately, focal copy number calls for genes falling
in any region not included in the bait design would not be possible, as such genes would
be captured as part of a larger segment with no pronounced change across specific genes
as such gene-specific SNPs will be absent. However, as there are SNPs widely distributed
across the genome, this still allows for whole genome low resolution copy number analysis
as well as more detailed analysis of over 500 genes.
2.4 Experimental work to validate findings
2.4.1 siRNA-mediated knock-down
RVH421 is an adherent cell line, cultured in RPMI-1640 supplemented with 10% FBS and
2mM L-glutamine. Cells were seeded at 200,000 cells/well in 6-well plates and incub-
ated at 37°C overnight. The following day cells were transfected using siRNA (Dharma-
con, ON-TARGETplus SMARTpool) designed against IRF4, ERH (positive control) or a
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Table 2.3: Number of ASCAT SNPs per chromosome. Number of SNPs per chromosome
that could be used by ASCAT for copy number analysis. Further information can be found
in Section B.2.
nontargeting pool (negative control) according to manufacturer’s instructions. Cells were
retransfected after 3 or 6 days, and harvested for analysis after 10 days.
2.4.2 Flow cytometry viability assay
Cells were collected following trypsin treatment (all culture media and PBS washes were
also kept), washed once with PBS and once with Annexin V binding buffer. The samples
were then subjected to Annexin V-PE staining (Biolegend, 5µl/sample for 15 minutes at
room temperature, followed by the addition of DAPI (Sigma, 1:5000 dilution). The samples
were then centrifuged, resuspended in Annexin V binding buffer and analysed using a flow
cytometer (BD Fortessa II), followed by data analysis using FlowJo v.10.
2.4.3 Confirmation of gene knock-down using Western blot
The cell culture dish was placed on ice, and the cells were washed twice with ice cold PBS,
followed by the addition of ice cold RIPA lysis buffer supplemented with protease inhibitor
(Sigma). Cells were scraped and transferred to an eppendorf tube, and incubated at 4°C
for 30 minutes with agitation. Cells were then centrifuged at 12,000 rpm for 30 minutes,
and the supernatant collected. Protein concentrations were measured using the Pierce BCA
assay (Thermo Fisher) and a western blot analysis performed as described previously [463].
Samples were run under reducing conditions, stained with rabbit primary antibodies against
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GAPDH (Cell Signaling, clone 14C10), IRF4 (Cell Signaling, #4964) or c-Myc (Abcam,
clone Y69) followed by a Horseradish Peroxidase-conjugated goat anti-rabbit secondary
antibody (Abcam, #ab6721). Protein chemiluminescence detection was performed using
ImageQuant (GE LifeSciences).
2.5 Evaluation of chapter aims
• Ensuring the low amounts of DNA from primary melanomas will provide enough
coverage to assess the driver gene landscape
– Despite a loss in coverage due to limited amount of tumour DNA and limitations
in the bait library design, this should not significantly reduce the possibility for
driver gene discovery.
– A high concordance between my mutation calls in known melanoma hotspots
BRAF V600E, NRAS codon 61 and codon 12/13 and patient clinical records
brings high confidence in my data.
• Assessing the consequences of FFPE preservation on the data quality
– The strict filters applied limits the mutation calls at lower allele frequencies,
which are more likely to arise from FFPE artefacts.
– The final mutation calls contain low frequencies of C>T mutations at 10%
MAF, therefore limiting FFPE-induced false positives.
• Ensuring the choice of method used for variant calling will provide the highest accur-
acy and is best suited for my dataset
– 94% of mutations could be verified using a second algorithm, proving a high
rate of robust calls.
– Strict filters using Caveman yields lower sensitivity to detect subclonal muta-
tions, but this selective approach will reduce false positives, and is therefore the
best choice going forward.
Chapter 3
Key genetic alterations in primary
melanoma
3.1 Introduction
In this chapter I will present the analyses I have performed to discover and understand some
of the most important genetic alterations found in primary melanoma. Genetic alterations in
cancer cells can promote tumourigenesis, but whilst melanoma is a cancer type with a high
burden of neutral mutations, it is important yet challenging to uncover the critical genes
and variants driving disease development. The advantages of using large patient cohorts in-
clude the possibility to utilise recurrence as a way of separating essential perturbations from
irrelevant events. However, this criteria alone is insufficient, and other methods including
patterns of positive selection and mutual exclusivity have also been explored in this chapter
of my thesis.
Somatic mutations can have three outcomes for a cell: they can provide a survival ad-
vantage, disadvantage or exert no effect. Most mutations will not have any consequence
on the selective advantage of a cell, while acquired mutations providing a survival benefit
for the tumour will be selected for. An example of a positively selected mutation is the
activating BRAF V600E mutation. This results in up to 700x increased MAPK pathway
activity [94, 464], which leads to a proliferation and cell survival benefit for the cell with
this mutation. These patterns of positive selection can be utilised when determining which
genes are of greater importance in melanoma development. In non-driver genes, I expect to
find a consistent pattern of silent, missense and loss of function mutations, with fewer non-
sense mutations as these tend to be rarer events, compared to missense and silent mutations.
However, positively selected driver genes will have an elevated ratio of nonsynonymous
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mutations compared to silent mutations [430], and this mechanism can be utilised to define
the genes driving melanoma development.
Another key method of discovering important genes contributing to melanoma develop-
ment, is to investigate patterns of mutations across tumours. Mutations repeatedly affecting
the same gene, or pathway, in different patients are more likely to be associated with patho-
genicity. Additionally, positively selected cancer mutations do not occur randomly, as these
often target pathways which provide a survival advantage for the cell. When mutations are
not random, there are two main mutational patterns: mutual exclusivity and co-occurrence.
Mutual exclusivity looks at the occurrence of multiple mutations with the same effect on
one specific pathway. Such mutations may not be selected for as their mutual presence
does not provide an additional advantage to the cell. Furthermore, the coexistence of such
mutations might even be harmful for the cell, as shown in several studies [465–467] as well
as being evident in patient cohorts including mine (Fig. 4.2). By studying the presence
of mutually exclusive gene pairs, novel genes involved in important oncogenic pathways
can be discovered. Co-occurring mutations on the other hand, suggest a co-operative or
even synergistic effect of the genetic mutations involved. This mutational pattern highlights
important pathways acting together to promote tumourigenesis. However, for this type of
analysis, one must be cautious, especially when dealing with tumour types with a high back-
ground mutation load. Tumours with a high mutation burden have an elevated chance of any
two genes being co-mutated. Additionally, due to the mutational heterogeneity across the
genome, certain genes are more likely to harbour mutations due to, for example, chromatin
accessibility or variations in DNA repair susceptibility [86, 468–471]. When performing
analyses of mutational patterns, it is important to take into account all of the factors men-
tioned above. These are the main reasons behind choosing DISCOVER for my analysis, as
this method employs measures to account for such variability [472].
With sun exposure being one of the main causative factors in melanoma development, it
is evident that primary tumours arising at different locations across the body can have differ-
ent properties. Tumours found on body sites frequently exposed to sunlight such as the head,
are sometimes referred to as chronically sun-damaged (CSD) melanomas. These tumours
show a particular pattern of high mutation load and a specific composition of genetic alter-
ations, such as MAPK activation independent of BRAF V600E [18, 45, 54, 473]. Tumours
arising on intermittently sun-exposed sites or sites commonly shielded from sunlight also
show distinct features, such as a higher frequency of BRAF V600E mutations or a higher
degree of chromosomal aberrations [54]. In this chapter, I will therefore also examine the
role sun exposure has on the melanoma driver gene landscape.
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3.1.1 Chapter aims
The aim of Chapter 3 is to present the key genetic alterations in primary melanoma, includ-
ing:
• Outline the landscape of mutations including the top mutated genes and copy number
alterations
• Identify melanoma driver genes and important genetic interactions
• Understand how sun exposure can shape the genetic composition in melanomas
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Figure 3.1: Summary of coding SNVs in the Leeds melanoma cohort. 524 samples were
grouped based on the type of primary tumour: cutaneous, unknown, acral, other rare or
mucosal, and by decreasing mutation load. Top panel: Number of exonic mutations and
the distribution of variant consequences. Bottom panel: Proportion of various base changes
across the samples.
Melanoma is a cancer type with a high mutational load (Fig. 3.1). As expected, as a
consequence of UV damage, a high proportion of C>T base changes were found in almost
all samples, with the exception of low mutational load samples and tumours classified as
acral melanoma. Mutational load was calculated as the total number of nonsynonymous
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mutations per sample. This value was then divided by 5.2, which is the target capture region
size in MB of the melanoma genes probe group 1, to give the nonsynonymous mutation load
per MB. The average nonsynonymous mutation rate was 5 mutations/MB (range of 0 to 72
mutations/MB).
I have categorised the primary tumours into cutaneous (excluding the acral), acral, mu-
cosal, “other rare” and “unknown” subtypes. As vulval, vaginal, anal and penile primaries
could not be accurately assigned as cutaneous or mucosal, they were grouped together as
“other rare”. A small number of tumours had been classified as nodal with an unknown
primary according to the clinical records. Judging by their mutational profiles (Fig. 3.1),
most contained a large proportion of C>T mutations, and were therefore assumed to be
cutaneous in origin.
The top recurrently mutated positions include well-known variants in the driver genes
BRAF, NRAS and TERT, but also hotspot mutations associated with sun exposure such as
RAC1 p.P29S (Fig. 3.2). In addition, RQCD1 p.131L mutations were seen at a similar
frequency in another cohort of primary melanomas [474]. However, lower alteration fre-
quencies have been reported in large cohorts of metastatic melanoma (TCGA pan-cancer
2.5%) [73, 85, 161, 475], which could reflect a difference between primary and metastatic
tumours. Previously undescribed hotspot variants discovered in this cohort include posi-
tions in PCDHA2, TPTE and AHCTF1. The S337L mutation in PCDHA2 targets one of
five Cadherin domains, while the S447L variant lies in the C2 domain of PTEN tumour sup-
pressor protein [476] of TPTE. All mutation changes in noncoding regions were reported
with respect to the strand location of the gene, where the position is shortened to the last
three digits. As an example, the common promoter mutation in TERT chr5:1295228 (human
genome assembly GRCh37), which is located on the reverse strand, is a C to T mutation in
respect to the gene but a G to A mutation in respect to the forward strand. It is thus referred
to in my thesis as a C228T mutation.
Interestingly, the C271T hotspot mutation in AT-Hook Containing Transcription Factor
1 (AHCTF1) affecting 3% of melanoma patients in this cohort, targeted a highly conserved
region in a GABPA transcription factor binding site (Fig. 3.3). In addition to the 13 pa-
tients with this C271T mutation, 1 patient had a C271A mutation and 2 patients had the
dinucleotide CC271-272TT mutation. A further six patients had mutations targeting ad-
jacent bases. Although this region is in the promoter of AHCTF1 and is annotated as a
transcription start site by Fantom 5, the location of the GABPA transcription factor binding
site suggests it will unlikely affect AHCTF1 gene expression. AHCTF1 is located on the
reverse strand, while the transcription factor binding site is on the forward strand, making it





















































































































































































































































































Figure 3.2: Top recurrent mutations in the Leeds melanoma cohort. The top recurrent
exonic and promoter variants are shown, together with the alteration frequency of each
variant in this cohort (n = 524). All mutation changes in noncoding regions were reported
in respect to the strand location of the gene, where the position is shortened to the last three
digits.
upstream and reverse in relation to the gene. However, some transcription factors have bi-
directional activity, and GABPA has been reported to have this feature [477]. Additionally,
disruption of ETS transcription factor binding sites such as GABPA have been reported to
be enriched in tumours as a consequence of UV damage [478, 479] (discussed in Section
3.6), and as such the effect of these variants on AHCTF1 gene expression and subsequently
its role in melanoma development remains unclear and will only be elucidated following
experimental validation.
5’-UTR hotspot mutations in Ribosomal Protein S27 (RPS27) have previously been de-
scribed [475]; however, the recurrent mutation I found in position C227T affecting 11 pa-
tients in this cohort, was only recently reported [91]. In this whole genome sequencing
study, patients with mutations in that position showed an almost two-fold increased expres-
sion of RPS27. In addition to the C227T position, an additional eight patients had variants in
the promoter region of RPS27, across a stretch of only 25 bp. Most large-scale sequencing
projects have used exome sequencing, hence would not retrieve information about noncod-
ing regions. Looking at genetic alterations through Cbioportal [480, 481], using data gen-
erated by TCGA (TCGA SKCM, Section C.2), a large proportion of the changes in RPS27
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Figure 3.3: Location of novel AHCTF1 hotspot promoter mutations affecting the
GABPA transcription factor binding site. Recurrent mutations in the promoter region
of AHCTF1. Each row of circles represents a sample, and the colour of the circle represents
the base change. The majority of patients with AHCTF1 mutations have the C271T vari-
ant, coinciding with a conserved GABPA binding motif base; however, other variants exists
and some patients have multiple mutations across the GABPA binding site. All mutation
changes in noncoding regions were reported with respect to the strand location of the gene,
where the position is shortened to the last three digits.
were amplifications, which may suggest the gene acts as an oncogene.
The frequency of nonsynonymous mutations in candidate driver genes were also studied
(Fig. 3.4). Hotspot mutations in BRAF, NRAS, KRAS, HRAS, RAC1 and IDH1 were defined
as recurrent missense variants known to be associated with an increased oncogenic activ-
ity. A high proportion of loss of function variants were found in tumour suppressor genes
CDKN2A, TP53, NF1, ARID2, PTEN, FBXW7, RB1 and RASA2. This is in contrast to on-
cogenes PPP6C, MAP2K1, KIT, CTNNB1, EZH2 and CDK4, which had an overwhelming
majority of missense mutations. Compared to other large metastatic melanoma sequencing
studies, the alteration frequencies in candidate driver genes of my primary melanoma data-
set was similar [73, 85, 91]. Some reported mutation frequencies varied between datasets,
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which could be reflective of cohort biases or sequencing coverage. Shain et al. reported al-
terations in cell cycle genes, the p53 pathway and multiple MAPK pathway genes to arise in
later stages of melanoma [48]. Therefore, slightly lower frequencies of mutations in genes
such as ARID2 in my dataset comprising early stage melanoma tumour samples, could be
reflective of melanoma disease progression.
Variants in the TERT promoter region were dominated by C250T, CC242-243TT and
C228T changes. No other recurrent mutations were found in TERT. All DPH3, NDUFB9
and NFKBIE variants found were in positions which have been reported previously. In
addition to known positions, one recurrent mutation in the promoter region of SDHD, in
chr11:111957596, was found in two samples of this cohort.
3.3 Copy number alterations in the Leeds melanoma co-
hort
Copy number data were generated using ASCAT [443, 482] by Dr. Kerstin Haase (Section
C.1). 401 samples successfully passed all filters, including the removal of 9 samples which
were excluded from the mutational analysis due to low average coverage. The samples
showed a mean purity of 66%, with 274 (68%) samples found diploid, and 127 (32%) tet-
raploid. To estimate the amount of copy number change in each sample, I looked at the total
length of amplified or deleted regions per sample (Fig. 3.6). Copy number alterations affect
most samples to some extent, with many samples showing a high amount of homozygous
deletions in particular.
Genetic aberrations in melanoma commonly include deletions involving chromosome
9p (CDKN2A), 10q (PTEN), 6q and 1p, whereas amplifications often involve chromosome
1q, 6p, 7 (BRAF) and 8 (MYC) [483–486]. A genomic overview of copy number alterations
across all samples in the Leeds melanoma cohort, along with a comparison with the TCGA
SKCM dataset are shown in Fig. 3.6A,B. Copy number gains and losses where the propor-
tion of all segments which differ more than 0.6 from a sample’s ploidy were used to generate
the figure. Similar alterations could be seen across the two datasets, suggesting similar copy
number profiles between primary and metastatic melanoma. Chromosome 1 shows loss of
the short arm, along with amplification of its long arm affecting genes such as AHCTF1 and
NOTCH1. Chromosome 6p is commonly amplified, whereas 6q were more often deleted.
Other frequently amplified regions include chromosome 7 and 8, while chromosome 9 and
10 were more regularly lost.
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B. Summary of copy number losses in human primary melanoma cohort
Figure 3.5: Amount of copy number alterations in each sample. Histogram showing the
per sample total length of all A) high level amplifications or B) homozygous deletions.
3.3.1 High level amplifications
The most frequently amplified genes in my dataset were CCND1 (n = 20, 5%), HIST1H2BG
(n = 16, 4%), TERT (n = 15, 4%), IRF4 (n = 11, 3%), UBR5 (n = 11, 3%), MYC (n =
10, 2%), NDUFB9 (n = 10, 2%) and SNX31 (n = 10, 2%). 7 samples showed high level
amplifications across the entire BRAF gene, with an additional 60 samples having a part of
BRAF amplified. UBR5, MYC, NDUFB9 and SNX31 are all located on chromosome 8q,
where MYC-amplifications have, in particular, been pointed out as the important disease-
driving event. Other genes reported to be amplified in different cohorts of melanoma had
a lower incidence in my dataset, with CDK4 and KIT showing amplifications in only five
samples each while MITF was amplified in just two samples. The lower frequency of copy
number events in my cohort could be due to stricter filters for copy number calls, as I elected
to only report high level amplifications in samples where the entire gene was affected by the
event. If choosing to look at high level amplifications affecting any part of the gene: KIT,
MITF and CDK4 would be affected in 18, 17 and 5 cases, respectively.
HIST1H2BG and IRF4 are both located on chromosome 6p, a region frequently amp-
lified in melanoma. As this region spans many genes, the specific amplification of these
two genes could therefore be a case of “guilt by association”, and not driven by a potential
biological advantage of amplification of any of these two genes specifically. Dr. Rashid
Mamunur (Section C.1) performed an analysis of the DepMap CRISPR-Cas9 dataset [487–
489], whereby he identified IRF4, one of the top amplified genes in my dataset, as 1 of
35 genes significantly associated with lethality in skin cancer cell lines compared to cell
lines of other tissue origin. In brief, this analysis was done by processing the publicly avail-
able DepMap data, where the effect of gene knock-down in CRISPR-Cas9 dropout screens
across a range of cancer cell lines were studied. Each gene and cell line were assigned a
CRISPR lethality score, indicating the dependency of that cell line on the gene being stud-
ied. A higher lethality score means a larger reduction in cell viability when the specific gene
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Figure 3.6: Whole genome copy number overview highlighting interesting genes. An
overview of copy number alterations for A) the human primary melanomas (Leeds melan-
oma cohort) and B) the TCGA SKCM dataset. All segments with a copy number differing
more than 0.6 from the sample average were used to generate the figures. Red illustrates
gains and blue losses. Both figures were originally created by Kerstin Haase. C) CRISPR
lethality scores (higher scores corresponds to a larger reduction in cell viability when the
specific gene is silenced) of eight genes associated with lethality in skin cancer cell lines
(Fisher’s exact test, p-adj < 0.01). Red = more lethal, blue = less lethal. Other cell types
include cell lines of tissue origin other than skin. D) Amplified regions in the TCGA SKCM
cohort overlaid with the genomic location of the eight genes associated with lethality in
skin cancer cell lines. E) Expression of IRF4 in Rahman et al., reprocessed TCGA data. F)
Correlation between IRF4 expression and cell line CRISPR lethality scores.
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is silenced. Lethality significance scores were used to perform a Fisher’s exact test compar-
ing number of cell lines being lethal versus non-lethal in skin cancer cell lines versus cell
lines of other tissue origin. All genes with a Benjamini-Hochberg multiple testing corrected
p-value of 0.01 were considered significant. Eight of the significant genes were analysed
as part of my sequencing panel, and their respective lethality scores across all cell lines are
visualised in Fig. 3.6C.
I found Interferon Regulatory Factor 4 (IRF4) particularly interesting (Fisher’s exact test
adjusted p-value 0.000015), as this is one of the top amplified genes in my dataset. It maps
to chromosome 6p, which is amongst the most frequently amplified regions in melanoma
[486, 490], but for which any specific oncogene associated with this amplification has yet
to be established [491, 492]. I first looked at the expression of IRF4 in TCGA tumours
[96, 493], including melanoma and normal tissue. I discovered an increased expression of
IRF4 in melanomas compared to normal tissues (Fig. 3.6.), which would support that IRF4
amplifications could be a potential oncogenic event in melanomas. This observation could
however be associated with IRF4 having an increased gene expression in the skin compared
to other organs, and indeed IRF4 does have a high expression among primary melanocytes
(Section A.6, C.2). However, The Human Protein Atlas does not report higher IRF4 protein
expression in the skin compared with other tissues (Fig. A.6) [494–496]. Finally, analysis
of the DepMap data showed that melanoma cell lines with high IRF4 expression were more
often associated with lethality when that gene was lost compared to other cancer types
(Fig. 3.6). Another three cell lines also showing high expression of IRF4 with a high
lethality score were of haematopoietic and lymphoid tissue origin. Immune cells also have
high expression of IRF4 (Fig. A.6), and interestingly in multiple myeloma, inhibition of
IRF4 was shown to reduce expression of the oncogene MYC, and cause cellular toxicity
[497]. Taken together, I hypothesise that IRF4 amplification could be an oncogenic event
in melanoma, whereby the loss of IRF4 expression through chemical perturbation might
expose a vulnerability of the tumour cell.
To test my hypothesis, I knocked down IRF4 in the human melanoma cell line RVH421.
This cell line shows high expression of IRF4, with the gene also being amplified [488,
489]. I confirmed through 3 independent experiments, that siRNA-mediated knock-down
of IRF4 in this cell line indeed resulted in apoptosis and cell death, but through a MYC-
independent mechanism (Fig. 3.7). Interestingly, I also observed that knock-down of IRF4
caused these cells to increase in size, which I speculate could be linked to senescence or cell
cycle regulatory effects. Collectively, the mechanism behind this IRF4-dependency seen
in a subset of melanomas is interesting to further interrogate, and these data suggest IRF4
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might be an interesting clinically actionable target [498].
Figure 3.7: The effect of IRF4 knock-down in the human melanoma cell line RVH421.
A) Apoptotic or dead cells were analysed using Annexin V-PE and DAPI staining, respect-
ively, and their fluorescence intensities measured using flow cytometry. B) Flow cytometry
analysis of forward and side scatter shows an increase in cell size in the cells where IRF4
is knocked down. C) Western blot analysis confirming the siRNA-mediated silencing of
IRF4 on a protein level and sustained c-Myc expression when IRF4 is knocked down. All
data is representative of 3 individual experiments. NC = Nontargeting siRNA control, PC =
Positive control (ERH knock-down).
3.3.2 Deletions of genomic regions
In my dataset, 80 samples (20%) had a homozygous deletion in a segment overlapping
CDKN2A, with 50 samples (13%) having the whole gene lost. An additional 171 samples
showed LOH in this region, resulting in a total of 251 samples (63%) showing copy number
loss targeting any part of CDKN2A. Other researchers have proposed that CDKN2A dele-
tions occur in the transition to invasive melanoma, therefore being less prevalent in primary
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melanoma [47, 136]. However, my results show for the first time in a much larger cohort
of primary melanomas than have previously been reported, that the frequency of CDKN2A
alterations is in line with reports of metastatic melanoma: 67% in the TCGA cohort [73] and
56% in a cohort of 143 primary invasive melanomas [499]. Furthermore, loss of 9p21, the
region harbouring CDKN2A, has been shown to occur early in melanoma progression [500];
however, this study is based on just one patient. CDKN2A germline variants are the single
most common genetic risk factor in familial melanoma [501, 502], which suggest CDKN2A
loss could be an early event in initiation of the disease.
After 9p21 and CDKN2A, the most frequently homozygously deleted entire gene was
PDCD1 (n = 6, 1.5%) followed by genes in the 10q region including PTEN (n = 5, 1.2%).
When including hemizygous deletions, a total of 147 (37%) and 89 (22%) samples showed
loss of PTEN and PDCD1, respectively. PTEN is a key tumour suppressor, frequently lost
in various cancers and an important melanoma driver gene. In the TCGA SKCM cohort,
PTEN is homozygously deleted in 28 out of 442 patients (6%), which is higher than in my
cohort of primary melanoma (1.2%).
PDCD1 encodes PD-1, an important inhibitory receptor expressed on immune cells,
which plays a key role in mounting a host anti-tumour immune response [242, 273]. As
PD-1 normally is not expressed on tumour cells, the gene being deleted could reflect its
loss in the immune infiltrate of the tumours. This observation is interesting, as loss of the
PD-1/PD-L1 signal would activate immune cells, and could be the result of mechanisms
in favour of tumour eradication by the immune cells. However, there have been reports in
literature of an existing subpopulation of melanoma cells, which do express PD-1 [503], and
this trait is curiously associated with enhanced tumourigenic properties. It is not possible to
determine from my data whether the loss would have occurred in tumour or immune cells;
however, the samples showing deletion of this gene did not have a higher proportion of
immune cells than other samples, as their average tumour purity were not different (Mann-
Whitney test, p-value = 0.33).
3.3.3 Loss of heterozygosity in conjunction with mutations
The two-mutation hypothesis postulated in 1971 describes how tumour suppressor genes
could need biallelic inactivation to drive tumourigenesis [504]. Strong selective pressures
exist to select for tumour-advantageous alterations, whereby the complete lack of a wild-
type allele strengthens the effect of tumour suppressor gene inactivation. Complete loss of a
gene can be achieved through multiple events, such as homozygous deletion, loss of function
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mutations affecting both alleles, epigenetic silencing, or a combination of these modifica-
tions. Therefore, I investigated the concurrent presence of mutations and LOH in the same
gene. I chose to focus on recurrently mutated genes with a minimum 5% mutation rate. Fig.
3.8 shows the genes with the highest fraction of samples having simultaneous mutation and
loss of the second allele. In the top are several well-known melanoma tumour suppressors,
including PTEN, CDKN2A and TP53, genes recognised to drive melanoma development
[145, 505–508]. Next on the list is SVEP1, a gene involved in cell adhesion [509, 510], with
very limited reports linking the gene to melanoma, other than it being frequently mutated
in cutaneous melanoma [511]. The gene also shows enrichment in functional mutations
by OncodriveFM analysis [511]. In my dataset, 76 samples show nonsynonymous muta-
tions in this gene, 139 samples have hemizygous loss across this gene, but no samples
show homozygous deletion. As such, it appears inactivation of this gene mainly results
from the combination of mutation and hemizygous deletions. Therefore, analysis combin-
ing several different genetic alterations is necessary to pick up this signal. Various other
melanoma-associated genes also show loss of heterozygosity with a mutation in the other
allele, including tumour suppressors PTPRK, NF1 and ARID1A. Several genes described in
other sections of my thesis, such as TLR4 and TPTE also show this feature. Interestingly,
although the important tumour suppressor TP53 shows frequent mutation and loss of the
other allele, not a single sample has a biallelic homozygous deletion of TP53.
Through concurrent analysis of multiple important genetic alterations, such as mutations
in combination with copy number alterations, one might get a more comprehensive view of
melanomas. Most researchers study mutations and copy number alterations individually;
however, I find it valuable in particular when studying tumour suppressor genes, to look at
such changes all together. Genes can be silenced through a range of mutational, complex
structural variant, copy number and epigenetic events, either in isolation or in combination.
As I don’t have information on structural variants or on an epigenetic level, I can only
focus on the former two alterations. One caveat with this analysis though, is the accuracy
with which it can be performed. Most mutations, in particular loss of function events, are
difficult to predict based on the change observed in the gene. Additionally, allelic loss is
a common genetic event in cancers [512], and therefore the specificity towards individual
genes can be debated. Therefore, there will be inherent noise in the data, making follow-
up studies even more important. Nevertheless, researchers have linked LOH to a selective
advantage as well as showing prognostic value [513–516]. In my analyses, I’ve discovered a
high fraction of samples which show concurrent mutation and loss of the other allele in key
tumour suppressor genes such as PTEN, CDKN2A and TP53. Several other genes showing
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Figure 3.8: Top genes with coincident mutation and loss of the other allele. Genes with
the highest proportion of mutations with simultaneous loss of heterozygosity. The number
above each bar denotes the total number of samples showing both mutation and loss of the
other allele.
this pattern were also discovered, such as SVEP1, TLR4 and the novel candidate driver gene
TPTE, discussed in Section 3.4.
3.4 Driver gene discovery
I used both SNVs and indels to feed into dNdScv (Table A.1), to identify cancer driver
genes based on positive selection in my primary melanoma dataset (Fig. 3.9). Reassuringly,
well-established melanoma driver genes dominate the top of the list; however, several less
known and novel melanoma driver genes were also found. FAM58A, RQCD1 and MSR1
have recently been proposed to harbour properties that could make them potential driver
genes [161, 428, 474]. TPTE on the other hand, has not been described in association
with melanoma previously. Relaxing the driver gene discovery FDR threshold to 10%,
an additional five driver genes reached significance. Two of these genes are known to be
important for melanoma (PPP6C and ARID1A) [85, 155, 430, 517], while ZFX, IFRD2 and
IFNL2 are additional novel candidates.
The novel gene Transmembrane Phosphatase With Tensin Homology (TPTE) showed
a mutational pattern resembling those of known driver genes. The gene has several re-
currently mutated positions, including deletions and truncating mutations (Fig. 3.10A). In

























































Figure 3.9: Human primary melanoma driver genes. The alteration rate of driver genes
identified in the human primary melanomas (Leeds melanoma cohort) using dNdScv with
FDR-adjusted p-values below 0.05.
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particular, the S447L missense mutation, affected eight tumours making it one of the top
altered positions in this cohort (Fig. 3.2). This mutation is located in the PTEN C2 do-
main [476, 518], a functional domain which is conserved between the paralogues TPTE,
TPTE2 and the essential tumour suppressor gene PTEN. Intriguingly, this functional do-
main is not the only shared structure between these proteins. All three proteins also have
a Dual specificity phosphatase catalytic domain (DSPc) [519]. Upon closer inspection, I
also discovered that mutations across PTEN and TPTE2 (and also PTEN and TPTE to some
extent), are largely mutually exclusive (Fig 3.10B,C), indicating similar function and there-
fore functional redundancy of co-occurring mutations. It is thus possible that by disrupting
TPTE or TPTE2 one might accomplish a similar effect to PTEN silencing, which has such
an important role in cancer progression. In normal tissue, TPTE is mainly expressed in the
testis; however, TPTE2 has more widespread distribution [520]. Research has shown that
TPTE2 is catalytically active and might be involved in negative regulation of cell growth and
proliferation [521, 522], while TPTE on the other hand has not been shown to possess any
phosphatase activity to date [523]. However, studies have revealed an aberrant expression
of TPTE in tumour tissues, as well as the presence of autoantibodies in a subset of those
patients, indicating a potential immune-associated role of this target gene [524, 525]. Thus,
TPTE2 might be more similar to PTEN in function, while the cancer-associated function
of TPTE is less clear. As TPTE mutations are positively selected for by melanoma cells,
and the closely related TPTE2 possesses PTEN-related functions, both these genes would
be interesting candidates for functional studies beyond the scope of my thesis.
3.5 Analysis of mutational patterns
I used the R package DISCOVER (Table A.1, A.5), a tool to assess mutational patterns,
which deals with the mutational load confounder by assigning both an individual tumour
alteration rate and gene alteration rate [472]. Eight gene pairs were found to show a mutually
exclusive pattern (Table 3.1). Six involved BRAF (Fig. 3.11) and two included CDKN2A
(Fig. 3.12). No co-occurring gene pairs were found.
3.5.1 BRAF-mutually exclusive gene pairs
Of the six genes showing mutual exclusivity with BRAF, the top two genes (NRAS and NF1)
are well-known members of the MAPK pathway, and key driver genes in melanoma. Their
mutual exclusivity with BRAF is established and reflects redundant activation of the MAPK
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EGFR (n = 27)
ARHGAP21 (n = 29)
GABRA6 (n = 36)
TLR4 (n = 49)
NF1 (n = 51)
NRAS (n = 149)
BRAF (n = 209)
Mutation and amplification Amplification Mutation Mutation and LOH
All BRAF  mutually exclusive genes at FDR 5% by DISCOVER analysis in Leeds melanoma cohort (n = 524)
NRAS (n = 149)
BRAF (n = 209)
BRAF  and NRAS  variant only samples
NF1 (n = 51)
BRAF (n = 209)
BRAF  and NF1  variant only samples
TLR4 (n = 49)
BRAF (n = 209)
BRAF  and TLR4  variant only samples
GABRA6 (n = 36)
BRAF (n = 209)
BRAF  and GABRA6  variant only samples
ARHGAP21 (n = 29)
BRAF (n = 209)
BRAF  and ARHGAP21  variant only samples
EGFR (n = 27)
BRAF (n = 209)
BRAF  and EGFR  variant only samples
Summary of BRAF  mutually exclusive genes
*Groupwise mutual exclusivity test p.value = 2.6e−9
*Pairwise mutual exclusivity test p.adj: 7.8e−46
*Pairwise mutual exclusivity test p.adj: 2.5e−6
*Pairwise mutual exclusivity test p.adj: 8.0e−6
*Pairwise mutual exclusivity test p.adj: 3.1e−5
*Pairwise mutual exclusivity test p.adj: 2.4e−4
*Pairwise mutual exclusivity test p.adj: 0.003
Figure 3.11: BRAF mutually exclusive gene pairs found using DISCOVER. Genes
showing significant mutually exclusive patterns (FDR-adjusted p-value < 0.05) with BRAF.
Top panel: All significant gene pairs together with their alteration patterns, with the DIS-
COVER groupwise mutual exclusivity test p-value shown (Table A.1). Bottom panel: Each
significant gene individually with BRAF, and their alteration patterns, with pairwise mutual
exclusivity test p-values shown. For visualisation, relevant copy number events are included
in the figure, although these were not used in the analysis. Amplification refers to high level
amplifications.
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Table 3.1: Mutually exclusive gene pairs found using DISCOVER. Gene pairs showing
significant mutually exclusive patterns (FDR-adjusted p-value < 0.05) found using DIS-
COVER analysis of the Leeds melanoma cohort (n = 524). The number of patients with
mutations in each or both genes are also shown.
pathway. Hotspot mutations in both BRAF and NRAS are rarely discovered in the same
patient, confirming either event is enough to activate the MAPK pathway and promote tu-
mourigenesis. My data agrees with this concept and provides further support to the theory
of a synthetic lethal nature between the presence of BRAF and NRAS hotspot variants, as
these events are almost always completely mutually exclusive [465–467]. Furtheremore, if
the coexistence of both events is not harmful to the tumour, I would expect a small num-
ber of patients to have both variants by chance although it would not provide additional
survival advantages to the tumour. Loss of function mutations in NF1 also activates the
MAPK signalling pathway, which explains the mutual exclusivity seen between BRAF and
NF1 in mine and other studies [73, 161, 526]. However, as different mutations will disrupt
gene function to a varying extent, it is expected that a small number of patients will have
mutations in both genes, as seen in my dataset.
Of the remaining four BRAF-mutually exclusive genes, Toll Like Receptor 4 (TLR4)
and Epidermal growth factor receptor (EGFR) are both involved in BRAF-associated sig-
nalling pathways including the MAPK pathway [527–529], which also makes their mutually
exclusive pattern with BRAF natural by function. However, these genes both encode recept-
ors, which have a diverse range of ligands and can exert varying downstream effects not
exclusive to MAPK signalling [530–535]. Therefore the impact of specific mutations might
differ, and absolute mutual exclusivity cannot be expected of these gene pairs. To validate
my findings in a separate dataset, I used the TCGA SKCM dataset through Cbioportal and
discovered a trend towards mutual exclusivity between BRAF and EGFR, as well as BRAF
and TLR4 alterations. I chose to only look at the trend rather than the significance levels, as
their mutation pattern analysis method is based on the flawed assumption of independent and
identically distributed alterations across tumours [472]. Taken together, these results suggest
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there might be a fraction of melanoma patients with the MAPK pathway activated through
EGFR or TLR4 rather than BRAF, and brings forth the possibility of new possible treatment
options for melanoma. EGFR inhibitors have previously been tested without much success
in clinical trials on unselected melanoma patients [536], and there are cases where resistance
to BRAF inhibition have led to increased activity through EGFR [537–539]. This reactiva-
tion of the MAPK cascade through EGFR, is evident in colorectal cancers, but is minimal
in melanomas which often express low levels of EGFR. Therefore, it would be interesting
to test whether existing EGFR inhibitors such as erlotinib, gefitinib or cetuximab could be
repurposed to effectively treat the subpopulation of EGFR-altered melanoma patients only.
Similarly, for TLR4, several inhibitors are under development [540–543], and could be used
to test treatment efficacy on the subset of patients showing alterations in TLR4.
The final two BRAF-mutually exclusive genes in my analysis were Gamma-Aminobutyric
Acid Type A Receptor Alpha6 Subunit (GABRA6) and Rho GTPase Activating Protein 21
(ARHGAP21). When looking in the TCGA SKCM dataset, neither of these genes were re-
ported to have a mutually exclusive tendency with BRAF. Hence, these findings could either
be the result of differences in patient cohorts, or it might be these findings are false positives.
The presence of a putative ERK phosphorylation site in GABRA6 [544], could strengthen
the claim of this gene as a player in the MAPK pathway. However, this is not likely to be
its main role, as GABRA6 has important neurological functions in the brain, and the impact
this gene has on activating the MAPK pathway to subsequently contribute to tumour de-
velopment is likely limited. ARHGAP21 silencing has proven to be functionally similar to
that of BRAF activation [545–550], and with studies suggesting shared interaction partners
[551–553] this could indicate ARHGAP21 has a novel role in MAPK signalling. But, as
this gene also seems to have multiple functions, the specific activation of MAPK signalling
might therefore only be a small part of its role, and subsequently its contribution to promot-
ing tumour development might be insufficient. As many of the genes discovered through my
analysis have broad functions, their MAPK-specific role could therefore be diluted by this
multi-functionality, and I would not expect mutations affecting these genes to completely
negate any effect a simultaneous BRAF activating mutation would have on tumourigenesis.
To follow up and confirm the novel discoveries made here, each gene’s specific contribution
to MAPK signalling could be tested by assessing binding partners, by studying direct down-
stream effects such as phosphorylation of ERK, or their final impact on cell proliferation and
survival.
70 Key genetic alterations in primary melanoma
PRDM2 (n = 26)
ADAMTS18 (n = 67)
CDKN2A (n = 132)
Homozygous deletion Mutation and LOH Mutation
All CDKN2A  mutually exclusive genes at FDR 5% by DISCOVER analysis in Leeds melanoma cohort (n = 524)
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*Pairwise mutual exclusivity test p.adj: 0.0411
Figure 3.12: CDKN2A mutually exclusive gene pairs found using DISCOVER. Genes
showing significant mutually exclusive patterns (FDR-adjusted p-value < 0.05) with
CDKN2A. Top panel: All significant gene pairs together, with their alteration patterns,
with the DISCOVER groupwise mutual exclusivity test p-value shown (Table A.1). Bottom
panel: Each significant gene individually with CDKN2A, and their alteration patterns, with
pairwise mutual exclusivity test p-values shown. For visualisation, relevant copy number
events are included in the figure, although these were not used in the analysis.
3.5.2 CDKN2A-mutually exclusive gene pairs
My DISCOVER analysis identified two mutually exclusive gene interactions with CDKN2A
(Fig. 3.12). Both genes are suggested tumour suppressor genes: ADAMTS18 is a metallo-
proteinase shown to be highly mutated in melanoma [554] and PRDM2 encodes a zinc-
finger protein that interestingly also has Rb-binding properties [555, 556]. Using the TCGA
SKCM dataset, genetic alterations between CDKN2A and PRDM2 but not CDKN2A and
ADAMTS18 showed a trend towards mutual exclusivity.
ADAM Metallopeptidase With Thrombospondin Type 1 Motif 18 (ADAMTS18) is si-
lenced through deletion, mutation or methylation in a range of tumours, with several mem-
bers of the ADAMTS family showing tumour-suppressive capabilities [557–566]. One
particular study reports evidence of ADAMTS18 being highly altered in melanoma, with
mutated cells showing increased proliferation, cell migration and metastasis [554]. Recent
experimental evidence has also linked overexpression of ADAMTS18 in cancer cell lines to
cell cycle arrest, apoptosis and decreased migratory and invasive properties [567, 568]. It
is therefore possible that defects in ADAMTS18 might confer the same cell cycle mediated
effects as loss of CDKN2A. However, ADAMTS18 specifically has not been well-studied
compared to other members of the same family, and its substrates are still unknown.
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PR/SET Domain 2 (PRDM2) encodes two main proteins: RIZ1 and RIZ2, which can reg-
ulate expression of other genes through several mechanisms [569–571]. These mechanisms
include histone methyl-transferase activity through its N-terminal PR-domain [572, 573],
recruitment of epigenetic factors [574, 575] and by binding of DNA or proteins directly
[555, 576–579]. The only region distinguishing RIZ2 from RIZ1, is the lack of the N-
terminal methylation-associated PR domain, as RIZ2 is transcribed through an internal pro-
moter at amino acid position 202 [580]. This property is sometimes referred to as “yin-
yang” regulation, where the full-length protein has tumour-suppressive capabilities, while
the shorter length protein instead has oncogenic properties [570, 571, 580–582]. Con-
sequently, RIZ1 specifically is found inactivated in human malignancies [583–586]. In
addition to this, in vitro experiments have shown a link between RIZ1 expression and cell
cycle arrest, decreased proliferation and increased apoptosis [584, 585, 587, 588]. This
mutually exclusive pattern found between CDKN2A and PRDM2, might therefore indicate
PRDM2 is involved in CDKN2A-associated cell cycle regulation. However, the mutations
found in the primary melanomas are spread across the gene (Fig. 3.13), with only four pa-
tients showing mutations in or around the PR-domain. Most mutations might thus affect
both RIZ1 and RIZ2 function. However, some studies have shown that the region close to
the C-terminal of PRDM2 is important for PR-binding, and thus for the PR-domain activity
[589, 590]. As an example, this terminal region of PRDM2 has been shown to be necessary
for binding to the histone methyltransferase PR-Set7, and for conferring cell cycle regulat-
ory and tumour-suppressive functions [589]. In my dataset, a cluster of mutations is present
in this area (Fig. 3.13). Additionally, the Rb-binding capability of PRDM2 does support
a link to downstream CDKN2A functions [555]. Due to this shared substrate, silencing of
RB1 through both CDKN2A and PRDM2 would likely be functionally redundant, and not
convey an additional tumour-promoting benefit. This could therefore explain the mutually
exclusive pattern of CDKN2A and PRDM2. Experimental validation to assess if silencing
of PRDM2 could substitute for CDKN2A loss can be tested using the following steps: First,
the physical interaction between PRDM2 and RB1 can be verified through protein pull-down
experiments or using a proximity ligation assay, for example. Next, the physiological ef-
fect of PRDM2 loss in melanocytes can be examined through cellular senescence assays, to
check whether senescence can be bypassed when PRDM2 is silenced. This would suggest
loss of PRDM2 gives the cell cancerous properties similar to that of CDKN2A loss. Finally,
to evaluate whether loss of both genes simultaneously is redundant for the cell, is more chal-
lenging. One possible method is to knock out both genes or either gene separately in vitro
or in vivo, to then compare cell growth, death or tumour growth in mice.
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Figure 3.13: Mutations along the RIZ1 protein (PRDM2). All mutations observed in
PRDM2 in the Leeds melanoma cohort is visualised by their amino acid change. For splice
variants, the closest amino acid to the splice site was used to annotate its position. Domain
information was extracted from Pfam.
3.5.3 Co-occurring gene interactions
No co-occurring gene pairs were found with my analysis, which is not surprising consid-
ering the high background mutation rates in melanoma. Many former studies claiming co-
occurrence of gene pairs have not taken the essential information regarding tumour-specific
alteration rates into account [161, 591–595]. As an example, the previously reported co-
occurrence between NF1 and RASA2, looks convincing with 73% (11 out of 15) of patients
with RASA2-variants having a simultaneous mutation in NF1 in my dataset. However, the
patients with NF1-mutations were both older and had a higher mutation rate than other
samples, consistent with previous reports [161, 526, 596]. These patients with higher muta-
tion rates will therefore have an increased likelihood of any two gene pairs showing co-
occurrence by chance, stressing the importance of accounting for mutational load. The
low patient tumour alteration rate of RASA2 in my dataset meant this gene could not be
included in my DISCOVER analysis. Therefore a final conclusion regarding the proposed
co-occurring mutation pattern between RASA2 and NF1, where tumour and sample altera-
tion rates are accounted for, cannot be confirmed nor denied from my analysis.
3.6 The role of sun exposure on driver mutations
Exposure to sunlight is an important risk factor in melanoma, whereby UV-exposure driven
tumours often have a higher frequency of mutations. Mutation densities are however not
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equally distributed across the genome, and regional differences arise as a consequence of
chromatin state [86, 478, 479, 597]. This means regions associated with a compact chro-
matin state or particular transcription factor binding, will have increased damage formation
or be less accessible to nucleotide excision repair (NER) activity. This will subsequently
cause a higher susceptibility of mutations across certain genes or regions of the genome
[598, 599].
3.6.1 Pattern of UV damage in transcription factor binding sites
UV damage has been shown to selectively enrich for mutations in regions bound by the
ETS family of transcription factors including ETS1, GABPA, ELF1, ELK4 and E4TF1
[478]. Well-established examples of recurrent promoter mutations in melanoma are as-
sociated with ETS transcription factor binding sites, with the mutation spanning the UV
damage-associated consensus binding motif CTTCCG [478, 479]. As this pattern defines
positions with elevated UV mutation vulnerability, it emphasises caution should be exerted
in implementing the pathogenic role of such variants without functional studies. Several
known recurrent variants overlapping ETS transcription factor binding sites have been dis-
covered in melanoma [600–602]; however, the pathogenic effect of such variants have not
been fully explored in the majority of cases. That being said, the presence of recurring
mutations overlapping this pattern do not rule out the importance of the genes affected, in
particular as this pattern is only seen in active transcription factor binding sites and therefore
suggests an active role of the downstream gene. I interrogated the main hotspot promoter
mutations discovered in my cohort for the presence of this pattern, and found it overlapped
with most of the top recurrent variants (Fig. 3.14). This CTTCCG pattern was found in
most frequent recurrent variants in DPH3, SDHD, NFKBIE, NDUFB9 and MRPS31. The
novel promoter mutations I discovered in AHCTF1 (Section 3.2) also overlapped with such
a binding site; however, the pattern was on the reverse strand. Again, this finding stresses the
importance of functional validation of the effect of these promoter mutations on tumouri-
genesis. On the contrary, all of the variants in RPS27 and less frequent variants in SDHD did
not appear to be linked to this UV damage-induced mechanism. TERT hotspot mutations
all lacked the CTTCCG pattern, which suggests these mutations are accumulated by other
mechanisms than UV damage. However, in the case of C228T and C250T, these mutations
create an ETS binding site instead of disrupting one.
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Figure 3.14: ETS transcription factor consensus motif pattern among recurrent pro-
moter mutations. Recurrent variants are marked red, while the UV damage-associated
CTTCCG pattern is highlighted with blue. TERT and RPS27 recurrent variants were the
only ones lacking this UV damage-associated pattern. The position in RPS27 marked with
green is a variant previously reported by others but filtered out in my analysis due to a
population allele frequency < 0.001 in ExAC.
3.6.2 Association of frequent promoter variants with sun exposure
As I confirmed the presence of the UV damage ETS motif signature spanning many re-
current promoter variants, I wanted to check whether the top recurrent promoter mutations
were enriched in primary tumours located on the head, as another indicator of sun exposure
(Fig. A.7). In line with expectations, all the top recurrent promoter variants except TERT
C250T and CC242-243TT, were highly associated with an increased mutation load (all p-
values < 0.01, univariate logistic regression). The distribution of promoter mutations were
also different across tumours arising on the head, limbs, trunk or other sites, with all top
promoter variants shown to harbour the UV damage pattern (MRPS31, DPH3, NFKBIE,
NDUFB9, AHCTF1, SDHD) showing a trend of enrichment in melanomas arising on the
head. TERT hotspot mutations are likely not associated with UV exposure, as they were not
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associated with a higher mutation load (except C228T). They also had a similar distribution
across melanomas from the head, limbs and trunk. However, a lower frequency of TERT
hotspot variants were observed in melanomas of other sites compared to those on the head,
suggesting TERT activation might not be a key event in these tumours. The RPS27 C227T
variant, which did not overlap with the ETS motif, was also more common amongst primary
tumours on the head. This suggests that variant could be linked to a UV-dependent mech-
anism not associated with the increased susceptibility of ETS transcription factor binding
sites, such as mutation load.
3.6.3 Association of frequent coding variants with sun exposure
Tumours arising on body sites with varying degrees of sun exposure have been shown to
feature distinct properties. Therefore, I also looked at the distribution of frequent coding
changes across body sites. Of the top recurrent coding variants, no variants showed a strong
preference towards the head (Fig. A.8), but a weak statistically significant trend was found
for NRAS Q61R (head vs other site), PCDHA2 S337L (head vs limbs) and TPTE S447L
(head vs limbs). In addition, RAC1 P29S, KDR R1032Q, PCDHA2 S337L and TPTE S447L
were all associated with a higher mutation burden, whereas BRAF V600E showed an inverse
correlation with mutation burden (all p-values < 0.001). BRAF V600E mutations were also
highly associated with site of primary on the trunk rather than the head (p-value = 0.001,
OR = 3.2), in line with other reports of chronically sun-exposed versus intermittently sun-
exposed sites [18, 52]. BRAF V600K tumours, which in addition to the c.1799T>A base
change resulting in the BRAF V600E variant, has a concurrent c.1798G>A base change, ap-
pears to show a different mutation pattern. In concordance with other studies, BRAF V600K
tumours had a higher mutation load than BRAF V600E tumours (p-value = 0.0007, OR =
1.02); however, in contrast to other studies [603, 604], BRAF V600K tumours were not as-
sociated with sun-exposed sites compared to BRAF V600E or BRAF wild-type tumours. In
addition, it has been proposed that the higher mutation load found in BRAF V600K tumours
compared to BRAF V600E tumours might result in a better response to immunotherapy in
these patients [605]. However, my analysis shows that although BRAF V600K tumours
have a higher mutation load compared to BRAF V600E, comparing the respective groups to
the rest of the cohort, BRAF V600K patients did not show a significantly higher mutation
burden, while BRAF V600E tumours correlated with a lower mutation burden (Fig. A.9).
Therefore, making the comparison between the two BRAF variants only, would not reflect a
melanoma patient cohort in its entirety and my data do not suggest that patients with BRAF
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V600K alterations specifically would benefit from immunotherapy.
3.6.4 Association of mutations in driver genes with sun exposure
Finally, I also sought to understand the distribution of driver gene mutations across body
sites commonly subjected to different sun exposure levels (Fig. 3.15). Mutations in TPTE,
NF1, ARID2 and FAM58A were more associated with tumours on highly sun-exposed sites
(head) compared to intermittently sun-exposed areas (limbs and trunk), while CDKN2A-
mutant tumours showed a preference towards head over limbs and other sites but not the
trunk (Fig. 3.15). Tumours with mutations in the former four genes were also correl-
ated with a higher mutation burden (all p-values < 0.001), as expected as a consequence
of sun exposure. Additionally, tumours with mutations in TP53, MSR1, FBXW7, RAC1 ,
RQCD1 and RB1 were also associated with a higher mutation load. With the exception of
BRAF, NRAS, and tumour suppressor genes PTEN and TP53, most of the other driver genes
show a high proportion of the common UV radiation-induced C>T transitions. Mutations
in RQCD1 and RAC1 were exclusively composed of C>T mutations, an effect in part me-
diated by each frequent hotspot variant in these genes. Interestingly, all FBXW7 variants
seen in tumours located on the head were C>T events, while those arising on the limbs and
trunk showed a mix of other base changes too. The opposite effect was seen for FAM58A,
where tumours from the limbs and trunk were all C>T mutations, while one third of tumours
arising on the head had other base substitutions as well. However, these observations are
all based on few events, and inferences from these analyses should therefore be treated with
caution. Although not statistically significant, I observed RQCD1 mutant tumours had a
higher frequency in tumours of intermittent sun exposure compared to those on chronically
sun-exposed sites, contradicting a previous study of this gene in primary melanoma and cell
lines [474].
Mutations in the main melanoma genes BRAF and NRAS are generally thought of as
early events in melanoma progression [47], and it is therefore not surprising to find these
were not associated with sun exposure. MAP2K1 mutations are probably also linked to UV-
independent MAPK pathway activation, alongside BRAF and NRAS. PTEN, which was not
found associated with sun exposure or particularly high proportions of C>T alterations, was
interestingly completely absent in melanomas arising on sites other than the head, limbs and
trunk. In Section 4.3, I also discussed the absence of PTEN mutations in triple wild-type,
acral and mucosal melanoma. This is intriguing, as it is one of very few driver genes which
appears to be constricted to a patient population where sun exposure usually plays a larger
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role (non-acral cutaneous melanoma), yet appears to arise independently of UV damage
mechanisms.
Previous smaller studies have found alterations in KIT to occur exclusively in melano-
mas of acral and mucosal origin, or skin with chronic sun-induced damage [604, 606, 607].
KIT mutations in my cohort were distributed amongst patients with tumours across all the
four categories of body sites; however, KIT amplifications were found exclusively in melan-
omas arising on the head and other sites. This is an interesting observation, as I expected
the mechanism driving rarer subtypes of melanoma to be distinct from those arising as a
consequence of UV damage. Focal gains of CCND1 and CDK4 have also been reported
to occur more frequently in tumours with chronic sun-induced damage [54, 428]; however,
this result was not replicated in my larger cohort (CCND1 head n = 2, limbs n = 6, trunk n
= 7, other n = 5 and CDK4 limbs n = 1, trunk n = 2, other n = 2).
Melanomas arising on frequently sun-exposed sites such as the head, had a significantly
higher mutation load than those arising on limbs (p-value = 3x10 12, OR = 0.0008), trunk
(p-value = 3x10 14, OR = 0.0004) or other sites (p-value = 6x10 14, OR = 9x10 5) in a
multivariate model taking into account age (p-value = 2x10 6, OR = 1.12) which is known
to correlate with mutation load [82, 608, 609]. Furthermore, I investigated the difference
in survival depending on the anatomical site of primary tumour (Fig. 3.16). In a univarate
model using the Kaplan-Meier method and a global log-rank statistic, I observed a similar
survival curve between melanomas arising on the head and limbs; however, patients with
tumours on the trunk or other sites showed significantly worse survival. When including
other variables known to correlate with survival into a multivariate model, the only statist-
ically significant difference in survival between body sites was higher survival of patients
with tumours on the limbs compared to the trunk (Fig. 3.16B).
3.7 Evaluation of chapter aims
• Outline the landscape of mutations including the top mutated genes and copy number
alterations
– Frequent somatic mutations were profiled which include the following results:
  Primary melanomas generally have a high mutation load with a high pro-
portion of C>T mutations.
  The most frequently mutated genes include BRAF (45%), NRAS (29%),
CDKN2A (16%), TP53 (10%) and NF1 (10%).
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Figure 3.16: Survival differences between primary melanomas of different anatomical
location. A) Kaplan-Meier survival analysis stratified by the site of primary melanoma.
The global log-rank statistic is shown as well as the result from pairwise comparisons. B)
Multivariate survival analysis using Cox proportional hazards regression analysis, looking
at the site of primary melanoma together with known contributors to melanoma survival as
additional covariates.
  Promoter mutations most frequently involve TERT (37%) and DPH3 (15%).
  The top recurrent exonic variants are BRAF V600E (35%), NRAS Q61R
(16%) and Q61K (10%), RQCD1 P131L (5%), RAC1 P29S (4%) and BRAF
V600K (4%).
  Novel recurrent mutations identified include PCDHA2 S337L (2%), TPTE
S447L (2%) and AHCTF1 C271T (2%).
– Frequent copy number alterations were assessed as showcased by the following
results:
  Copy number alterations are found in most primary melanomas, with ho-
mozygous deletions being most common.
  The most frequently amplified genes were CCND1 (5%) and TERT (4%),
followed by genes located on chromosome 6p such as IRF4 (3%) and 8q
such as MYC (2%).
  IRF4 might be an interesting clinically actionable target, showcasing a po-
tential tumour cell vulnerability.
  CDKN2A was the most repeatedly deleted gene (13% of samples showed
homozygous loss across the whole gene), followed by PDCD1 (1.5%) and
PTEN (1.2%).
• Identify melanoma driver genes and important genetic interactions
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– 15 melanoma driver genes were identified in this primary melanoma cohort:
  Established melanoma driver genes were confirmed as drivers: BRAF, NRAS,
ARID2, NF1, TP53, CDKN2A, PTEN, RB1, RAC1, MAP2K1 and FBXW1.
  Genes implicated to play a role in melanoma development were identified
as driver genes: FAM58A, RQCD1 and MSR1.
  One novel melanoma driver gene was identified for the first time in this
cohort: TPTE, which is a paralogue to PTEN.
– 8 mutually exclusive gene pairs were found, potentially reflecting novel genes
involved in important oncogenic pathways:
  6 genes were mutually exclusive with BRAF, where in particular TLR4 and
EGFR might indicate an alternative activation of the MAPK pathway driv-
ing oncogenesis in these tumours.
  2 genes were mutually exclusive with CDKN2A, where PRDM2 is an inter-
esting candidate to study as both encoded proteins interact with Rb.
– No co-occurring gene pairs were identified, which could reflect the challenge of
accounting for a high background mutation rate in melanomas.
• Understand how sun exposure can shape the genetic composition in melanomas
– Primary melanomas generally have a high mutation load with a high proportion
of C>T mutations, which is particularly profound in tumours arising on sun-
exposed sites.
– UV damage targets ETS transcription factor binding sites, giving rise to recur-
rent mutation patterns in promoter regions, which highlights the importance to
further study the oncogenic impact of the mutations involved.
– BRAF V600E mutations were inversely correlated with mutation load, and more
frequently arise on body sites with intermittent sun exposure.
– 11 of the 15 driver genes showed links to sun exposure. The exceptions were
PTEN and three MAPK pathway genes: BRAF, NRAS and MAP2K1, potentially
reflecting a difference in melanoma development in these tumours compared to
UV damage-associated melanoma.
Chapter 4
Dysregulated biological pathways in
primary melanoma
4.1 Introduction
It is now widely established, that studying the underlying genetic events in cancers, brings
valuable insights into the key mechanisms driving disease development. Additionally, it
helps us understand the complex molecular heterogeneity that exist between tumours. Al-
though previous efforts have taught us a great deal about melanoma biology, melanoma as
a disease is incredibly complicated and we still have far more to learn about how tumour
growth is regulated. The properties a cell need to acquire in order to develop into a tu-
mour, include the ability to grow and divide uncontrollably, thereby evading regular growth
suppression and cell death mechanisms. Melanoma cells select for mutations providing
such favourable traits; therefore, by studying the genes and biological pathways altered in
tumours we can understand how tumours are wired, and reverse these mechanisms. An
overview of the genetic landscape of primary melanoma from my dataset (Fig. 4.1) shows
tremendously diverse alteration patterns between patients, with large variabilities not only
in the genes harbouring alterations, but also the total number of events impacting each pa-
tient. There are several key pathways associated with melanomagenesis, where the MAPK
pathway, PI3K/AKT pathway, and CDKN2A-associated cell cycle control are amongst the
most important and will be discussed in greater detail throughout this chapter [93, 610, 611].
Several different methods of melanoma classification exist. Melanoma in general is a
heterogenous cancer type, commonly impacted by a high burden of genetic alterations, and
often characterised by the activation of the MAPK pathway. In 2015, the TCGA network
established four genomic classes of melanoma, based on hotspot mutations in BRAF, RAS
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Figure 4.1: An overview of the genetic landscape of primary melanoma. The key al-
terations in each patient (Leeds melanoma cohort) are shown in this tile plot format. From
top to bottom the panels show: mutation load (nonsynonymous mutation load per MB),
melanoma type (cutaneous, acral, mucosal or other rare sites), coding mutations in candid-
ate driver genes, mutations in the promoter regions of genes with recurrent variants, copy
number alterations across relevant genes. The tiles are coloured by the variant consequence.
Other rare sites refers to vulval, vaginal, anal and penile primaries which could not be ac-
curately assigned as cutaneous or mucosal.
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genes or NF1. Patients without mutations in these genes were classified as triple wild-type.
Another classification approach is based on histopathological presentation [56, 57, 612].
Superficial spreading, nodular, lentigo maligna and acral lentiginous are some of the most
common types of melanoma, which are often described together with other less common
subtypes arising from the skin, as cutaneous melanoma. Acral melanoma differs from the
former three by its presentation on non hair-bearing skin such as the palms, soles and under
the nails. Occasionally, melanoma can also arise in the eye or from mucosal membranes,
and is then termed uveal or mucosal melanoma, respectively. In this chapter, I will examine
the composition of genetic alterations across patients belonging to the subgroups of these
two melanoma classification systems. Finally, I will also explore how genetic alterations
can affect the immune response in these patients.
Unless otherwise stated, all statistical analyses of gene associations comprising two cat-
egorical variables (i.e. the association of BRAF mutation with site of primary melanoma)
were done using logistic regression. In the cases with one categorical and one continuous
variable (i.e. the association of BRAF mutation with mutational load), linear regression was
used instead. All analyses were univariate, with their reported p-value and odds-ratio (OR)
without multiple testing correction, except when elsewise explicitly indicated.
4.1.1 Chapter aims
The aim of Chapter 4 is to study the heterogeneity of melanomas:
• Analyse the different genetic changes across melanoma subtypes
• Investigate the main genetic alterations and signalling pathways altered in different
tumours
• Assess the impact of genetic alterations on the immune response in treatment-naive
patients
• Evaluate the possible prognostic potential of genetic alterations
4.2 Analysis of mutational subtypes and pathway altera-
tions
Mutations in key MAPK components are important events towards melanoma development.
Hotspot mutations in BRAF and the RAS genes NRAS, HRAS and KRAS were completely
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Figure 4.2: Melanoma subtype variant distribution. BRAF, RAS and NF1 mutations in
the Leeds melanoma cohort. Top panel: Distribution across patients of known hotspot muta-
tions in BRAF, NRAS, HRAS and KRAS and any mutation in NF1. Bottom panel: Proportion
of specific variants in BRAF, NRAS and nonsynonymous mutations in NF1 in the Leeds
melanoma cohort. Nonsynonymous and promoter variants were counted.
mutually exclusive (Fig. 4.2). Most non-missense mutations in NF1 followed a mutually
exclusive pattern with BRAF and RAS hotspot mutations; however, there were a few oc-
currences where both genes were co-mutated. This is consistent with previous studies of
melanoma [73, 85, 161], and might be due to the presence of less damaging NF1 variants
(discussed in Section 3.5.1). The majority of BRAF variants were V600E, whilst a small
proportion had V600K alterations. For NRAS, mutations in codon 61 were the most com-
mon, followed by a few percent of patients showing mutations in codon 12 and 13. The
tumour suppressor gene NF1 was mainly affected by loss of function mutations, represen-
ted by nonsense, frameshift variants or mutations in positions affecting splicing.
4.2.1 Sambar: Pathway-level mutational subtypes
Patient BRAF mutation status is used to inform targeted therapy decisions in the clinic
[207, 613], but unfortunately, the current established mutational subtypes in melanoma can
not distinguish between patient outcome [73]. Therefore, I set out to investigate if my muta-
tional data can be used to outline further, more defined, mutational subtypes, that could
partly explain the biological or clinicopathological differences among patients. The struc-
ture of these analyses were three-fold: First, I strived to compare the new classes with
currently established mutational subtypes in melanoma, to understand the value of further
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dividing patients based on mutational profiles. Second, I explored the differences between
the new classes on a pathway-level, to understand how patients could be distinguished based
on the composition of genetic alterations in their tumours. Lastly, I set out to test if these
new classes could be used to identify particularly favourable or adverse patterns of genetic
alterations in terms of patient survival.
This work was done in collaboration with Dr. Marieke Kuijjer (Section C.1), who de-
veloped the tool Sambar, which utilises mutation data projected on a pathway-level to clas-
sify patients into subtypes [614]. Sambar successfully grouped 85% of all patients into six
classes based on the presence of pathway-associated mutations (Fig. A.10, Table A.1).
NF1-mutant and triple wild-type tumours comprised a large proportion of the samples
which could not be subtyped. NF1-mutant patients are often older, harbouring a higher
number of total mutations, which could overcrowd and complicate the clustering algorithm,
explaining why they were particularly difficult to subtype. 17 of the 84 patients (20%)
that could not be subtyped had a nonsynonymous mutation load above 20, with several
patients showing very high mutation burden (Fig. 4.3). Triple wild-type patients on the other
hand, reflect the other extreme - often affected by very few mutational events, which would
provide too limited data for subtyping purposes. All 17 cases where no nonsynonymous
mutations were found, and an additional 7 each having 5 or less nonsynonymous mutations
in total (29%), were triple wild-type melanomas. To summarise, I can conclude at least
50% of the tumours unsuccessfully subtyped were likely due to them having very high or
low numbers of mutations.
4.2.2 Tumour distribution into Sambar classes
Sambar clustered the patients into six groups comprising three larger (black, red, green) and
three smaller (blue, cyan, magenta) classes (Fig. 4.3). To compare the new classes with the
previously established, known mutation subtypes in melanoma, I looked at the distribution
of BRAF, NRAS, NF1 and WT subtypes across the Sambar classes. The black Sambar class
almost exclusively contained wild-type patients, reflecting the distinct molecular compos-
ition of these patients. Previous research has shown triple wild-type melanoma patients,
compared to other subtypes, have low numbers of mutations, different driver genes and a
larger proportion of genetic alterations other than mutational events [73, 91, 615]. My data
strengthens these findings, as the mutational composition of these patients clustered them
together into one separate group.
The other five Sambar classes were more difficult to interpret, although they seem to
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be driven not only by pathway data but also mutation load, with the cyan and magenta
clusters in particular showing high mutation burden. Patients with hotspot mutations in
BRAF seemed to dominate the red and blue clusters, which indicates that there is hetero-
geneity within the BRAF subtype, as a small portion of BRAF-mutant patients presented a
different pathway mutation composition. Similarly, the magenta group contained largely the
NRAS subtype, but NRAS hotspot mutant patients also comprised large fractions of the green
and cyan classes. In view of these results, I conclude that the underlying genetic events in
primary melanoma patients are very heterogenous, and cannot be purely explained with the
currently defined mutational subtypes.
Interestingly, NF1-mutant samples were mainly distributed into three classes, each show-
ing similarities with the BRAF (blue), NRAS (magenta) and WT (black) groups, respectively.
This indicates NF1-mutant samples do not comprise a distinct molecular subtype by itself.
However, as over half of the NF1-mutant samples in my cohort could not be subtyped via
Sambar, many of which show very high mutation burden, it cannot be completely ruled
out that a subset of NF1-mutant patients belong to a separate group with a different mo-
lecular background. In my opinion, it is also important to distinguish between some triple
wild-type patients and NF1-mutant patients, because the genetic composition between these
groups of patients is vastly different. While triple wild-type patients often show very few
mutations, NF1-mutant patients are rather characterised by a much higher mutation load. It
is possible, this latter group is driven by the high mutational burden, which distinguishes
them from other patients, rather than attributing this separation specifically to harbouring
a NF1-mutation. To conclude regarding NF1-mutant patients, my analysis suggest these
patients can be divided into four subsets, of which the first three groups show similarities
with BRAF, NRAS and WT subtypes, respectively, while the fourth group is driven by high
mutational load.
4.2.3 Pathways operating in the Sambar classes
Next, I wanted to see which pathways were enriched in each Sambar class. For this ana-
lysis, Dr. Marieke Kuijjer made word clouds using the following steps: First, she assigned
Sambar class-specific pathways by selecting pathways mutated in over 95% of all samples
of one specific Sambar class, but for which less than 5% of samples in other Sambar classes
showed mutations. Next, she calculated the number of times a specific word was observed
per Sambar class in relation to the total number of words observed in that class. Finally, a
correction was performed by normalising the word frequency to the background mutation
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Figure 4.3: Mutational subtypes identified using Sambar. A) Six clusters identified by
Sambar based on the composition of pathway mutations in the tumours (Figure prepared
by Marieke Kuijjer). B) The proportion of known mutation subtypes across the six Sambar
classes. C) The mutational load across the six Sambar classes. D) Word clouds comprising
enriched words associated with the pathways of the green, blue, cyan and magenta Sam-
bar classes (Figure prepared by Marieke Kuijjer). E) Survival curves showing melanoma-
specific survival stratified by Sambar class. F) Survival curves showing melanoma-specific
survival stratified by the current known mutation subtypes in melanoma.
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pathway list. For a more detailed description, see the methods section of Marieke’s paper
[614]. Unfortunately, the black and red classes did not yield any words, whilst the green
class did not provide any informative words (Fig. 4.3D). However, the remaining three
classes did show some specific pathway-enrichment of certain words. CD28, an important
co-stimulatory receptor of T cells, is shared between the blue and cyan class, although it is
more pronounced in the blue class. This indicates an immune component is active in these
groups. The blue class also seem to be dominated by PI3K, IL2 and to some extent AKT, the
downstream effector molecule to PI3K, which suggests the PI3K pathway is altered in this
group of patients, potentially through CD28-mediated activation [616, 617]. The cyan class
on the other hand is enriched in RAC1, integrin and S1P, which could suggest an enhanced
importance of cell adhesion, migration and trafficking [618–623]. Lastly, the top enriched
words in the magenta class were SHC and B, reflecting SHC-mediated events and B cell
signalling. This analysis concludes the heterogenous landscape of mutations in primary
melanoma, showing a diverse range of biological pathways playing a role in different pa-
tients. The currently established mutational subtypes in melanoma do not comprehensively
explain the underlying genetic events is these patients. The Sambar classes further unravels
patient’s biological differences, by suggesting one group of patients with enriched altera-
tions in the PI3K pathway (blue), a second group showing links to cell migration (cyan),
and a third group of patients having mutations associated with SHC and B cell signalling
(magenta).
4.2.4 Prognostic value of the Sambar classes
Finally, I also wanted to check if Sambar could help identify mutational differences between
patients impacting their survival. The established mutational subtypes in melanoma are not
capable of predicting patient survival, in the Leeds melanoma cohort (Fig. 4.3F) or in
other cohorts [73, 624, 625]. Unfortunately, the six Sambar classes also failed in providing
prognostic value in a univariate model (Fig. 4.3E). I also investigated whether any of the
classes were dominated by other clinicopathological features, such as site of primary melan-
oma, sun exposure, ulceration, Breslow thickness and relapse. However, there appears to
be no bias towards any of the tested variables in any one class. This suggests the diversity
in mutation composition, does not in itself explain the observed difference in clinical char-
acteristics. However, this does not completely rule out the possibility of genetic alterations
contributing to such factors. Little research to date has focused on building models based on
extensive somatic mutation data [614], and such analyses are especially difficult to do for
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melanoma because of the high background mutation rate. Other groups have successfully
shown alterations in a small number of genes to associate with survival probability, as well
as using transcriptomic data to find biological differences amongst patients of a particular
cancer type [73, 626–631]. It is possible more sophisticated methods capable of separat-
ing key mutations from the excess of uninformative alterations are necessary to tease out a
true signal. Furthermore, it would be valuable to also explore the possibility to improve the
current clinical prognostic factors with information regarding the mutational landscape of
melanoma.
4.2.5 Prognostic value of other pathway-level alterations
To conclude my pathway-level analysis, I wanted to check if any prognostic effect, unrelated
to the Sambar classes, could have been missed. I used a simple model whereby I defined
in a binary format whether a patient had alterations in any of the MSigDb canonical path-
ways (file “c2.cp.v5.0.edges.gmt”) individually, and then I did a log-rank test to detect if
alterations in any one pathway could explain a patient’s survival difference. After adjusting
for multiple testing (n = 1025) and removing pathways where the alteration rate were below
5%, the only pathway falling below the FDR-adjusted p-value threshold of 10% was the Re-
actome T cell receptor signalling pathway (Fig. 4.4A). The increased risk associated with
mutations in the Reactome TCR signalling pathway held true also in a multivariate model
taking into account covariates known to be associated with survival (Fig. 4.4B). It would be
intriguing to test these patterns in other datasets of primary melanoma.
4.3 Genetic changes across melanoma subtypes
In the Leeds melanoma cohort, 90% of patients were diagnosed with a subtype classified
as non-acral cutaneous melanoma, but there were also cases of acral (n = 24) or non-
conjunctival mucosal (n = 7) melanoma. Additionally, 13 patients had vulval, vaginal, anal
or penile melanoma. As their clinical records did not state whether the primary tumour
arose on the skin or mucosal surfaces, I have grouped these separately as melanoma from
rare sites.
In comparing the genetic alterations present across different subtypes of melanoma, it is
clear a distinction can be made between cutaneous and non-cutaneous melanoma (Fig. 4.5).
Firstly, the number of mutational events per patient, although varied, were a lot higher in
patients with non-acral cutaneous melanoma, with patients showing as high as 72 nonsyn-
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Figure 4.4: Survival analysis by mutations in the Reactome TCR signalling pathway. A)
Kaplan-Meier survival analysis stratified by presence of mutations in genes of the Reactome
TCR signalling pathway. The FDR-adjusted p-value was computed after correcting for
multiple testing across all 1025 pathways analysed. B) Multivariate survival analysis using
Cox proportional hazards regression analysis, looking at the presence of mutations in genes
of the Reactome TCR signalling pathway together with known contributors to melanoma
survival as additional covariates.
onymous mutations per MB. The mutation load in non-acral cutaneous melanoma samples
(average 5.4 mutations per MB) were significantly different from that of acral (average
0.83 mutations per MB, Mann-Whitney test, p-value = 7.5 x 10 10) and mucosal (average
1.5 mutations per MB, Mann-Whitney test, p-value = 0.008) melanoma. This observation is
however not surprising [632], as tumours arising on sun-shielded body sites would not show
the high UV mutation pattern of melanomas arising on sun-exposed locations. Secondly,
mutations in candidate driver genes were more sparse in acral and mucosal melanoma com-
pared to non-acral cutaneous melanoma. This is likely a consequence of lower mutation
burden but reflects a difference in disease biology between these melanoma subtypes.
4.3.1 Mucosal melanoma
Hotspot mutations in BRAF are the most frequent somatic changes in non-acral cutaneous
melanoma patients, whereas mucosal melanoma patients completely lacked BRAF muta-
tions, and only one patient had a high level amplification of BRAF. No recurrent mutations
were found in mucosal melanoma samples, and only one mutation each was found in NRAS
(Q61R) and in NF1 (M817V). In contrast, genes recurrently mutated in mucosal melanoma
samples include LZTR1 (n = 3), ATRX (n = 2) and TP53 (n = 2). Single cases of coding
mutations were also observed in MAP2K1 and CDKN2A. Activating mutations in GNAQ,
GNA11 and SF3B1 commonly found in uveal melanoma, with few cases reported in mu-
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cosal melanomas [91, 633–636], were completely absent in my cohort of mucosal melan-
oma. SF3B1 was amplified in one sample. Two samples showed oncogenic alterations in
TERT, with one being a hotspot mutation (C250T), and the other a high level amplification.
Over 50% of the mucosal melanoma samples had high level amplifications of chromosome
8q, including genes such as MYC (n = 3), PREX2 (n = 4), TRPA1 (n = 4) and NDUFB9 (n
= 3). Only one case of a homozygous deletion was found amongst the mucosal melano-
mas, targeting PTEN with one patient affected. Previous reports of mucosal melanoma have
shown frequent KIT alterations [606, 607]; however, the small number of mucosal samples
in my cohort showed neither KIT mutations nor amplifications. However, when examining
the group of tumours from other rare sites, cases where it could not be determined whether
the tumour originated on mucosal surfaces or the surrounding skin, I found another case of
a MYC amplification. Additionally, one case harbouring a KIT amplification and another
with both a coding KIT mutation and high level amplification in the same patient were also
discovered. Furtheremore, I also found two cases of coding mutations in SF3B1. These
findings suggest genetic changes in KIT and SF3B1, if present in mucosal melanoma, might
be more common in tumours of genital origin.
4.3.2 Acral melanoma
Only small cohorts of acral melanomas have comprehensively studied a larger number of
genes to date [91, 637–639]. Those studies report mutations affecting key members of the
MAPK pathway such as BRAF, NRAS and NF1 but also genes less frequently mutated in
non-acral cutaneous melanoma. Recurrent alterations affecting KIT [606, 607, 638] and
CDK4 pathway genes [640] have been reported, as well as an abundance in copy number
alterations and structural variants in general [91]. The genetic changes observed in acral
melanomas of the Leeds melanoma cohort included six cases of BRAF V600E, two cases of
NRAS Q61K and two cases of TERT C228T promoter mutations. Although the frequency of
these changes were lower compared to melanomas originating from non-glabrous skin, this
still suggests the genetic drivers in acral melanoma are more similar to non-acral cutaneous
melanoma than mucosal melanoma. The top mutated genes in acral melanoma were BRAF
(n = 8), TTN (n = 7) and KIT (n = 3). The most frequent copy number aberrations affect-
ing acral melanomas were amplifications targeting chromosome 11q, harbouring CCND1
and GAB2 (n = 5), followed by chromosome 8q where MYC is located (n = 3). TERT was
found amplified in three samples, while KIT and CDK4 were amplified in two samples re-
spectively. One of the samples with KIT alterations showed the presence of both a mutation
and high level amplification. Two out of three patients with MYC amplifications showed
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co-presence of CCND1 amplifications. Homozygous deletions were found in CDKN2A af-
fecting two patients with acral melanoma. Interestingly, homozygous deletions were also
found in genes associated with increased risk of developing cancer: the breast cancer sus-
ceptibility gene BRCA1 and the familial melanoma gene BAP1 were each found deleted in
one patient.
Figure 4.5: Key genetic alterations in acral, mucosal and other rare subtypes of melan-
oma. Tile plot showing an overview of the genetic alterations for each patient with acral,
mucosal and other rare subtypes of melanoma. From top to bottom the panels show: muta-
tion load (nonsynonymous mutation load per MB), melanoma type (acral, mucosal or other
rare sites), and important genetic alterations in candidate driver genes coloured by their
respective variant consequence.
4.3.3 Copy number profiles across major melanoma subtypes
To further study copy number alteration differences between melanoma subtypes, I looked
at a stratified genomic overview of such alterations by visualising the proportion of all seg-
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ments which differ more than 0.6 from a sample’s ploidy (Fig. 4.6). Striking similarities
were found between acral and non-acral cutaneous melanoma, where the copy number pro-
files looked almost identical. The acral melanomas had slightly more alterations including
more frequent amplification of 1q and 8q, and deletions in 6q and 11q. Mucosal melanomas
were also found to have abundant copy number changes, with 100% of samples in particular
showing amplification of 6p and 8q. Similarly to acral melanomas, a high number of mu-
cosal samples showed amplifications in 1q and deletions in 6q. Mucosal melanomas were
also enriched in deletions affecting the X chromosome; however, this is likely a bias because
all patients of this cohort presented with mucosal melanoma were female. The other rare
sites group of melanoma samples showed a copy number profile with resemblance to both
cutaneous and mucosal melanoma.
4.3.4 Copy number profiles across established mutational subtypes
To disentangle differences between patient groups of non-acral cutaneous melanomas, I also
looked at the whole genome copy number profiles of each mutational subtype BRAF, RAS,
NF1 and WT. Most subgroups had some distinct copy number alterations specific for re-
spective subtype. The BRAF subtype showed a sharp peak comprising samples which had
deletions in chromosome 10, which was not seen amongst the other subtypes. The top al-
terations in the NRAS subtype were amplifications of chromosome 1q, 6p and 8q, thereby
showing similarities with the acral and mucosal subtypes of melanoma. NF1-mutant melan-
omas showed a skewed copy number profile favouring amplifications across chromosome
5, as well as deletions targeting 11q and 17p. In contrast to the literature, the WT group
did not seem to harbour abundant copy number alterations compared to the other subtypes
[73, 85, 91]. However, the design of the copy number probes for my project allowed only
for analysis of focal copy number alterations across specific genes, and therefore events
outside of these regions could not be studied at high resolution. In addition, I did not invest-
igate complex structural variants such as gene fusions, rearrangements or larger insertions.
Therefore, it cannot be concluded whether such genetic aberrations not analysed as part of
this project would contribute to the pathogenesis in this group of patients, as proposed by
other researchers [73, 85, 91].
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4.4 The MAPK pathway
Gain of function mutations activating the MAPK pathway are key events in progression to-
wards melanoma development, leading to uncontrolled cell proliferation [102, 103, 641].
Following stimulation of receptor tyrosine kinases such as KIT, the cascade starts with the
stepwise activation of key signalling molecules RAS and RAF, which sequentially phos-
phorylates MEK and thereafter ERK, resulting in the transcriptional activation of genes
involved in promoting cell proliferation [642, 643], survival [644], and differentiation [645,
646]. Activation of the MAPK pathway is the most common alteration found in melanoma
patients, with approximately 40% of patients in the Leeds melanoma cohort having obtained
a recognised activating mutation in BRAF, and another 30% of patients affected by hotspot
mutations in NRAS. In contrast to other cancers which are often regulated by KRAS muta-
tions [647, 648], NRAS is the dominant RAS gene altered in melanoma. This could reflect
differences between genes in oncogenic propensity between the cells of origin giving rise to
the tumour [649]. Hotspot mutations in HRAS were found in seven patients, while for KRAS
only one case was found.
Mutations in genes encoding the downstream pathway components MEK and ERK, are
less frequent in melanoma and other cancers, possibly owing to redundancy when the com-
monly altered BRAF or NRAS genes are already activating the cascade. In the Leeds melan-
oma patients, MAP2K1 and MAP2K2, encoding MEK1 and MEK2, were mutated in 4.6%
and 2.3% of patients, respectively. Several recurrent mutations were found across MAP2K1,
with amino acid position 124 of MAP2K1 altered in 10 patients, including 7 patients with
the P124L variant and 3 patients with the P124S variant. Additionally, a missense muta-
tion targeting E203K, a 6 bp in-frame deletion of L101-E102 and amino acid position 53
(single cases of F53L and F53S) were mutated in two patients respectively. In the TCGA
melanoma cohorts (Pan-cancer and SKCM) [96], amino acid 124 and 203 of MAP2K1 were
the top altered positions. Additionally, the TCGA pan-cancer cohort reports recurrent in-
frame deletions targeting amino acid position 102 and 103, suggesting the positions around
amino acid 102 might be important for activation of the MAPK pathway through MEK1.
All of the recurrent mutations in MAP2K1 found in my primary melanoma samples, with
the exception of the specific L101-E102 in-frame deletion which has not been tested to
my knowledge, have been shown to cause constitutive activation of the MAPK pathway
[650, 651]. Deletions targeting amino acid position 101-102 have been reported to increase
ERK phosphorylation [651], therefore this in-frame deletion is likely to also induce MAPK
signalling. No positions across MAP2K2 were recurrently mutated; however, one F57C
96 Dysregulated biological pathways in primary melanoma
mutation which corresponds to position F53 in MAP2K1, has been shown to increase phos-
phorylation of ERK [652]. In addition, the TCGA SKCM cohort reported two variants in
the same position, albeit the amino acid change differed (F57V and F57L). Both of these
alterations were deemed as likely oncogenic by OncoKB [653]. Mutations in both MAP2K1
and MAPK2K2 were never found in the same patient (Fig. 4.7).
Mutations in MAPK3 (ERK1) and MAPK1 (ERK2) are rare both in melanoma and other
cancers [73, 96], therefore I chose not to include them in my bait design. Hence, I cannot
study alterations affecting these genes in my cohort. Sporadic mutations in these genes
affected less than 2% of melanoma patients in the TCGA SKCM cohort.
NF1, a tumour suppressor and negative regulator of RAS, is one of the top mutated genes
in melanoma, and has gained increasing interest the past five years [654]. It has now been es-
tablished as an important regulator contributing to melanoma development by activation of
the MAPK pathway [73, 161]. NF1 loss of function mutations mainly occurred in samples
which did not harbour hotspot mutations in BRAF and NRAS (Fig. 4.1). A strong correlation
was also observed between NF1 mutations and higher mutation burden (univariate logistic
regression p-value = 4.62 x 10 13, OR = 1.19), suggesting a UV-associated disease mech-
anism in these patients. Patients with NF1 mutations were also found to be older (univariate
logistic regression p-value = 2.23 x 10 4, OR = 1.06), which could be another factor adding
to the connection with high mutation load. A weak correlation was observed between NF1
mutation and site of primary melanoma, with tumours arising on sun-exposed areas such
as the head being more common than those arising on limbs (univariate logistic regression
limbs over head p-value = 0.0017, OR = 0.26) or the trunk (univariate logistic regression
trunk over head p-value = 0.03, OR = 0.42). This observation led me to explore a possible
correlation with sun sensitivity, and indeed NF1 mutations were more prevalent in patients
reported to be sensitive compared to non-sensitive (univariate logistic regression p-value
0.0055, OR = 2.65). Taken together into a multivariate model: mutation load, age and sun
sensitivity were all correlated with NF1 mutation (age p-value = 0.04, OR = 1.04, mutation
load p-value = 1.61 x 10 9, OR = 1.18, sun sensitivity p-value = 0.006, OR = 3.11). I there-
fore hypothesise, that NF1 mutations arise as a consequence of UV damage in people who
are sensitive to sunburn.
RAC1, another established melanoma oncogene, was mutated in 23 primary melanoma
samples, of which 19 were the known gain of function alteration P29S, which has been
shown to increase cell proliferation through increased ERK phosphorylation [85, 155]. Al-
terations in RAC1 have been associated with UV exposure; however, in my dataset RAC1
changes only weakly correlated with mutational load (univariate logistic regression, p =
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0.013, OR = 1.04). Tumours with this alteration were not associated with either gender, site
of primary melanoma, sun sensitivity, suntan or sunburn susceptibility. RAC1 was mutated
in only one melanoma from rare sites, and mutations were completely absent in the triple
wild-type, acral and mucosal melanoma subtypes (Fig. 4.1).
Receptor tyrosine kinases such as KIT are important upstream components of the main
members of the MAPK signalling cascade. One known oncogenic recurrent mutation in
KIT, L576P, was found in five patients [655, 656]. Single cases of V559A, K642E and
N822Y mutations overlapped with TCGA-reported melanoma variants, with reported onco-
genic or potential oncogenic capability [653]. Additionally, one in-frame deletion affecting
E554, was located within a cluster of other recurrent oncogenic deletions in gastrointestinal
stromal tumours [96]. Mutations targeting KIT have been shown by previous studies to be
less prevalent in non-acral cutaneous melanoma compared to other subtypes [91], except for
tumours arising on chronically sun-damaged skin [606], or in triple wild-type melanomas
[73]. In my cohort, this observation was in agreement with previous studies. Out of 19
KIT mutations, 1 occurred in the BRAF subtype and 5 in the RAS subtype (5 with NRAS
and 1 with HRAS). Two patients showed co-mutated KIT and NF1, five triple wild-type pa-
tients had KIT mutations, and the remaining five patients had melanomas classified as acral
or melanoma from other rare sites. Again, because of the high prevalence of BRAF and
NRAS mutations activating the MAPK pathway among the non-acral cutaneous melanoma
patients, additional mutations of KIT would be excessive and not selected for. However, this
does suggest gain-of-function mutations in KIT might be important in wild-type and rarer
subtypes of melanoma in driving tumourigenesis through activation of the MAPK pathway.
It is intriguing to find KIT mutations in such a diverse range of tumours: from high mutation
load sun-exposed tumours to rarer melanomas arising on sun-protected sites. This further
exemplifies the complexity and disease heterogeneity of melanoma.
KIT might be the most important receptor tyrosine kinase in the context of melanoma;
however, there are other upstream receptors of the MAPK pathway which are mutated in
melanoma (Fig. A.11). Mutations in these receptor tyrosine kinases were of a mutually
exclusive pattern; however, a larger fraction of co-mutated genes were observed with higher
mutation burden, such as in the NF1-mutant patients. This suggests the presence of muta-
tions in multiple receptor tyrosine kinases are not selected for, yet does not provide a disad-
vantage to the tumours.
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4.5 The PI3K/AKT pathway
Activation of the PI3K/AKT pathway is another crucial step towards melanoma develop-
ment [99, 118, 657, 658], conferring enhanced cell proliferation and survival [100, 118].
Although the PI3K/AKT pathway is often described as an independent route towards melan-
oma progression, there are several components overlapping with other important pathways,
most notably the MAPK pathway, including receptor tyrosine kinase activation and regula-
tion through RAS proteins.
With the exception of RAS, which modulates both the MAPK and PI3K/AKT pathway,
melanomas seem to activate the PI3K/AKT pathway mainly through inactivating mutations
or deletions of PTEN [73, 85, 91, 132, 659]. Mutations in PIK3CA, which encodes the
p110a catalytic subunit of PI3K, or overexpression of AKT3 have also been reported but
are less frequent [660–662]. In my cohort of primary melanomas, the key components
of the PI3K/AKT pathways, including RAS, were modulated through mutation, high level
amplification or homozygous deletion in 55% of all tumours (Fig. 4.8).
PTEN was altered through mutation or copy number loss in a total of 153 samples (38%
of all samples analysed for both mutation and copy number events), including 31 samples
where the gene was either mutated or homozygously lost, emphasising the essential role
PTEN has in controlling oncogenic processes. Of the class IA PI3Ks: PIK3CA, PIK3CB
and PIK3R1 were possible to study due to my sequencing design. No recurrent exonic
mutations were found in PIK3CA, and of the eight exonic mutations found, two single cases
were in previously discovered hotspot positions [663, 664], although none included the most
common E545K variant [96, 665]. PIK3CB and PIK3R1 were altered in nine samples each.
AKT1, AKT2 and AKT3 were mutated in four, seven and five samples, respectively, with no
shared variants between patients. The known oncogenic hotspot E17K was altered in one
case in AKT1, while both AKT2 (3 out of 7) and AKT3 (3 out of 5) had altered amino acid
positions overlapping with reports from other cancer studies [73, 96]. Of the AKT genes,
only AKT3 was amplified (n = 5), and these cases were free of AKT3 mutations. Most
mutations targeting the main PI3K/AKT pathway components were mutually exclusive (Fig.
4.8), emphasising the central role of these genes in activating this pathway. Additionally,
this shows that excessive stimulation of this pathway is unnecessary for the development of
melanoma in these cases. Interestingly, no cases of PTEN mutations were found in triple
wild-type melanomas, an observation that I confirmed by looking at the largest study of
major melanoma subtypes to date [91]. This indicates that this group of patients might
activate this pathway in a PTEN-independent way. As TP53 and PTEN regulate each other
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in a dual dependent manner, it is not surprising to see alterations in these genes show a trend
of mutual exclusivity. PTEN is also more frequently co-mutated with BRAF compared to
NRAS, which has been observed previously [666, 667] and could reflect both the functional
redundancy double mutation of PTEN and NRAS would confer in respect to activating the
PI3K/AKT pathway, but also the pro-tumourigenic potential of dual activation of the MAPK
and PI3K pathway. Earlier studies have shown that mice only develop aggressive melanoma
after both BRAF activation and PTEN loss [668]. Using my cohort of primary melanomas,
I could show that patients with mutations in both PTEN and BRAF had a lower survival
compared to none or each mutation alone (Fig. 4.9).
Figure 4.9: Survival comparison between patients with mutations in BRAF and PTEN.
Kaplan-Meier survival curves showing melanoma-specific survival stratified by the presence
of mutations in BRAF , PTEN, BRAF and PTEN, or neither gene. The global log-rank
statistic is shown as well as the result from pairwise comparisons.
Looking at some effectors downstream of AKT (Fig. 4.8), frequent amplifications were
found in CCND1 and MYC (presented in Section 3.3.1), as well as four cases affecting
MDM2. Mutations in these genes were rare, with CCND1, MYC and MDM2 variants dis-
covered in three, six and eight cases, respectively. Only one missense mutation in MDM2
was recurrent (S304F, n = 2). TSC2 was sporadically mutated in 13 samples, mTOR in 23
samples and CTNNB1 mutations targeted 11 patients, with 2 recurrent changes (S45F n = 3
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and S37F n = 2). The mutation pattern of these effectors, both in respect to each other but
also to the upstream key regulators of pathway initiation, suggests activation of this pathway
could be successful irrespective of the specific gene targeted. Therefore, it is also not sur-
prising medical interventions trying to block enhanced signalling through this pathway have
proven extremely challenging, in particular with regards to drug resistance [98, 669–671].
4.6 CDKN2A-associated regulatory pathways
CDKN2A is arguably the most important gene when discussing melanoma development,
both in terms of familial melanoma [133, 134], but it is also one of the most frequently
silenced genes in sporadic cases of melanoma [73, 672]. This tumour suppressor gene is
also the top homozygously deleted gene in my cohort of primary melanomas. In addition
to the 50 samples with complete loss of the whole gene, 42 samples showed co-mutation
and loss of heterozygosity of the entire gene. A further 24 samples had a nonsynonymous
mutation in the gene alone, and an additional 129 samples showed loss of heterozygosity
alone across the entire CDKN2A region. This brings the total percentage of samples with
CDKN2A alterations in my cohort to 61%. Several recurrent deleterious variants in this gene
were found, including hotspot and known loss of function mutations P114L (n = 10), R58*
(n = 12), R80* (n = 11).
CDKN2A encodes two proteins with distinct functions: p14ARF and p16INK4A. The
p16INK4A protein is involved in the regulation of cell cycle progression and replicative
senescence [137], through negative regulation of CDK4 and CDK6, thus preventing com-
plex formation with Cyclin D (CCND1) and subsequent phosphorylation of Rb (RB1) [138].
Seven out of nine mutations in CDK4 clustered to amino acid positions 22 and 24 (K22M n
= 2, K22Q n = 2, R24L n = 2, R24S n = 1). Mutations at these positions have been reported
to disrupt binding to the p16INK4A protein product of CDKN2A [673], and would there-
fore circumvent its inhibitory effect and enable cell cycle progression. An additional five
samples had high level amplifications of the oncogene CDK4. CDK6 alterations in melan-
oma were less common and its tumourigenic role has not been as well-studied as CDK4
[73, 91, 674]. However, the gene was amplified in four samples and mutated in another two
samples in my cohort, in a mutually exclusive manner to both CDK4 and RB1 alterations,
which would speak in favour of its importance in tumour progression (Fig. 4.10). Amplific-
ations of CCND1 are often more frequent than mutations in this gene [73], and in my cohort
it was the top amplified gene (n = 20) whereas only three samples were affected by muta-
tions. 17 samples had alterations in RB1, with the majority being loss of function-associated






















































































































































































































































104 Dysregulated biological pathways in primary melanoma
consequences. In addition, RB1 was never mutated or lost in acral or mucosal melanomas of
my cohort. PRDM2, a gene discovered to be mutually exclusive to CDKN2A (discussed in
Section 3.5), and which has a Rb-binding domain, might therefore play a role in CDKN2A-
associated cell cycle regulation of melanoma cells. A mutual exclusivity pattern could be
seen between all key members of the p16INK4A-mediated cell cycle regulatory pathway
(Fig. 4.10). This pattern held true also for PRDM2, emphasising its potential contribution
to tumour regulation through the CDKN2A/CDK4/RB1 cell cycle regulatory pathway.
p14ARF, the alternative protein produced by CDKN2A, on the other hand has tumour-
suppressive properties through its activation of TP53 directly or through inhibition of MDM2
[139–143]. These three key components of this pathway are commonly altered in various
cancers, with a pattern of mutual exclusivity (Fig. 4.10). However, direct inactivation of
TP53 is less common in melanoma compared to other tumour types [73, 85, 91, 96, 675].
MDM2 was amplified in four samples and mutated in an additional eight. MDM4, which
also negatively regulates TP53, has been implicated in melanoma [676]; however, its overex-
pression is mainly achieved on a protein level, and would therefore not be picked up through
mutational analysis. Nevertheless, two cases of missense mutations and five samples show-
ing high level amplifications targeting MDM4 were found amongst my primary melanoma
samples, with all but one case showing mutual exclusivity with TP53 and MDM2. TP53
was mutated in 10% of my primary melanomas, with several known and recurrent loss of
function consequences [653]. No samples showed biallelic copy number deletion of the
entire gene; however, 98 samples showed heterozygous loss. As CDKN2A is frequently
silenced in melanoma, this event alone might suffice to dampen the activity of TP53 and
thereby overcome tumour suppression, which might explain the low frequency of targeted
loss of TP53 itself. Moreover, when tumours progress, more alterations might be necessary
to maintain tumour aggressiveness, which could explain why other researchers have found
higher frequencies of TP53 mutations in later stages of melanoma [48]. Several cases of
double alteration of CDKN2A and TP53 could be observed in BRAF mutant melanoma pa-
tients compared to only a few sporadic cases in most other subtypes of melanoma. This
could be the result of specific CDKN2A mutations giving rise to loss of only the p16INK4A
product, or the increased need to deactivate TP53 compared to RAS mutant tumours, which
could already modulate TP53 though the PI3K/AKT pathway (discussed in Section 4.5).
Additionally, in the absence of CDKN2A alterations, co-mutation of key members of both
the CDKN2A/CDK4/RB1 pathway and the CDKN2A/MDM2/TP53 pathway could be bene-
ficial for the melanoma, as several cases of same-patient CDK4 and TP53 alterations were
found amongst the BRAF subtype melanomas. I also observed frequent co-amplification of
4.7 Additional driver genes and the interplay between key biological pathways 105
MDM2 with CDK4 (3 out of 4 cases), another feature that might activate both CDKN2A-
associated pathways while CDKN2A itself is still functional.
4.7 Additional driver genes and the interplay between key
biological pathways
MYC and MITF are important genes encoding transcription factors which play diverse roles
through the modulation of several biological pathways. MYC is tightly regulated by a mul-
titude of transcription factors and signalling pathways including the MAPK and WNT/b-
catenin pathway, and is itself a master regulator of a great number of target genes including
CDKN2A and TP53 [677, 678]. MYC is commonly overexpressed in melanoma and other
tumour types [679], and it was amongst the top amplified genes in my dataset. MYC ampli-
fications were more frequent in rarer types of melanoma (43% in mucosal, 13% in acral and
<1% in non-acral cutaneous melanoma), consistent with other studies which have showed
a higher frequency of MYC alterations in rarer subtypes [73, 680–682]. This suggests MYC
might play a particularly important role in the progression of less common subtypes such as
acral and mucosal melanoma.
MITF is an important melanocyte master regulator, controlling a range of cellular pro-
grams including melanocyte differentiation, proliferation, and survival [683]. Mutations in
MITF are relatively rare in melanoma, but tumours tend to instead upregulate expression
through amplification, transcriptional or epigenetic modifications [646, 684]. In addition,
MITF expression has been used as a way to distinguish between different categories of
melanoma, some which has prognostic value [73, 646, 685–687]. In my primary melan-
omas, I observed very few cases of MITF alterations (amplification n = 2, mutation n =
3), but this finding does not exclude possible other mechanisms of MITF overexpression in
other tumours of my cohort. However, other researchers have reported a lower frequency of
MITF alterations in primary tumours and melanocytic nevi [646] compared to metastatic le-
sions, and this observation is in line with MITF expression correlating with more advanced
high-grade tumours [686, 687].
Genes involved in epigenetic regulation such as chromatin remodelling and histone
modification have also been implicated in melanoma. These include ARID2, EZH2, IDH1
and DDX3X. ARID2 is mutated in 8% of my samples, and show a clear tumour suppressor
mutation pattern with half of the variants being nonsense mutations. Both oncogenes EZH2
and IDH1 have recurrent hotspot variants (EZH2 Y646N n = 2, IDH1 R132C n = 13). Of
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the mutations observed in DDX3X, 83% were missense mutations.
PPP6C and FAM58A are both genes involved in cell cycle regulation and survival [517,
688], which show a positive selection mutation composition (discussed in Section 3.4).
PPP6C is a negative regulator of CCND1, and mutations in PPP6C (n = 21) occurred
only in samples which lacked detectable alterations of CCND1. Additionally, mutations
in PPP6C were found exclusively in BRAF, NRAS or NF1-mutant samples of non-acral cu-
taneous origin. FAM58A on the other hand, was mutated in 12 patients, and was found in
all mutational subtypes of non-acral cutaneous melanoma.
The emerging driver genes RQCD1 and MSR1 were altered in non-acral cutaneous
melanoma exclusively. 89% of mutations in RQCD1 were in the hotspot P131L. FBXW7,
another driver gene identified in Section 3.4, is yet another broad-acting tumour suppressor
gene, regulated by TP53 [689] and which modulates several important oncogenes includ-
ing MYC, MTOR and MITF [690–693]. Mutations in this gene were found exclusively in
patients with non-acral cutaneous melanoma.
In addition to coding changes, melanomas harbour frequent hotspot mutations in pro-
moter regions of some genes. TERT, an important driver gene both in sporadic and familial
melanoma, can be activated by amplification, but is more often activated by mutations in
specific regions of its promoter [148, 151]. TERT alterations were found in 202 samples,
and comprised of 44% C250T, 38% C228T, and 7% CC242-243TT hotspot variants, and
7% high level amplifications. All hotspot mutations were completely mutually exclusive
(Fig. 4.11). Three patients had co-occurring missense mutations and hotspot C228T vari-
ants, and a fourth patient harboured both a high level amplification and the C250T promoter
variant. Interestingly, these four patients were all of the NF1 mutant subtype, with a high
mutation burden, which suggests these missense mutations were obtained at random and do
not confer an additional advantage for the tumour cell.
Several melanoma driver genes have dual roles, and can alter more than one biological
function. NRAS is upstream and activates both the MAPK and PI3K/AKT pathway, while
CDKN2A modulates cell cycle progression and apoptosis by encoding two different pro-
teins. TP53 can be activated through a range of events, including regulation through PTEN
and the PI3K/AKT pathway or by CDKN2A and MDM2-dependent mechanisms. Further-
more, TP53 is also activated by cellular stress signals, including DNA-damage response
genes ATM and CHEK2 or hypoxia-induced mechanisms involving ATR and VHL [146].
These pathways of TP53-associated regulation are not considered to drive melanoma pro-
gression; however, they play a major role in some other cancers [694–696]. No coding
changes or copy number alterations in VHL were found; however, few cases of mutations
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were seen in ATM (n = 23, plus 1 amplification), CHEK2 (n = 12) and ATR (n = 24)[677]
in my cohort. A proportion of these alterations were found in patients which did not show
inactivation of TP53 through the more commonly altered genes PTEN and CDKN2A, which
could suggest modulation of TP53-activity in some patients might be dependent on altern-
ative pathways such as through ATM/CHEK2 or ATR/VHL (Fig. A.12).
4.8 Immunological impact of genetic alterations
With the exciting development of immune checkpoint inhibitors, and their success in treat-
ing a subset of melanoma patients, comes the endeavour to further understand and utilise
the immune system to combat cancer. Immunotherapies have had the highest success rates
in tumour types such as melanoma, non-small cell lung cancer and bladder cancer, which
share features such as a high mutation load [82]. Subsequently, tumour mutation load has
been used in immunotherapy decision-making as it has been shown to have predictive value
[220, 263, 264, 697–699]. Yet, the more mutations a tumour acquires should give the im-
mune system more chances to discover and eliminate the tumour. Therefore, I aimed to in-
vestigate whether such an intrinsic capability exist, and whether particular alterations could
disable or weaken the host immune response.
First, I tested whether mutation load would be prognostic in my cohort of primary melan-
oma patients. 507 patients were immunotherapy-naive (the 17 patients who had received
immunotherapy were excluded from the analysis). Therefore, this analysis should reflect
the baseline host capability to recognise tumour antigens. Although a trend could be seen
towards better survival in the patient group which showed the highest mutation load (Fig.
4.12), this finding was not statistically significant. My hypothesis is therefore, that the mech-
anisms the tumour employs largely disables the immune system, to an extent where this
suppressed state is incapable of tumour eradication irrespective of mutation burden. This
state can however be reversed upon administration of checkpoint inhibitors, which would
explain the benefits seen in immunotherapy-treated patients with a high mutation load.
In order for the host immune system to recognise a tumour as foreign, the acquired
mutations need to give rise to mutant peptides to be presented on the tumour cell surface.
As not all mutations would give rise to such neoantigens, my next step was therefore to study
the relationship between neoantigen burden and patient survival. This analysis was done in
two steps. First the patient HLA types were computed against the IMGT database v.3.12
using HLAssign v.3.21 [433]. Then, the pVAC-Seq pipeline (Table A.1) with NetMHCpan
v.2.8 was used to predict the MHC class I-associated neoantigen load [700]. As expected,
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Figure 4.12: The effect of mutational load on patient survival in an immunotherapy-
naive cohort of 507 patients. A) Kaplan-Meier survival analysis stratified by mutation
load grouped into top 10%, middle 80% or bottom 10%. B) Kaplan-Meier survival analysis
stratified by mutation load grouped into top 20%, middle 60% or bottom 20%. C) Kaplan-
Meier survival analysis stratified by mutation load grouped into tertiles. D) Multivariate
survival analysis using Cox proportional hazards regression analysis, looking at mutational
load as a continuous variable together with known contributors to melanoma survival as
additional covariates.
there was a high degree of correlation between mutation load and predicted neoantigen load
(Fig. A.13). Similarly to mutation load, neoantigen load also failed to explain a significant
difference in survival between patients. Additionally, tumour aneuploidy have also been
shown to correlate with immunotherapy treatment response, although this relationship is
inverse [701]. I therefore sought to test this association in my treatment-naive cohort. For
each sample, I calculated the percentage of the captured genomic length comprising gains
and losses, as defined by segments showing a log2 fold change   |0.1| [702]. The tumour
copy number burden estimate was not prognostic in my cohort (Fig. A.14), and this measure
did not correlate with mutational load (Spearman correlation coefficient rho = -0.06, p-value
= 0.24), an observation in agreement with other reports [701]. To conclude, none of the
factors mutation load, neoantigen load or copy number burden had a prognostic impact on
survival in my cohort of immunotherapy-naive patients.
Tumour mutation load and neoantigen load are measures of alterations by which the
tumour risks being detected by the immune system. Yet, tumours will only be vulnerable
towards destruction by the immune system provided the host defence is functional. One such
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measure, which can also be used to predict immunotherapy response, is the cytolytic score
[703], defined as the geometric mean of Granzyme A (GZMA) and Perforin 1 (PRF1) gene
expression. The expression of these genes are linked to the anti-cancer cytotoxic activity of
Cytotoxic T Lymphocytes (CTLs, also known as CD8 T cells) and Natural Killer (NK) cells,
as a higher cytotoxic activity is linked to more potent tumour eradication [704, 705]. As this
measure would indicate whether the patient’s immune system is active, I thought it might be
prognostic either alone or in combination with mutation load even in patients not receiving
immune-stimulating intervention. Therefore, I decided to study this variable in my cohort.
After excluding 7 patients which had received immunotherapy, analysis was possible for 311
patients for which both mutation data and gene expression data were available. The cytolytic
score did not appear to better explain a difference in survival compared to tumour mutation
load alone. Interestingly, the 311 patient subset of the original 507 appeared to show a more
visible separation of the survival curves whereby tumour mutation burden was significantly
prognostic in the 311 patient subgroup. This is likely due to tumour-specific biases such
as larger tumours yielding sufficient input material for both genomic and transcriptomic se-
quencing; however, no major differences were found between these two subsets in the main
clinical variables (Fig. A.15). Cytolytic score, categorised into high, medium and low, did
not show a significant survival difference in a univariate model; however, multivariate sur-
vival analysis with cytolytic score as a continuous variable showed a significant association
with survival (Fig. 4.13). Interestingly, grouping by both mutation load and cytolytic score
showed more distinct differences in the respective survival curves, in particular for the pa-
tients with either very high or very low mutation load. This effect was reduced by using
a broader tertile classification of cytolytic score, which suggests this observation is limited
to few extreme cases on both ends of the mutation load spectrum. Therefore, I looked into
these patients and found the low mutation and cytolytic score group to be dominated by
triple wild-type (78%), including 36% acral melanomas, which are known to be associated
with a low mutation load and poor survival [66]. Therefore, the poor survival seen in the
low mutation and cytolytic score group is likely influenced by these factors already known
to be important contributors to patient outcome. Conversely, the high mutation and cyto-
lytic score group were all non-acral cutaneous melanomas, mostly from body sites with high
UV exposure, and were all found to lack copy number deletions in key tumour suppressor
genes CDKN2A, TP53 and PTEN. To further investigate genetic alterations associated with
the cytolytic score, I performed genetic association tests for driver mutations or key copy
number alterations. Interestingly, CDKN2A mutations were associated with a high cytolytic
score (logistic regression p-value = 9.93 x 10 5, OR = 1.55), whereas CDKN2A deletions
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were linked to lower cytolytic score (logistic regression p-value = 0.011, OR = 0.74). Weak
correlations were also found between lower cytolytic scores and mutations in MSR1 (lo-
gistic regression p-value = 0.023, OR = 0.76) or RPS27 C227T (logistic regression p-value
= 0.038, OR = 0.62). Finally, activation of TERT through hotspot promoter mutation or
amplification were highly associated with a lower cytolytic score (univariate logistic regres-
sion p-value = 4.47 x 10 5, OR = 0.77).
Figure 4.13: The impact of cytolytic score on patient survival in an immunotherapy-
naive cohort of 311 patients. A) Kaplan-Meier survival analysis stratified by mutation load
grouped into top 20%, middle 60% or bottom 20%. B) Kaplan-Meier survival analysis strat-
ified by cytolytic score grouped into top 20%, middle 60% or bottom 20%. C) Multivariate
survival analysis using Cox proportional hazards regression analysis, looking at mutational
load (continuous variable) and cytolytic score (continuous variable) together with known
contributors to melanoma survival as additional covariates. D) Kaplan-Meier survival ana-
lysis stratified by both mutation load and cytolytic score, each grouped into high (top 20%),
middle (middle 60%) or low (bottom 20%). E) Kaplan-Meier survival analysis stratified by
both mutation load and cytolytic score, each grouped into tertiles defining high, middle and
low subgroups.
Furthermore, I wanted to also test whether mutations in immune-associated genes could
explain specific patient survival differences. Very few patients had alterations affecting B2M
(deletion n = 3, missense mutation n = 1, amplification n = 2), CD274 (nonsense mutation
n = 1) and CTLA-4 (no samples with alterations). Biallelic loss of B2M was associated with
poor survival (Fig. A.16); however, loss of only one allele did not show any difference. B2M
plays an essential role in antigen presentation and the anti-tumour immune response [706],
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which could explain why such alterations would have a negative effect on patient survival
in my cohort but also why other studies have linked B2M-deficiency to immunotherapy
resistance [157, 707]. However, the data from my cohort on B2M is based on too few
observations for any final conclusions to be drawn.
Tumour loss of IFN-g pathway genes mediates resistance towards anti-CTLA-4 im-
munotherapy [543]. I therefore asked, whether this mechanism would impair intrinsic host
immune responses already prior to immunotherapy, which could consequently serve as a
marker to highlight tumours that have escaped immune regulation. Neither mutation nor
copy number status of IFN-g pathway genes made a significant difference towards patient
survival in my treatment-naive cohort (Section B.3). I further investigated whether strati-
fying by mutation load or cytolytic score might make a difference, as I hypothesised that
IFN-g pathway defects should hinder IFN-g-mediated upregulation of PD-L1, subsequently
making tumours less protected against an immune response. A high mutation load or cyto-
lytic score should therefore in theory be associated with an active immune environment
where tumours with flawed IFN-g pathway signalling might be more prone to elimination.
Alterations of any kind did not show a prognostic value in my cohort (Section B.3). As
IFN-g also suppresses tumour growth and triggers apoptosis [708, 709], the relationship
between IFN-g defects, immune regulation and patient survival might be far more complex
than could be explained by my analysis.
4.9 Evaluation of chapter aims
• Analyse the different genetic changes across melanoma subtypes
– The simplest established molecular subtypes: BRAF, RAS and NF1 account for
73% of all primary melanomas in this cohort, whilst the remaining 27% were
grouped together as triple wild-type. Heterogeneity within these classes of tu-
mours is present. Based on the mutational composition in each tumour, six bio-
logical pathway-defined Sambar subtypes could be defined. 1. The black group
showed limited mutation-driven events. 2. The blue group showed an enrich-
ment in PI3K pathway-associated mutations. 3. The cyan group was dominated
by pathways associated with cell adhesion, migration and trafficking. 4. The
magenta group had an overrepresentation in SHC-mediated events and B cell
signalling. 5. The red and green groups did not yield any meaningful enrich-
ments, potentially reflecting further diversity amongst these groups.
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– Cutaneous (non-acral) melanomas are distinct from non-cutaneous melanomas
in the mutation load and the composition of genetic alterations. Cutaneous
melanomas have the highest mutation load, with BRAF mutations being the most
common genetic alteration. Non-conjunctival mucosal melanomas completely
lacked BRAF mutations and showed a different driver gene composition (recur-
rently mutated genes include LZTR1, TP53 and ATRX) compared to cutaneous
melanomas. These tumours were also targeted by frequent copy number al-
terations including high level amplification of chromosome 8q (where MYC is
located). Acral melanomas had the lowest mutation load, with a pattern of muta-
tions showing shared similarities with both the cutaneous (e.g. hotspot BRAF
and NRAS mutations) and mucosal (e.g. copy number alterations including MYC
amplification) melanomas.
– The most frequently altered genes were: BRAF, NRAS, TERT and CDKN2A in
cutaneous melanoma, BRAF, TTN, CCND1 and TERT in acral melanoma and
MYC, TTN, TERT and MAP2K1 in mucosal melanoma.
• Investigate the main genetic alterations and signalling pathways altered in different
tumours
– MAPK pathway activation is the most common genetic alteration in primary
melanomas, with 78% of tumours harbouring alterations in the main pathway
components. Hotspot mutations in BRAF (39%) and NRAS (28%) were most
common, followed by NF1 mutations (10%). Mutations in HRAS, KRAS, MAP2K1,
MAP2K2 and KIT accounted for the remaining 5% of MAPK-associated altera-
tions. High level amplifications in any of these MAPK-associated genes affected
in total 5% of all copy-number analysed tumours.
– The PI3K/AKT pathway is another important process frequently targeted by ge-
netic alterations in melanoma. Modulation of PTEN is the most common event,
where 38% of tumours showed mutation or copy number loss. Additionally, a
small number of tumours harboured mutations in PI3K and AKT genes (5.2%).
As RAS genes also regulate the PI3K/AKT pathway, this brings the total genetic
alterations affecting the PI3K/AKT pathway to 66%.
– 61% of all primary melanomas showed alterations in CDKN2A, making it the
single most frequently modulated gene in primary melanoma. The regulatory
pathway linked to p16INK4A activity is modulated in an additional 5% of tu-
mours through alterations in CDK4, CDK6 and CCND1, while RB1 is mutated
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or show copy number loss in a another 5%. The p14ARF-associated pathway
is further targeted through TP53 mutation or copy number loss in another 10%,
followed by 1.2% with alterations in MDM2 and MDM4. The p16INK4A and
p14ARF pathways are therefore mainly altered in 70% and 73% of tumours,
respectively. Collectively, any of the CDKN2A-associated regulatory pathways
are altered in 78% of all primary melanomas.
– TERT is one of the most important melanoma genes commonly targeted through
non-coding mutations. 36% of samples had hotspot promoter mutations, 3.5%
high level amplifications and another 1.7% coding mutations in this gene, res-
ulting in a total of 42% of samples with TERT alterations.
• Assess the impact of genetic alterations on the immune response in treatment-naive
patients
– The burden of genetic alterations including mutation load, neoantigen load and
copy number burden are associated with immunotherapy response, but did not
have a prognostic impact in my cohort of melanoma patients not receiving im-
munotherapy. I therefore hypothesise that the suppressive immune microenvir-
onment in tumours remain dysfunctional irrespective of its genetic composition,
to a certain extent. Only upon administration of immune-activating agents can a
prognostic difference be seen between patients with varying degrees of genetic
alterations.
– Stratification by immune cell activity mediated by the cytolytic score, was mildly
significant in a multivariate model. Interestingly, categorisation by cytolytic
score showed a larger effect on survival with varying mutation load than us-
ing mutation load alone. This observation is in line with my hypothesis, where
mutation load will be prognostic only in a state where the immune system is not
fully inhibited.
– TERT-activating genetic alterations were associated with a lower cytolytic score.
Weak correlations were also found between tumours with lower cytolytic score
and CDKN2A deletions, MSR1 mutations or RPS27 C227T variants. In contrast,
CDKN2A mutations were linked to a high cytolytic score.
– Genetic alterations targeting the IFN-g pathway have been shown to mediate
resistance to immunotherapy; however, no prognostic value was found in my
treatment-naive cohort, either alone or in combination with mutation load or
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cytolytic score.
• Evaluate the possible prognostic potential of genetic alterations
– Neither the established mutational subtypes (BRAF, RAS, NF1, WT) nor the
Sambar pathway-level subtypes could provide prognostic value.
– Mutations targeting components of the TCR signalling pathway was associated
with worse survival.
– Patients with mutations in both BRAF and PTEN had a survival disadvantage
compared to patients with none or one of these mutations alone.
– Mutation load, neoantigen load, copy number burden or alterations of the IFN-g
pathway are not prognostic in immunotherapy-naive patients.
– Cytolytic score showed a weak prognostic effect, with a higher cytolytic score
being associated with better survival.

The overarching goal of Part II is to understand how PD-L1 expression on tumours can be
downregulated in order to reverse immune cell exhaustion and facilitate tumour cell killing.
Immunotherapy targeting the PD-1/PD-L1 axis is currently at the forefront of melanoma
therapies, proving the power of inhibiting this signal to trigger tumour eradication. How-
ever, antibody-based therapeutics come with ckeaveats including low bioavailability, high
costs and specific resistance mechanisms involving antibody internalisation and ectodomain
shedding. Additionally, at the start of my PhD, the cellular regulation of PD-L1 expression
had not been adequately studied. Through understanding the pathways and mechanisms
involved in limiting cell-surface PD-L1 expression, it is possible to investigate if small mo-
lecule druggable targets interfering with these processes could be identified. Coupling this
research question to the powerful approach of whole genome CRISPR-Cas9 screening, I
am hoping to identify key processes controlling PD-L1 regulation, with the ultimate goal to
identify novel druggable targets.
Part II




Design and application of a
CRISPR-Cas9 screen to identify
regulators of PD-L1
5.1 Introduction
Melanoma and other cancer cells can upregulate cell surface PD-L1 expression to avoid
elimination by the host immune system. Such a dysfunctional state can be induced through
processes including genetic alterations, oncogenic signalling or a change in the tumour mi-
croenvironment [226, 237, 248, 273]. Inhibiting the interaction between PD-1 and PD-
L1, through blocking antibodies or by reducing the expression levels of these compon-
ents, would therefore reverse immune cell exhaustion and facilitate tumour cell killing. Tu-
mour PD-L1 expression can be controlled on several levels, which include modulation of
gene expression, targeting protein stabilisation or degradation and by extrinsic or epigen-
etic regulation. Some of these processes can be explored using a phenotypic marker-based
CRISPR-Cas9 screening approach whereby the effect of specific gene knock-outs on PD-
L1 expression can be studied using a fluorescently labelled antibody against PD-L1. By
understanding the biological processes PD-L1 undergoes in order to be presented on the
cell surface, we may not only learn more about PD-L1 biology, but we could potentially
identify novel druggable targets.
In this chapter, I will outline the experimental design, rationale and set up of controls
that provide the foundation for a successful whole genome CRISPR-Cas9 screen. After
establishing the optimal conditions to perform a screen aimed at identifying regulators of
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PD-L1 expression, I continue by presenting the screening experiment, quality control and
results. Finally, I will discuss the discoveries from the screen, the follow-up validation
experiments and how this information could be used to understand and target the modulation
of cell surface PD-L1 levels.
5.1.1 Chapter aims
The aim of Chapter 5 is to ensure an optimal experimental design and discuss the results
obtained, including:
• Selection of experimental conditions best suited for my project
• Confirm adequate controls are set up and their use validated
• Verify that the screening conditions are appropriate for hit discovery
• Identify the various intracellular pathways by which PD-L1 is presented on the cell
surface
• Assess the novel hits and their potential druggability
• Present top candidate hits for follow-up validation
5.2 Methods
5.2.1 Cell culture
All cell lines are adherent and express Cas9. C092, SKMEL25, HCC44 and LCLC103H
were cultured in RPMI-1640 supplemented with 10% FBS and 1% Penicillin-Streptomycin.
5637 was cultured in RPMI-1640 supplemented with 10% FBS, 1% Sodium pyruvate and
1% Penicillin-Streptomycin. UKEMEL118C was cultured in DMEM supplemented with
10% FBS and 1% Penicillin-Streptomycin, and 647V in DMEM/F12 supplemented with
10% FBS and 1% Penicillin-Streptomycin. UBLC1 was cultured in 1/3 RPMI-1640 and
2/3 DMEM media, supplemented with 10% FBS and 1% Penicillin-Streptomycin. All cell
lines were maintained at 37°C in 5% CO2.
5.2 Methods 121
5.2.2 Generation of Cas9-expressing cell lines using lentiviral trans-
duction
The parental cell line was transduced in suspension with Cas9 virus (prepared from the
Addgene pKLV2-EF1a-Cas9Bsd-W plasmid) and 8µg/ml Polybrene (Merck). Cells were
seeded in a T75 culture flask, and incubated at 37°C. The virus was removed through a
media change after 20 hours. Blasticidin was added 3 days post infection and the cells
grown in Blasticidin-supplemented media for an additional 10 days, until the cells stably
express Cas9.
Cas9 efficiency was assessed using lentivirus carrying reporter vectors BFP and GFP
(Addgene, pKLV2-U6gRNA5(Empty)-PGKBFP2AGFP-W) or BFP, GFP and a gRNA tar-
geting GFP (Addgene, pKLV2-U6gRNA5(gGFP)-PGKBFP2AGFP-W). Cas9-expressing
cells were transduced in suspension with the lentivirus carrying either reporter vector, and
incubated overnight. The virus was removed the following day through a media change,
and the cells grown for another two days. Cells were analysed using a flow cytometer (BD
Fortessa II), followed by data analysis using FlowJo v.10. Cas9 efficiency was calculated as
the ratio between the BFP/GFP positive cells using the empty vector and the BFP+/GFP 
population using the BFP/GFP/gGFP vector. A minimum Cas9 efficiency of 90% was re-
quired for all cell lines generated.
5.2.3 Generation of PD-L1 and OR14A16 knock-out control cell lines
gRNAs against CD274 (PD-L1) and OR14A16 were designed by Dr. Martin Del Castillo
Velasco-Herrera (Section C.1) according to the guidelines described in [710]. Complement-
ary oligos for each gRNA sequence (PD-L1: GGCTGCACTAATTGTCTATT and OR14A16:
CAAAGAATTGGCGATAGATT) were purchased (Merck, Easy Oligos) and ligated into
the pKLV2-U6gRNA5(BbsI)-PGKpuroBFP-W vector following the protocol from [411].
Proper incorporation of each gRNA sequence into the plasmids were confirmed using Sanger
sequencing (Eurofins).
HEK293T cells were used for lentivirus production. Low passage HEK293T cells were
seeded in 10cm round dishes one day prior to transfection to allow cells to reach 80%
confluency. 2 separate tubes were prepared: the first containing 40µl Lipofectamine 3000
(ThermoFisher) mixed with 1ml Opti-MEM. In the second tube 35µl P3000 and 1ml Opti-
MEM were mixed with plasmids: 3.74µg pMD2.G, 5.6µg psPAX and 7.5µg of the transfer
plasmid. Both tubes were vortexed, allowed to stand for 5 minutes at room temperature,
followed by the addition of the first mixture to the second and a further 20 minute incuba-
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tion at room temperature. Immediately prior to transfection, media was removed from the
HEK293T cells and replaced with 3.5ml pre-warmed Opti-MEM, followed by addition of
the transfection mixture. Cells were incubated at 37°C approximately 15 hours, after which
the media was replaced with 8ml pre-warmed IMDM. 48 hours after transfection, virus was
harvested and filtered through a low protein-binding filter.
The parental cell line was transduced in suspension according to the protocol in Section
5.2.2, except Puromycin was used instead of Blasticidin and selection was complete after
7 days. Validation of knock-outs were performed using the Surveyor mismatch cleavage
assay according to manufacturer’s instructions (IDT). Primers were designed to yield a 561
bp product cut into 200 bp and 361 bp fragments using DNA from the OR14A16 KO cell
line and a 610 bp product cut into 426 bp and 184 bp fragments from the PD-L1 KO cell
line.
5.2.4 Titration of lentivirus to achieve optimal multiplicity of infection
(MOI)
Cells were infected in suspension with varying volumes of virus stock and 8µg/ml Poly-
brene (Merck). Cells were seeded at 250,000 cells/well in 6-well plates and incubated at
37°C for 24 hours. The virus were then removed through a media change and incubated
for a further 48 hours. Cells were harvested, fixed with 4% paraformaldehyde and analysed
using a flow cytometer (BD Fortessa II), followed by data analysis using FlowJo v.10. The
percentage of cells expressing BFP was analysed, and the virus volume corresponding to a
BFP percentage of 30% calculated (Fig. A.19).
5.2.5 CRISPR-Cas9 screen in C092 cells
60 million Cas9-transduced C092 cells were infected in triplicates with the genome-wide
Yusa human v.1.1 lentiviral gRNA library at a MOI close to 0.3 (Fig. A.18). Success-
fully infected cells were selected using Puromycin, and expanded for a total of two weeks.
A library representation of at least 200x were maintained at all times. 200 million cells
were harvested on day 14 and day 15 respectively, due to logistic reasons. Half of the cells
were kept as the unsorted control population, while the other half were stained with APC-
conjugated anti-PD-L1 antibody (eBioscience, clone MIH1) and e780 fixable viability dye
(eBioscience, #65-0865-14). A FACS two-way sort was performed, capturing BFP+, live
and the lowest 1% (low) or 1-6% (dim) of PD-L1-expressing clones. The sorts were per-
formed on a MoFlo XDP (Beckman Coulter) cell sorter with help from the Sanger cytometry
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core facility. Sample processing varied between control and sorted samples due to different
cell numbers and library coverage. DNA was extracted according to manufacturer’s in-
structions using the QIAamp DNA mini kit (Qiagen) for the sorted samples and the Qiagen
Blood & Cell Culture DNA Maxi Kit (Qiagen) for the control samples. DNA concentrations
were quantified using Qubit, after which sorted samples were split into 200ng aliquots for
PCR amplification. DNA from control samples were split into 36 x 2µg reactions. Final
PCR products were purified with beads (Beckman Coulter, Agencourt AMPure XP), mul-
tiplexed at equimolarity and run using a custom sequencing primer on an Illumina HiSeq
2500 machine using 19 bp Single End (SE) reads, yielding an average sequencing depth of
36.6 million reads per sample. Samples were processed from second round of PCR through
to sequencing by the CGP and sequencing support facilities at Sanger. The whole screen
was performed once.
5.2.6 Small-scale validation of selected genes
Complementary oligos for the best-performing gRNAs from my screen were selected and
purchased (Merck, Easy Oligos), see Section B.4 for detailed information. Stable knock-
outs of each gene were made following the protocol outlined in Section 5.2.3. Cell surface
PD-L1 expression was assessed post viral transduction, by staining with APC-conjugated
anti-PD-L1 antibody (eBioscience, clone MIH1) and e780 fixable viability dye (eBios-
cience, #65-0865-14). Cells were analysed using a flow cytometer (BD Fortessa II), fol-
lowed by data analysis using FlowJo v.10. Validation experiments were performed once in
C092 and twice in LCLC103H (Once at day 9 and 14 by me and once at day 14 with help
from Dr. Victoria Harle, see Section C.1).
5.2.7 Pooled validation using a custom CRISPR-Cas9 screening lib-
rary
A custom CRISPR-Cas9 gRNA library (Section B.4) comprising 1000 gRNAs was designed
as follows:
1. 60 genes from screen (low or dim hits, FDR < 10%) at 8 gRNAs per gene
2. 36 additional PD-L1-associated genes from literature review at 8 gRNAs per gene
3. 4 safe targeting guides per chromosome, excluding the Y chromosome
4. Control gene OR14A16 not present in the original library, at 8 guides per gene
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5. 17 cancer drivers or top mutated genes from literature review at 8 gRNAs per gene
The gRNA sequences were selected from three commonly used genome-wide libraries
[399, 405, 411, 711], and where the sequence did not start with a G, this was added to the
5’ end of the gRNA sequence as this has been shown to improve efficacy when the gRNA
is transcribed from the human U6 promoter [712]. Forward oligos for each gRNA, with 20
nucleotides on each flanking side matching the empty vector backbone, were purchased as
an oligo pool (TWIST Bioscience). The assembly and production of the gRNA library were
carried out by Dr. Victoria Harle (Section C.1). In brief, the oligos were PCR amplified us-
ing forward TCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAA primers. The
empty vector backbone was cut using BbsI restriction enzymes. The gRNAs were then
inserted into the digested backbone by Gibson assembly (NEB, Gibson Assembly Master
Mix), followed by electroporation of electrocompetent cells (Lucigen Endura), culture of
bacteria and plasmid DNA extraction (Qiagen). The plasmid DNA library was sequenced
on an Illumina MiSeq machine using 21 bp SE reads. Lentiviral production was performed
using HEK293T cells as described in Section 5.2.3, and where Cas9-lines were not already
established (UKEMEL118C, 5637, 647V and UBLC1) this was done as described in Sec-
tion 5.2.2. Lentiviral production, Cas9-transductions for SKMEL25, UKEMEL118C, 5637,
647V and UBLC1 cell lines, antibiotic and library titration were done by Dr. Victoria Harle
(Section C.1). The screen was performed with eight technical replicates, where 4.5 million
cells of each replicate were transduced with the validation library at a MOI close to 0.3
(Section B.5). Successfully infected cells were selected using Puromycin, and expanded for
a total of 9, 14 or 28 days. A minimum library representation of 3000x were maintained at
all subculturing steps. Each sorting day, 3-5 million cells were harvested as control, while
7-20 million cells were stained with APC-conjugated anti-PD-L1 antibody (eBioscience,
clone MIH1) and e780 fixable viability dye (eBioscience, #65-0865-14), and subjected to
FACS. The number of sorted cells differed between conditions due to technical difficulties.
A two-way sort was performed, where the wild-type (uninfected) cells were used to set the
gates comprising the lowest 1% (low) and 1-6% (dim) PD-L1-expressing clones. These
gates were then maintained for the screening replicates, collecting the cells falling within
the respective gates. The validation screen was executed together with Dr. Victoria Harle.
The sorts were performed on a MoFlo XDP (Beckman Coulter) cell sorter by the Sanger
cytometry core facility. The final 576 samples were then subjected to DNA extraction, PCR
amplification, purification and sequencing which were performed by the CGP and sequen-
cing support facilities at Sanger. The whole validation screen was performed once.
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Figure 5.1: PD-L1 expression across melanoma cell lines. Scatter plot showing CD274
(PD-L1) gene expression in fragments per kilobase of transcript per million mapped reads
(FPKM) across melanoma cell lines, overlaid with flow cytometry plots showing PD-L1 cell
surface protein expression for selected cell lines.
5.3 Experimental design
To ensure the success of the screen, a number of factors need to be optimised, and will be
discussed in the following subsections.
5.3.1 Selection of cell line
The goal of this project was to identify targets involved in downregulating PD-L1 expres-
sion. It is therefore critical that the cell line used to perform the screen in has a high expres-
sion of PD-L1, ensuring the highest resolution for discovering genes and pathways involved
in modulating PD-L1 cell surface expression. I evaluated a range of melanoma cell lines
for PD-L1 gene expression using RNA-sequencing data generated in-house by Dr. Marco
Ranzani (Section C.1). The majority of cell lines showed low PD-L1 gene expression, with
a few exhibiting moderate to high expression. I selected some of the cell lines with the
highest gene expression, and conducted protein level expression analysis using flow cyto-
metry (Fig. 5.1). The ideal cell line for my project should not only show a high endogenous
cell surface expression of PD-L1, but this expression also needs to be uniform across the
cells as a clonal cell line would limit noise in the downstream analyses. Out of the tested
cell lines, C092 was the ideal candidate which fulfilled both of these criteria.
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General practicalities such as the growth properties and size of the cell line would also
impact the feasibility of the screen. As such, C092 cells are reasonable cells to work with
as they are medium to large, show adherent growth and have a doubling time of approxim-
ately 30 hours. In addition, it is a human melanoma cell line, derived from a lymph node
metastasis of a Caucasian male diagnosed with metastatic melanoma where the primary was
never identified [713]. Notably, it is characterised by a low number of mutations (13 non-
synonymous mutations in total), none in any established melanoma driver genes or genes
associated with regulation of PD-L1 such as IFN-g pathway genes.
A cell line can only be selected to be used in the screen if it can be effectively trans-
duced and functional in terms of generating gene knock-outs. Therefore, the next step in
preparation for the pooled genome-wide CRISPR-Cas9 screen, was to generate a cell line
expressing Cas9. This was done using lentiviral transduction of the parental C092 line. Cas9
cleaving efficiency was assessed through the transduction of the Cas9-expressing cells with
lentivirus containing BFP, GFP and a gRNA targeting GFP (Fig. 5.2). Uninfected cells and
cells infected with BFP and GFP but without a gRNA (empty) were used as controls. Using
this system, Cas9 efficiency was estimated to be very high, with 94% of the transduced cells
showing Cas9 activity. Therefore, it could be concluded that this cell line can be efficiently
transduced and successfully used to generate gene knock-outs. Taken together, the C092
cell line fulfils all of the above-mentioned criteria and was deemed suitable for use in the
screen.
5.3.2 Set up of appropriate controls
The set up and use of appropriate controls is paramount in maximising the chance of a
successful screen. First, I wanted to make sure loss of PD-L1 would not have a big impact on
the growth properties of the cells. Additionally, creating a cell line where PD-L1 is knocked
out, is useful as a positive control for the screen, as it would showcase the maximum loss of
PD-L1 cell surface expression that is achievable in the C092 cell line. Second, I sought to
test whether PD-L1 expression would be influenced by the CRISPR-Cas9 screening process,
i.e. viral infection, Cas9 cleavage and antibiotic selection. Therefore, I selected OR14A16
as a control gene from the BAGEL list of non-essential genes [714], as I deemed it unlikely
to interfere with PD-L1 function.
To mimic the screening conditions, gRNAs against CD274 (PD-L1) or OR14A16 were
cloned into the empty lentiviral backbone (Fig. 5.3A), in the same position as the gRNAs
part of the genome-wide gRNA library. This was then followed by lentiviral production and
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Figure 5.2: Cas9 reporter and efficiency test. Top panel shows the schematics of the
lentiviral Cas9 reporter vector used. Bottom panel shows the results from the Cas9 efficiency
test. Reporter schematics adapted from [411], with permission under the Creative Commons
Attribution License (CC BY).
transduction of C092 cells to create knock-out cell lines. The successful knock-out of the
respective genes were confirmed using the Surveyor assay and their impact on cell surface
PD-L1 expression along with the incorporation of BFP was assessed using flow cytometry
(Fig. 5.3B,C). Knock-out of PD-L1 showed a large reduction in PD-L1 cell surface ex-
pression, showcasing the high signal to noise ratio which will be advantageous in capturing
PD-L1 loss using this cell line. The OR14A16 KO did not show any difference in PD-L1 cell
surface expression compared to the parental wild-type cell line, confirming the negligible
impact of the aforementioned CRISPR-Cas9 screening steps on PD-L1 expression.
5.3.3 Establishing optimal screening conditions
A number of factors are important to consider when assessing the optimal variables for a
successful screen. A whole range of commercial gRNA libraries exist [405, 407, 408, 411],
and it is also a possibility to tailor-design and create a custom library from scratch. For my
project, I did not want to limit the discovery by using specialised libraries focused on e.g.
kinase, nuclear, chromatin-regulatory or cell cycle-associated genes specifically [399, 715].
Therefore, I sought a wide and unbiased approach whereby it is possible to identify targets
on a genome-wide scale. I selected the Yusa human v.1.1 genome-wide gRNA library which
was designed and gifted by Prof. Kosuke Yusa (Section C.1). The original v.1 of this
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Figure 5.3: Generation of knock-out controls for the screen. A) Plasmid map showing
the empty lentiviral backbone. To generate the controls, gRNAs were ligated upstream of
the U6 promoter, into the improved CRISPR scaffold (purple). The plasmid also contains
markers for puromycin resistance and a BFP tag. B) Expression of BFP and PD-L1 by
flow cytometry shows the successful transduction of lentivirus carrying the plasmid with
inserted gRNAs against CD274 (PD-L1) or OR14A16. PD-L1 cell surface expression is
reduced drastically in the CD274 (PD-L1) KO cells, whereas expression is unchanged with
OR14A16 loss. C) Knock-out of the respective genes were confirmed using the Surveyor
mismatch cleavage assay. Left figure shows the product sizes on an agarose gel stained
with ethidium bromide. Right figure shows the primer sequences (blue), the sizes and the
sequences of the full or cleavage products. The gRNA sequence is highlighted in grey,
where the red line denotes the cleavage (mismatch) site.
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library has shown high performance and success in previous screens [405, 411, 716–718].
In addition to the original library, this extended v.1.1 contains 1004 nontargeting guides
and an additional 9380 gRNAs targeting 1876 selected genes at 5 guides per gene from the
Lander and Sabatini gRNA library [399, 719].
After deciding which library to use, the size of the screen would be the next variable
to establish. As with any screening approach, it is important to ensure a high library com-
plexity from start to finish to avoid biasing and losing gRNA representation. The gRNA
library I selected contains 101,095 gRNAs in total, and when transducing cells in a pool,
a multiplicity of infection (MOI) of 0.3 would be ideal as it strengthens the probability of
each cell being infected with only one gRNA [720, 721]. This means more than 300,000
cells would be required to ensure each gRNA is represented once, but it is common prac-
tice to use a library coverage in the range of 200x-500x [411, 719, 721]. However, the
maximum plausible library representation becomes a trade-off between boosting screening
performance and ensuring the practicalities of the experiment. As approximately 10 million
C092 cells reaches confluency in a T150 culture flask, I decided to transduce and maintain
a library coverage of 200x at all times. This meant an initial infection of 60 million cells,
and I opted to perform the screen in triplicates. For logistical reasons, as it was not feasible
to sort all replicates in one day, at the final subculturing step each replicate was split into
two sets, where one set was harvested on day 14 and the other on day 15. I selected a final
assay time point of two weeks, as this would allow enough time for the gene disruption to
manifest and subsequently exert its effects on PD-L1 cell surface expression. Additionally,
this time point is short enough to reduce the extent of faster-growing clones to overtake and
skew the population.
To reduce the probability of each cell being infected with multiple gRNAs, it is essen-
tial to infect at a low MOI. A MOI of 0.3 is aimed for as it maximises the number of cells
receiving just one lentiviral particle, while minimising the number of uninfected cells and
cells infected by more than one genetic perturbation [720, 721]. To achieve this, each len-
tiviral pool was titrated and customised for each cell line and assay setup in preparation for
the large screen (Fig. A.19).
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Figure 5.4: Screening approach to identify regulators of PD-L1. C092-Cas9 cells were
infected in suspension with the Yusa human v.1.1 lentiviral gRNA library at a MOI close
to 0.3. Successfully transduced cells were then selected using Puromycin, followed by
continuous expansion and cell culture for a total of two weeks. Due to logistic reasons, at
the final subculturing step each replicate was split into two sets, where one set was harvested
on day 14 and the other on day 15. 200 million cells each were harvested on day 14 and day
15, where half of the cells were kept as the unsorted control population, while the other half
were subjected to FACS. A two-way sort was performed, capturing the lowest 1% (low) and
1-6% (dim) PD-L1-expressing clones. DNA was extracted from each sample, subjected to
sequencing and analysis where gRNAs enriched in the PD-L1 low and dim sorted fractions
compared to the unsorted control were identified.
5.4 Pooled genome-wide CRISPR-Cas9 screen to identify
regulators of tumour PD-L1 expression
After establishing the optimal parameters for a successful screen, I set out to perform a
pooled genome-wide CRISPR-Cas9 screen to identify regulators of cell surface PD-L1 ex-
pression in the human melanoma cell line C092. The schematics of the screening process is
depicted in Fig 5.4.
Cells were infected in triplicates, at a MOI close to 0.3 (Fig. A.18) and with a library
coverage of 200x. Successfully transduced cells were selected using Puromycin, and the
cells were cultured for a total of two weeks. On day 14 and 15, cells were harvested for
FACS to identify cells infected with gRNAs causing a phenotype of reduced cell surface
PD-L1 expression. 100 million cells were kept as the control population, while another
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100 million cells were subjected to FACS, selecting the lowest 1% (low) or 1-6% (dim) of
PD-L1-expressing cells (Table A.21). DNA was extracted, PCR amplified and subjected to
sequencing yielding an average of 36.6 million reads per sample. Second round of PCR and
sequencing were performed by the Sanger core facilities (Section C.1).
5.4.1 Quality control
Two samples (Day 14 replicate 1 dim and Day 14 replicate 2 low) failed PCR amplification
and a third sample (Day 15 replicate 1 low) showed very low number of total reads. These
three samples were therefore excluded from further analyses. The plasmid library had been
sequenced previously, providing information about the original gRNA pool counts.
The first quality control measure I sought to assess was the potential skewing of the lib-
rary during the experiment. As an example, knock-down of specific genes including critical
tumour suppressors such as CDKN2A could provide a growth advantage [722]. These cells
would therefore expand faster and become overrepresented with time compared to neutral or
growth-suppressing knock-out clones. If this would have happened, the possible hits from
the screen would be misleading. I first checked the distribution of gRNAs across the control
samples, ensuring the profiles looked similar (Fig. A.20). Then, I looked at the number
of gRNAs with zero counts in the respective samples, as this would indicate whether the
library representation had been compromised during the experiment. 199 gRNAs had zero
counts in the plasmid library. In addition to these, 141 gRNAs had zero counts in all con-
trols, indicating the possible absence of these gRNAs early in the selection process. The
total number of zero counts across all replicates were similar, accounting for <1% of the
gRNA library (Fig. 5.5). 47% of any gRNA with zero counts were uniquely lost in only 1
sample. The low number of total gRNAs with zero counts, where the majority of gRNAs
lost were specific to one sample, implies that appropriate maintenance of library complexity
was achieved throughout the screen.
Next, I analysed the correlation of the gRNA counts between control replicates, as this
would indicate possible limitations with a specific control sample. Pearson’s correlation
values between all control samples ranged between 0.86 and 0.90 (Fig. 5.6A), suggesting
the screening process was robust with the library complexity maintained across all control
samples throughout the screen.
As the screen was performed using a genome-wide library, it also covers genes essential
for the survival of a cell. Therefore, a measure of the dropout of such essential genes over
time could also be used as a quality control measure. I made a comparison between the
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Figure 5.5: Zero count gRNA statistics. Left figure shows the number of gRNAs with zero
counts in each control sample. Right figure shows the number of gRNAs with zero counts
which are shared between control samples.
gRNAs present at the start (plasmid sample) with those found in the control samples cultured
for two weeks. Genes from the Bagel core reference set of essential and non-essential human
genes [714] were used to infer the effect of its knock-down. gRNAs targeting genes known
to be essential were indeed found less frequently in the control samples compared to the
plasmid sample. This is in comparison to the non-essential genes which did not show this
dropout pattern (Fig. 5.6B).
Finally, the Bagel core reference genes were also used to assess the performance of the
screen by computing the Receiver Operating Characteristic (ROC) curve, where the Area
Under The Curve (AUC) is used to evaluate the sensitivity and specificity of the screen. A
detailed description can be found in Section A.22. Briefly, the analysis was performed using
the output from Mageck v.0.5.6 (Table A.1) comparing control samples versus the plasmid.
The Bagel core reference genes were then used to estimate the false positive, true negative,
sensitivity, specificity and false positive rates used for the ROC curve computation (Fig.
5.6C). The calculated AUC value of 0.91 suggests the screen performance was satisfactory,
confirming its high ability to discriminate between true and false positives. Collectively,
all quality control analyses performed demonstrate a robust and high-performing screen. I
could therefore confidently move on to analysing the results.
5.4.2 Results
This genome-wide CRISPR-Cas9 screen allows for the discovery of new molecular path-
ways which downregulate PD-L1, and could therefore provide new insights into PD-L1
biology with the potential discovery of novel targets for drug development. Two weeks
post infection with the pooled gRNA library, cells were harvested and FACS performed to
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Figure 5.6: Quality control metrics from the screen. A) Correlation of gRNA counts
(log2 normalised) between the control replicates, with Pearson’s R values shown for each
comparison. B) Dropout of essential genes shown by gRNA counts between plasmid sample
and each control sample. Bagel core reference set of essential genes shown in red, and non-
essential genes in blue. C) ROC curve analysis with AUC calculated.
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C. Read counts (dim vs ctr)
Figure 5.7: CD274 (PD-L1) gRNA read counts. A) Read counts for each gRNA targeting
CD274 across all samples. Each gRNA is assigned a different colour. The black line depicts
the median gRNA count. B) Read counts shown for one representative low vs ctr sample.
All six gRNAs targeting CD274 are highlighted in red. Dotted line shows the line of unity.
C) Read counts shown for one representative dim vs ctr sample. All six gRNAs targeting
CD274 are highlighted in red. Dotted line shows the line of unity.
identify gRNAs enriched in cells which had reduced PD-L1 cell surface expression. The
gRNAs present in the lowest 1% (low) and 1-6% (dim) were each compared with the un-
sorted control samples. Mageck v.0.5.6 (Table A.1) was used to score the enrichment of all
genes in the library in the sorted fractions compared to the controls. Briefly, the Mageck
analysis begins with a total read count normalisation. This is followed by a comparison
of the gRNAs present in the control versus the sorted samples, using a negative binomial
model followed by a robust rank aggregation algorithm. Genes consistently enriched in the
sorted samples are given a higher rank and a permutation-based statistical test is applied.
As expected, CD274 (encoding PD-L1) was the strongest hit in the low fraction (rank
1, FDR-adjusted p-value = 0.0002). However, although CD274 showed enrichment in the
dim fraction, it was not top ranked (rank 24, FDR-adjusted p-value = 0.023). This reflects
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Figure 5.8: Regulators of PD-L1 identified through the CRISPR-Cas9 screen. A)
Visualisation of the robust rank aggregation (RRA) scores (-log10 adjusted) for all genes
comparing low with ctr samples. Genes enriched in the low fraction with FDR < 10% are
marked, and coloured by function. B) Visualisation of the RRA scores (-log10 adjusted) for
all genes comparing dim with ctr samples. Genes enriched in the dim fraction with FDR <
10% are marked, and coloured by function.
its drastic removal from the cell surface upon knock-out (Fig. 5.7).
A total of 60 genes were identified as regulators of PD-L1 expression (FDR-adjusted
p-value <10%), with 32 genes enriched in the low fraction and 45 genes in the dim fraction
(Fig. 5.8). The hits from the screen reflect a diverse range of intracellular processes involved
in presentation of PD-L1 on the cell surface. Broadly, hits could be grouped into general cat-
egories covering early glycosylation, basal transcription factors and intracellular transport
mediators. Furthermore, a range of novel targets were also discovered including CMTM6,
GTF3C2, SPNS1, F8A3, SHROOM1, HRCT1, DUPD1 and HTT. During the course of my
project, CMTM6 was identified by other researchers as an important regulator of PD-L1
through stabilisation of its cell surface expression and by protecting it from lysosomal de-
gradation [366, 367]. Therefore, the identification of CMTM6 in my screen provides further
evidence of the screen being successful.
136 Design and application of a CRISPR-Cas9 screen to identify regulators of PD-L1
5.4.2.1 Basal transcription factors controlling PD-L1 expression
Five TATA box binding protein (TBP)-associated factors (TAF) genes: TAF1, TAF2, TAF6,
TAF7 and TAF8 were discovered in my screen as positive regulators of PD-L1 surface ex-
pression. These genes encode transcription factors which are involved in many general
processes to initiate gene transcription, including promoter recognition and selectivity, in-
teraction with nucleosomes, coactivation, enzymatic or chromatin modification regulation
[723–726]. TAF proteins can function as subunits in larger multi-protein complexes, where
its association with Transcription factor II D (TFIID) for RNA polymerase II-mediated tran-
scription initiation is the most well-studied. To date, thirteen human TAFs have been iden-
tified to participate in TFIID complexes [727, 728], including some which act in a tissue-
specific manner [729]. Transcriptional regulation by TAFs in the context of cancer has been
studied, where alterations targeting the TFIID machinery are frequent events in various
cancers. In melanomas, over 30% of TCGA SKCM (Section C.2) samples had TAF gene
mutations or copy number amplifications [73, 730]. Additionally, TAF genes are important
for many cellular processes which are commonly hijacked to promote tumourigenesis, such
as regulation of differentiation, cell cycle progression and apoptosis [731–733]. Besides the
TFIID networks, TAF proteins have also been found in chromatin remodelling complexes
such as SAGA in yeast and STAGA or PCAF in human [734, 735].
Interestingly, the five TAF proteins identified in my screen are all structurally connected
when they participate in the TFIID complex, and together they complete the structure of
the C lobe (Fig. 5.9). This suggests that the C lobe might be particularly important in
regulation of PD-L1 expression. In the centre of the TFIID complex, TAF6 is found as a
dimer, tethering the three lobes together [728, 736]. The C-terminal tail of TAF8 then forms
a helical structure connecting TAF6 and TAF2 [736], and this structure has an important
role in the incorporation of TAF2 into the complex [737]. DNA binding is likely mainly
facilitated by TAF1 and TAF7 together with TAF2 [728, 738–740].
Among the TAF genes found in my screen, TAF1 is the most well-studied. It has been
reported to have both protein kinase activity [741, 742] and histone acetyltransferase activ-
ity [731, 743]. Additionally, it has ubiquitin-activating/conjugating functions [744–746], as
well as harbouring two tandem bromodomains, indicating an additional role in chromatin
remodelling [747]. TAF1 regulates the expression of cell cycle and apoptosis-related genes
[742, 748–751], as shown by late G1 arrest, induction of apoptosis and DNA damage re-
sponse in the ts13 hamster cell line which bears the G690D temperature-sensitive mutation
in TAF1 [752].
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Figure 5.9: Arrangement of TAFs in the human TFIID complex. A) Transparent cryo-
EM map showing the TFIID complex, highlighting the 3 lobes. B) View of the individual
lobes highlighting the intermolecular crosslinks between subunits. C) Structural view of the
TFIID subunits comprising 5 TAF, TBP/TFIIA and the DNA interaction through TAF1/7.
Figure A and B printed with permission from [728] and Figure C reproduced with permis-
sion from [736] under the Creative Commons CC BY 4.0 license.
Contradictory to these data, one study has instead shown an attenuation of oxidative
stress-induced apoptosis when TAF1 was depleted in HEK293T and two human cancer cell
lines [732]. This suggests TAF1-associated regulation might be complex and highly context-
dependent. Furthermore, overexpression of TAF1 has been reported to enhance androgen
receptor activity, thereby promoting prostate cancer progression [746].
TAF2 encodes the second largest TFIID subunit, but it can also bind DNA by itself or
through participation in other configurations [753]. When TAF2 assembles in a trimeric
138 Design and application of a CRISPR-Cas9 screen to identify regulators of PD-L1
complex with TAF1 and TBP, it shows a promoter specificity towards Inr sequences [754].
Similar to TAF1, TAF2 is also required for transcription of cell cycle regulatory genes [755].
Additionally, TAF2 is overexpressed in 73% of high-grade serous ovarian cancers [730].
TAF7 has been proposed to combat premature transcription initiation by temporarily
binding to TAF1, thereby inhibiting its acetyltransferase activity until the pre-initiation com-
plex assembly is complete [756]. However, TAF7 is also capable of TAF1-independent tran-
scriptional regulation, as exemplified by its inhibition of CIITA-mediated transcription of
MHC class I and II genes [757] or regulation of c-Jun [758]. Reduced TAF7 expression led
to lower polyamine transporter activity and resistance to methylglyoxal bis(guanylhydrazone)
(MGBG)-induced growth arrest in human prostate cancer cells [759].
Studies have shown that an interaction between p53 and TAF6 is important for transcrip-
tional activation [760]. Therefore, where this interaction is disrupted TP53 might show a
hampered tumour control capability. An apoptosis-induced isoform of TAF6 has also been
found, where its expression initiates transcription of a range of p53-responsive promoters
including those of GADD45 and CDKN1A, and its overexpression was found sufficient to
trigger apoptosis [761]. In another study, the two main isoforms of TAF6 were studied in
normal and cancerous breast epithelia. They found, that the growth-suppressive isoform
was predominant in normal tissues, whereas cancerous samples showed an opposite, and
markedly reduced ratio of this isoform [762]. The authors also found a physical interaction
between GADD45 and this growth-suppressive isoform, which is postulated to be causing
this growth-abrogation effect.
Taken together, my screen identified five TAF proteins which make up the C lobe of the
TFIID complex (Fig. 5.9), suggesting this part of the TFIID complex could be particularly
important for transcriptional regulation of CD274. However, it should be emphasised, that
regulation of gene expression by TAF genes and the TFIID complex is a generic, and in
many cases essential process. Nevertheless, overexpression of TAF genes has been associ-
ated with various cancers, with reduced expression of some genes being linked to resistance
towards growth arrest and apoptosis. It therefore appears TAF genes might contribute to
tumourigenesis; however, an immune-associated role of these genes has yet to be estab-
lished. Since many TAF genes regulate cell cycle progression, and recent data show PD-L1
expression can be regulated by cell cycle kinases [365], it is possible that some TAF genes
could have either a direct or indirect (through cell cycle regulation) effect on PD-L1 tumour
expression.
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5.4.2.2 Regulation of PD-L1 expression by N-linked glycosylation
Figure 5.10: Simple overview of the protein N-glycosylation process. Protein N-
glycosylation takes place in the ER, where a 14-sugar glycan is serially assembled, catalysed
by a range of ALG enzymes. GMPPB is involved in the synthesis of an intermediate sub-
strate which is added to the core N-glycan structure as part of this process. Upon completed
core glycan assembly, the oligosaccharyltransferase (OST) complex mediates the transfer
of this unit to newly synthesised polypeptides. Screen hits encoding the enzymes involved
in this process is highlighted in red.
Several glycosylation-related genes were enriched in the PD-L1 low and dim fractions, sug-
gesting such events are important for PD-L1 surface presentation. Of note, key members of
N-linked glycosylation processes including five members of the oligosaccharyltransferase
(OST) complex were found in my screen. Protein N-glycosylation is an important post-
translational process taking place in the endoplasmic reticulum (ER) and Golgi apparatus,
and governs protein folding and stability [763], subsequently controlling the function and
activity of many proteins [764]. The first step takes place at the ER membrane (Fig. 5.10),
where a 14-sugar glycan is serially assembled and mounted on a membrane-anchored do-
lichol phosphate [765]. These steps are catalysed by a range of enzymes encoded by ALG
genes, which includes the screen hits ALG1, ALG2 and DPAGT1 (also known as ALG7). Ad-
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ditionally, GMPPB is involved in the synthesis of an intermediate substrate which is added
to the core N-glycan structure as part of this process [766]. Upon completed core glycan
assembly, the OST complex mediates the transfer of this unit to newly synthesised poly-
peptides [763]. The human OST complex is made up of eight components [765, 767, 768],
five of which (RPN1, RPN2, DDOST, DAD1 and TMEM258) were hits in my screen. Taken
together, these data confirm PD-L1 is a glycosylated protein, where proper cell surface
presentation of PD-L1 relies on above-mentioned early N-glycosylation processes. Many
proteins which are not correctly glycosylated can be targeted for degradation [769, 770].
Therefore, this process is likely generic and essential for most proteins which are glyc-
osylated, not just PD-L1.
In the context of cancer, changes in glycosylation patterns are commonly observed
[771, 772]. As an example, enhanced expression of glycosylation-regulating genes MGAT3
and MUC1 are linked to increased tumour aggressiveness and metastases [771, 773, 774].
In breast or colorectal cancer, high expression of either RPN1 or RPN2 have been associ-
ated with shorter survival and more distant metastasis in different studies [775–777]. In
addition to this, DPAGT1 can be activated through canonical Wnt signalling, and exerts dir-
ect effects on E-cadherin glycosylation, subsequently causing a reduction in cell adhesion
[778]. Glycosylation is also important in the regulation of immune cell functions, playing a
role in for example ligand interactions [779, 780]. A global reduction in glycosylation due
to suppressed activity of early glycosylation genes might therefore be useful in mounting
an anti-tumour response, both through downregulation of tumour PD-L1 expression, and
by PD-L1 independent mechanisms [781, 782]. Indeed, recent studies have shown potent
cancer cell eradication by hampering PD-L1 glycosylation [783], and general inhibition of
glycosylation using tunicamycin does decrease PD-L1 expression [363]. However, as glyc-
osylation is such a key process, the potential therapeutic regulation of PD-L1 expression
through targeting this machinery needs to be designed with caution and warrants further
investigation.
5.4.2.3 Intracellular transport for presentation of PD-L1 on the cell surface
PD-L1 goes through a range of subcellular transportation processes before being presented
as a cell surface protein, and a recent study showed surface PD-L1 expression is maintained
and regulated by internalisation and recycling components such as CMTM6 [367]. Several
members of multi-subunit tethering complexes (MTCs) which regulate intracellular trans-
port (Fig. 5.11) were found in my screen, including transport protein particle (TRAPP), con-
served oligomeric Golgi (COG) and homotypic fusion and vacuole protein sorting (HOPS)
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complex components.
The TRAPP complexes are important in controlling ER, Golgi and vesicle traffick-
ing through regulation of membrane tethering and fusion events [784]. The screen hits
TRAPPC1 and TRAPPC4 encode essential core TRAPP subunits, while TRAPPC2L is an
adaptor subunit [785]. Interestingly, TRAPPC4 is overexpressed in colorectal cancer cells,
where high expression is linked to increased cell proliferation and invasiveness [786–788].
This effect is suggested to be mediated by a TRAPPC4-ERK2 interaction, which activates
the MAPK pathway. Given these results, it is possible that the TRAPP complex plays a role
in tumourigenesis, or that individual members could have separate independent functions.
Oncogenic activation of the MAPK pathway has been shown to alter PD-L1 expression and
contribute to immune escape [337, 338, 341].
COG proteins facilitate inter-Golgi and Golgi-vesicle transport by mediating the trans-
ition from tethering to vesicle fusion [789]. Cells with defective COG1 or COG2, show re-
duced steady-state levels of some integral membrane proteins due to vesicle sorting failure
and subsequent proteasomal degradation. It is therefore possible that lower PD-L1 expres-
sion by knock-down of COG genes is the result of a global and unspecific reduction in the
level of cell surface proteins [790, 791].
The endocytic pathway also plays a role in regulating PD-L1 expression, as evident by
my screen hits including members of the HOPS complex. This complex regulates tethering
and fusion events involving late endosomes, mediating vesicle sorting and protein recycling
[792, 793]. The core structure of the HOPS complex consists of VPS11, VPS16, VPS18
and VPS33A. gRNAs against VPS11 were absent from the screen library, therefore this
gene could not be studied in my screen. In addition to the core subunits, the HOPS complex
also includes VPS39 and VPS41. All of these HOPS complex components, including its
interaction partner Rab7, were found in my screen, suggesting the endolysosomal pathway
is involved in managing cell surface PD-L1 expression.
My screen also identified other genes involved in vesicle trafficking and membrane re-
cycling of proteins, such as PIK3C3 (also known as VPS34), VPS51, VPS53, VPS35 and
YKT6 [794–797]. Collectively, these results increase our knowledge of the biological mech-
anisms of cell surface presentation of PD-L1, emphasising how it is processed through vari-
ous vesicles from the ER, to the Golgi, endosomes, lysosomes and finally the plasma mem-
brane (Fig. 5.11). In the context of melanoma, alterations in endolysosomal genes such as
RAB7A are enriched, and facilitate tumour progression through promoting proliferation and
metastatic properties [798]. Other studies also link known oncogenic events such as BRAF
V600E mutations or the activation of the PI3K pathway to deregulated vesicle trafficking
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[799–801], further emphasising how these pathways can be altered to regulate tumourigen-
esis, whereby PD-L1 might also play a role.
Figure 5.11: Intracellular vesicle trafficking schematics. Key intracellular trafficking
pathways and the complexes involved. The subunits of the HOPS complex is shown in
the bottom left figure. Modified with permission from [802], and [803] under the Creative
Commons Attribution License CC BY 3.0.
5.4.2.4 Other processes involved in PD-L1 regulation
The results from my screen show that epigenetic modifications also impact PD-L1 ex-
pression, as exemplified with hits such as BRD2, HDAC3 and TBL1XR1. Recent studies
have shown that PD-L1 expression levels can be modulated using both histone deacetylase
(HDAC) inhibitors and bromodomain and extraterminal (BET) inhibitors [804–807]. The
cellular response to these epigenetic regulators is both broad and complex, involving a range
of biological functions such as inflammation, immunity, apoptosis and cell cycle regulation
in addition to changes in the expression levels of various genes [808–812]. This could there-
fore partly explain why the direction of change in PD-L1 expression appear to depend on
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inhibitor specificity and cell type studied [317, 319, 805, 806, 813]. My screen supports
the studies showing PD-L1 expression in melanoma cells can be diminished by the knock-
down of HDAC3 or BRD2. Additionally, another screen hit: the TBL1XR1-encoded protein
associating with HDAC3 in the nuclear receptor corepressor complex is overexpressed in
a range of cancers and linked to increased tumour aggressiveness [814–816] making it an
interesting therapeutic target.
A recent study showed that PD-L1 levels vary during cell cycle progression, with pro-
tein expression levels peaking in the M and early G1 phases [365]. Using inhibitors against
CDK4 and CDK6, they demonstrated that PD-L1 expression levels could be increased. My
screen identified that knock-down of CDKN2A, which encodes the Cyclin D-CDK4/6 inhib-
itor p16, reduces PD-L1 expression, which is in line with the data from the aforementioned
study. As CDKN2A is such an important tumour suppressor in melanoma, it would not be
feasible to exploit the PD-L1-regulatory effects of inhibiting its function therapeutically.
My screen also identified a range of novel genes, including but not limited to BLOC1S1,
CNTLN, DUPD1, F8A3, GET4, GTF3C2, HRCT1, HTT, SHROOM1, SLC10A7, SPNS1
and WRB. Some of these genes could be involved in PD-L1 regulation through mechanisms
mentioned in this chapter, or through other functions yet to be explored.
5.5 Small-scale validation of hits from the screen
As an initial validation, I chose to investigate genes from the top hits in the PD-L1 low
fraction, whilst also ensuring my choices would cover diverse biological functions. Us-
ing this selection method, the top three N-linked glycosylation genes (RPN1, DPAGT1 and
DDOST), two intracellular transport genes (VPS16 and VPS33A) and two basal transcription
factor genes (TAF8 and TAF2) were selected. In addition to these, I also picked YKT6, as it
is linked to the main intracellular transport complexes identified in my screen (Fig. A.23):
the HOPS, COG and TRAPP complexes. Finally, as the studies showing CMTM6-mediated
regulation of PD-L1 [366, 367] were published at the same time as my screen was analysed,
I also chose to include CMTM6 in my validation experiments.
The individual knock-out of each of the 9 genes in the C092 cell line resulted in a de-
crease in cell surface PD-L1 expression 14 days post viral transduction for all genes studied
(Fig. 5.12). The extent of PD-L1 surface expression loss varied between the samples, with
a heterogenous effect on individual cells. As I did not establish a clonal population for this
experiment, some fluctuations in the efficiency of knock-down will inevitably be recapitu-
lated in the results. Nevertheless, as 9/9 selected genes for validation did cause a degree of
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PD-L1 expression loss, this implies a high robustness in my original screen.
Figure 5.12: Validation of nine genes in the C092 melanoma cell line, 14 days post
viral transduction. Histogram of PD-L1 expression measured by flow cytometry, showing
the PD-L1 expression in the various conditions. Experiment was performed with technical
duplicates.
Next, I wanted to assess the reproducibility of the hits, and chose to validate the same
nine genes in an independent cell line. Based on endogenous PD-L1 cell surface expres-
sion, I picked the high PD-L1-expressing non-small cell lung cancer (NSCLC) cell line
LCLC103H for this experiment. Although the extent varied between the cases, all nine
genes when individually knocked-out by the CRISPR-Cas9 method showed some reduction
in PD-L1 expression (Fig. 5.13), again confirming a high reproducibility of my original
screen. Notably, in both LCLC103H and C092 cell lines, I observed a growth retardation
and lower viability when DPAGT1 or YKT6 were knocked-out. These cells also acquired
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a more spindle-shaped morphology, which is interesting as it is also a feature associated
with cells undergoing epithelial-mesenchymal transition (EMT) [817–819]. In contrast, the
CMTM6, TAF2 and TAF8 knock-out clones proliferated slightly faster than the other knock-
outs.
Surprisingly, in the LCLC103H cell line, the amount of PD-L1 knock-down varied with
time. Most genes caused a larger reduction in PD-L1 protein expression 9 days after viral
transduction compared to 14 days (Fig. 5.13). This effect could be mediated by a range of
different mechanisms. First, these two cell lines are of different cancer types, with vary-
ing doubling rates, genetic background and other cell line-specific properties . Second, and
more importantly, a single clone was not selectively expanded, thus the knock-out exper-
iments were performed on a non-clonal population of cells. Hence, the efficiency of the
CRISPR-Cas9 machinery could vary between cells in this population, causing a variation
in the degree of gene loss, leading to differences in cell proliferation and viability amongst
individual clones. This could bias the population as less damaging gene disruptions are fa-
vourable in terms of survival, and these cells could outgrow clones targeted by more severe
alterations. This could therefore contribute to the time-dependent discrepancy in the PD-L1
gene expression observed in my validation experiments. Third, PD-L1 expression is influ-
enced by cell cycle regulatory factors as recently described [365]. I also observed a minor
difference in PD-L1 expression based on cell confluency, where a higher confluency gener-
ally yielded slightly lower PD-L1 surface expression. It is possible that there is a joint effect
where knock-down of some genes could enhance the cells’ susceptibility towards cell cycle
mediated regulation of PD-L1 expression. Additionally, in cases where protein expression is
not completely abrogated by the CRISPR-Cas9 treatment, these cells could also show an in-
creased sensitivity towards cell cycle mediated effects, causing the observed fluctuations in
PD-L1 expression with time. Finally, it is also possible in cases where important or generic
pathways are targeted, that cell-intrinsic compensatory mechanisms are in place to combat
any such effect.
In hindsight, these validation experiments should all have been repeated in a FACS-
selected and established monoclonal cell line with a proven deleterious homozygous knock-
out in order to comprehensively assess their effects on PD-L1 expression. Nonetheless, the
small-scale validation of the nine selected genes confirmed all tested genes could modulate
PD-L1 expression to some extent, in the original melanoma cell line as well as a second cell
line of lung cancer origin.
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5.6 Pooled validation using a custom CRISPR-Cas9 screen-
ing library
In conjunction with performing the small-scale validation, where the results showcased a
high performance of my original screen as all nine genes validated in the two tested cell
lines, I decided to perform a second more extensive validation. I designed a new validation
screen library comprising 1000 gRNAs (Section B.4) to screen across 9 cell lines of 3 cancer
types. Unfortunately, one NSCLC cell line lost Cas9 expression and had to be excluded from
the screen, thus a total of eight cell lines were used in the validation experiments.
For each condition eight replicates were adopted, to ensure a high robustness of the
experiment could be maintained even if some samples did not pass all sample processing and
quality control steps. Three time points were selected (day 9, 14 and 28), as I experienced
from the small-scale validation experiments that cell line-specific properties and technical
issues such as confluency could impact the validation rate.
When selecting the cell lines to perform the pooled validation screen in, the following
criteria were taken into consideration. First and foremost, the cell line needs to have an
intermediate to high expression of PD-L1. This was challenging, as only a limited number
of cell lines I had access to showed an ideal PD-L1 expression profile. Therefore I had to
include a few cell lines with intermediate or broader expression. Second, I chose to focus on
therapeutically relevant tumour types i.e. cases where PD-1/PD-L1 therapies are currently
approved. I therefore decided to focus on three cancer types: melanoma, non-small cell lung
cancer (NSCLC) and bladder cancer. Third, cell lines with adherent growth properties, reas-
onable cell size and doubling times were chosen. Finally, I selected cell lines that were used
by other groups at Sanger, or could be easily accessible through collaborations. With these
selection criteria in combination, I chose the three melanoma cell lines C092, SKMEL25
and UKEMEL118C, two NSCLC lines LCLC103H and HCC44 (a third cell line had to be
excluded due to loss of Cas9 expression), and the three bladder cancer cell lines 5637, 647V
and UBLC1 for my experiments. UKEMEL118C is a patient-derived melanoma cell line,
gifted by Prof. Annette Paschen at Universitätsklinikum Essen (Section C.1). The PD-L1
protein expression of all cell lines used in the pooled validation screen, as measured by flow
cytometry is shown in Fig. 5.14.
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Figure 5.14: PD-L1 expression in the cell lines used for validation. Protein expression of
PD-L1 measured by flow cytometry for the eight cell lines selected for the pooled validation
screen (blue = wild-type (WT), grey = unstained). NSCLC = Non-small cell lung cancer.
5.6.1 Quality control
Unfortunately, when producing the gRNA library the Gibson reaction can introduce errors,
especially at the junctions [820, 821], leading to an imprecise gRNA sequence being inserted
into the plasmid. In my case, after sequencing the plasmid library, it was discovered that
the first or last base of the gRNA sequence were mutated in 27% of the library. After
this finding, a modified sequencing primer was designed and used to be able to identify
exact gRNA sequences as well as erroneous gRNA sequences in all samples of the pooled
validation screen. On average, 71% of all reads matched perfectly to the gRNA library, with
an additional 12% of reads showing a G to A substitution in the first base, and thus would
still work in transcription initiation [822]. This means the total number of useful gRNA
reads amounted to 83% (Section B.6).
The screen was performed with eight technical replicates, obtaining a median MOI
across all eight cell lines of 0.28 (Table A.24), thus ensuring a library representation of
1000x at infection. 55 out of 576 (10%) samples failed in the PCR amplification steps due
to technical issues, and were not submitted for sequencing. Unfortunately, these included
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all SKMEL25 day 14 dim samples, making analysis of this condition impossible. Addi-
tionally, five of the UBLC1 day nine low samples as well as six of the UBLC1 day nine
control samples also failed, making it difficult to do a robust analysis for this cell line and
time point. Luckily, in all other cases, at least four replicates could be maintained for each
condition. A median sequencing coverage of 1200x was achieved (Fig. A.25); however, two
samples had to be excluded due to low library coverage (SKMEL25 day 14 rep 6 low and
5637 day 9 rep 1 control). Correlation between gRNA counts in the control samples were
high for most comparisons (Fig. A.26); however, slightly lower values can be expected due
to increased noise with a small-scale library. In the cases where the sample correlation were
lower, visual examination of plotted gRNA counts were performed to assess the outliers and
no samples were excluded.
In summary, 519 out of 576 (90%) samples passed the quality control assessment and
were used in downstream analyses.
5.6.2 Results
The goal with the pooled validation screen was to simultaneously verify the findings from
the original screen, whilst exploring the robustness and biology of the hits by screening a
custom 1000 gRNA library across eight cell lines of three tumour types, with analysis at
three different time points. Mageck v.0.5.6 (Table A.1) was used to score the enrichment of
all genes in the library in the sorted fractions compared to the controls. Each condition (cell
line, time point and sort fraction) was analysed individually, followed by comparison of hits
between groups.
In total, 54 genes were hits (FDR < 10%) in any of the conditions, with 35 genes iden-
tified in the low fraction and 53 genes in the dim fraction. As expected, CD274 (PD-L1)
was the top hit in most of the conditions. The recently discovered PD-L1-regulator CMTM6
[366, 367] was also identified in the majority of the comparisons. Generally, most of the hits
were identified in the dim fraction, as opposed to the low fraction, which could reflect the
nature of PD-L1 control. When knocking down CD274, which encodes PD-L1, a complete
abrogation in PD-L1 expression is observed, resulting in this gene being predominant in the
low fraction but less detected in the dim fraction. The knock-down of other genes does not
appear to have a similarly drastic effect on PD-L1 surface expression, explaining why there
is an overall abundance of hits in the dim fraction.
I chose to mainly look at the profile of how hits validate across the different cell lines,
irrespective of timepoint and sort fraction. This analysis provides information regarding the
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Table 5.1: Number of hits identified per cell line. Statistics showing the total, dim or low
number of hits (FDR <10%) found in each cell line, and its cancer type.
robustness of these candidates, and is independent of the degree of modulation and potential
fluctuations with time. The number of genes identified across cell lines ranged between 4
and 45, with a median of 12 genes (Table 5.1). Some conditions could show lower valida-
tion rates due to technical issues, such as suboptimal cell confluences and limited number
of sorted cells. As expected, the high PD-L1-expressing C092 melanoma cell line which
the original screen was performed in, showed the highest number of validated genes. 45
out of the original 60 genes (75%) could be confirmed across any of the three timepoints as-
sessed. The bladder cancer cell line 647V, which also had a high baseline PD-L1 expression,
showed the second highest number of validated genes (26 genes). This does emphasise the
importance of selecting cell lines with an optimal PD-L1 protein expression profile in order
to get the highest possible window to identify regulators in a screen. This could also in part
explain why another recently published PD-L1 screen only identified two genes (CD274 and
CMTM6) as PD-L1 regulators in their baseline experiment [367], as the PD-L1 expression
in that cell line (BxPC-3) was only intermediate to low.
CD274 and CMTM6 were the only two genes which validated across all eight cell lines
(Fig. 5.15). These findings therefore strengthen the evidence of CMTM6 being a gen-
eral modulator of PD-L1 cell surface expression, holding true across multiple tissue types.
Two genes validated across five cell lines, which included VPS16, an important member
of the HOPS complex, and SPNS1, encoding a sphingolipid transporter which interestingly
might play a role in lysosomal transport and autophagy [823–825]. Looking in a tissue-
specific context, other interesting observations were made (Table A.27). The glycosylation-
associated gene DAD1, validated across all melanoma cell lines but not the other tissue
types, whilst TAF2, TAF8 and VPS39 validated in two out of three melanoma and bladder
cell lines, respectively, but not in any of the lung cancer cell lines. These findings could
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possibly reflect a tissue-dependent context of PD-L1 regulation; however, a negative result
most likely reflects the lack of resolution to identify genes in some cell lines.
Looking at the hits in each cell line, some additional observations were made. In the
melanoma cell line C092, the three main general processes identified in the original screen
(early glycosylation, basal transcription factor regulation and intracellular transport me-
diation) could be confirmed as pathways regulating PD-L1 cell surface presentation (Fig.
5.16). Some other genes were also validated, including SPNS1, which was a hit across mul-
tiple cell lines of different tissue types. In the other two melanoma cell lines, glycosylation-
associated genes and TAF genes validated in the SKMEL25 cell line, and a large number
of VPS genes could be identified in the UKEMEL118C cell line. Collectively, these res-
ults reflect the importance of these basal processes in the regulation of PD-L1 in melanoma
cells, but also suggest slight cell line specific variations exist in the dependency of respective
pathways.
Out of the three bladder cancer cell lines, 5637 and 647V yielded many significant hits,
possibly owing to their high endogenous expression of PD-L1, facilitating the discovery of
PD-L1 regulators. UBLC1 had the poorest baseline PD-L1 expression out of all cell lines in
the validation screens, and it is therefore not surprising to find a very sparse number of hits in
this cell line. One common theme in the 5637 cell line appears to be the intracellular trans-
port pathway including movement through lysosomes. Additionally, genes associated with
transcriptional control such as ARID1A, HDAC3 and YAP1 were also identified in the dim
fraction, across multiple time points. However, neither the N-linked glycosylation genes
nor the basal transcription factor TAF genes were identified in this cell line. The 647V cell
line had the second highest number of hits, after the original screen cell line C092. Genes
identified in this cell line cover glycosylation, TAF genes and transcriptional regulators,
VPS genes and intracellular transport mediators, as well as a few other hits such as TSC2,
CDKN2A, KIAA1432 and WRB. Most of the genes were identified in multiple conditions per
cell line, providing added support for the robustness of these findings. The identification of
tumour suppressors CDKN2A and PTEN is curious, and could arguably reflect an obtained
survival advantage of the cells which lost expression of these genes. However, if this would
be the only effect, these clones should be enriched in the control fraction but not specifically
found in the sorted fractions. Therefore, these findings suggest they mediate some level of
PD-L1 regulation; however, therapeutic silencing of these genes in a clinical setting would
most likely not lead to a favourable outcome.
The NSCLC cell lines had fewer hits than the other tissue types, which was unexpected
in terms of their satisfactory PD-L1 protein expression profiles. In the LCLC103H cell
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Figure 5.15: Gene validation results across cell lines. The number of cell lines where each
gene was successfully validated in is shown for genes validating in at least three cell lines.
A more detailed and extended list can be found in Table A.27.
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line, genes associated with intracellular transport dominated. HCC44 only had four hits in
total, where apart from CD274 and CMTM6, RAB7A and SPNS1 were also identified. These
genes are all presumed to play a role in lysosomal transport, providing further support of this
process in promoting PD-L1 surface presentation. The lack of validation of glycosylation
and basal transcription factor genes in these two cell lines could be reflective of differences
in cell-specific properties; however, as the total findings were very limited in these cell lines,
false negatives cannot be ruled out.
The eight cell lines show different patterns in the type of genes which control PD-L1
expression, but also in the dynamics of their PD-L1 regulation. Genes associated with
intracellular transport including VPS genes were robust hits in several cell lines irrespective
of the time point studied. However, N-linked glycosylation genes were only hits at day 14
in the C092 cell line, whilst in the SKMEL25 and 647V cell lines they validated at day 9
only. This discrepancy could potentially reflect cell-intrinsic differences, including growth
properties such as doubling rate.
The pooled validation screen succeeded in confirming individual genes as well as gen-
eral pathways involved in the regulation of PD-L1. In general, three main biological pro-
cesses were found to control PD-L1 expression in the various cell lines. In some melanoma
and bladder cancer cell lines, TAF genes are involved in the control of PD-L1. Furtheremore,
my results also suggest that in several cell lines, PD-L1 is targeted by N-linked glycosyla-
tion, which could possibly affect the folding and stability of the protein, explaining its lack
of cell surface expression when this machinery is inoperative. PD-L1 then gets processed
through the intracellular transport apparatus, including transitioning through lysosomes.
Targeting these three general pathways could be a method to reduce PD-L1 expression to
facilitate a host anti-tumour response, which could be tested using inhibitors such as tunica-
mycin (glycosylation) or chloroquine (lysosomal transport). However, the clinical utility of
targeting these broad pathways warrants caution, as these systems are likely to regulate the
expression of a plethora of other cell surface proteins as well as PD-L1. To conclude, my
PD-L1 screen and follow-up validation have provided insights into how PD-L1 expression
is intrinsically regulated, processed and presented on the surface of a tumour cell.
5.6.3 SPNS1 as a novel regulator of PD-L1
Some novel hits which were not linked to the above described generic processes were also
identified (Fig. 5.17). Sphingolipid Transporter 1 (SPNS1) was the most interesting hit,
being a recurrent finding across five out of eight cell lines. In the melanoma cell line C092
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and both the NSCLC cell lines, knock-out of SPNS1 caused sufficient removal of cell surface
PD-L1 for these cells to be identified in the low fraction. Additionally, SPNS1 was also
identified in the dim fraction of the melanoma cell line UKEMEL118C and the bladder
cancer cell line 5637. It is not possible to conclude whether the absence of hit discovery
in other cell lines only reflects the lack of detection capability in some settings. Several
conditions had CD274 or CD274 and CMTM6 as the only significant genes identified as
hits, which could be due to a low number of replicate samples such as for the UBLC1 cell
line at day 9 or 14, and the 647V cell line at day 9. In the original C092 screen, SPNS1
was identified as a hit in the dim fraction (FDR-adjusted p-value = 0.064), which was the
rationale for including this gene in the gRNA library used for the pooled validation screen.
The SPNS1 validation profile suggest it is a generic regulator of PD-L1 across mul-
tiple cell lines and tissue types. The SPNS1 gene encodes the Sphingolipid Transporter 1
(Putative), and is proposed to function in lysosomal transport and autophagy [823–826].
Genetic defects of SPNS1 homologues in mice, zebrafish and Drosophila have been re-
ported to present phenotypes associated with ageing, viability and nervous system defects
[823, 824, 827–829]. Some of these mutants show altered endosome-to-lysosome traffick-
ing, senescence and programmed cell death phenotypes or aberrant autolysosomal forma-
tion. I therefore hypothesise, that SPNS1-mediated control of lysosomal turnover and auto-
phagic processes might contribute to its regulation of cell surface PD-L1 levels. Defective
SPNS1 might cause PD-L1 to accumulate in intracellular vesicles, thus hampering cell sur-
face presentation and turnover of PD-L1. Overexpression of Spin in Drosophila triggers
autophagy [826], while hypomorphic loss leads to accumulation of enlarged autolysosomes
and impaired autophagic lysosome reformation [825, 830]. The capability of autolysosomes
to degrade its contents were only impaired in Spin mutants following prolonged starvation,
whilst in nutrient-rich conditions, the effect of Spin knock-down on autophagy were ameli-
orated [825]. It is therefore intriguing to compare how these studies performed under con-
ditions following starvation, resembles that of a hypoxic and nutrient-deprived environment
during tumour progression [831, 832]. In addition to reduced cell surface PD-L1 expression,
knock-down of SPNS1 might therefore confer a milder phenotype in normal cells compared
to nutrient-deprived tumour cells.
SPNS1 is expressed in various tissues of both normal (Fig. A.28) and cancerous origin
(Fig. A.29). The most common genetic events targeting SPNS1 in melanoma, NSCLC
and bladder cancer patients were mutations and amplifications (Fig. 5.18A). Additionally,
in the TCGA SKCM and TCGA BLCA cohorts, high expression of SPNS1 is associated
with worse survival (Fig. 5.18B). In the the Leeds melanoma cohort, high expression of
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Figure 5.17: Output from search tool for the retrieval of interacting genes/proteins
(STRING) analysis of pooled validation screen hits. All 54 genes identified as hits (FDR
< 10%) in any of the conditions studied, with selected general pathways or processes high-
lighted. SPNS1 was selected for follow-up partly because of it not being linked to any other
hits in the screens in this analysis.
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SPNS1 was also found to correlate with poor outcome, both when studying overall survival
(p.value = 0.031) and melanoma-specific survival (p.value = 0.031); however, the biggest
difference was found when comparing relapse-free survival (Fig. 5.18B). Collectively, these
data suggest SPNS1 function might be associated with more aggressive tumours.
Figure 5.18: SPNS1 alterations in human cancers and its association with patient sur-
vival. A) The most common genetic alterations in SPNS1 in human bladder cancers, melan-
oma and NSCLC were amplifications or mutations. B) Univariate survival analysis show
high SPNS1 gene expression is associated with worse outcome in melanoma (TCGA SKCM
and Leeds melanoma cohort [833]) and bladder cancer (TCGA BLCA). No survival differ-
ence was found in NSCLC (TCGA Pan-Lung). TCGA figures were generated using the
UCSC Xena platform (www.xenabrowser.net) [834].
Before proceeding to unravel the biology behind SPNS1-mediated PD-L1 regulation,
this finding needs to be further validated using individual and clonal knock-out experiments.
In the first instance, PD-L1 expression following SPNS1 loss should be confirmed in a range
of cell lines, including those part of the validation screen panel. When this effect has been
assessed, the mechanism behind its regulation can be further studied. Any direct interac-
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tions or co-localisation of this sphingolipid transporter with PD-L1, as well as the effect of
where PD-L1 accumulates when SPNS1 is absent, can be tested using e.g. specific intracel-
lular localisation markers such as RAB7 (late endosomes), LAMP1 (lysosomes) and LC3
(autophagosomes).
Furthermore, a range of compounds which block various vesicle functions could be used
[835], including chloroquine, which inhibit the fusion of lysosomes with autophagosomes,
and wortmannin, a PI3K inhibitor, which inhibits autophagy by blocking the formation of
autophagosomes. As autophagy is an important cellular process, it would be important to
also profile the specificity of SPNS1 regulation to understand if it modulates protein expres-
sion on a global level. This would be an important factor in determining the druggability of
SPNS1 and the clinical utility of targeting PD-L1 through this interaction. With that being
said, even if SPNS1 control is not PD-L1 specific, this does not necessarily rule out the pos-
sibility of targeting its function. Interesting data have emerged which show that targeting
autophagy on a broad level can mediate anti-cancer effects and it was recently proposed
as a new strategy of cancer therapy [836]. Ultimately, the effect of SPNS1 depletion on
the ability to sensitise tumour cells towards immune evasion would be essential to study in
co-culture or in vivo settings.
5.7 Evaluation of chapter aims
• Selection of experimental conditions best suited for my project
– C092 was established as the most preferable cell line to conduct the screen in
due to its high and uniform endogenous PD-L1 expression, optimal growth char-
acteristics and verified high Cas9 efficiency.
– To conduct an unbiased screen, a genome-wide gRNA library (Yusa human
v.1.1) with conditions ensuring 200x library representation, and a final timepoint
of two weeks were selected.
• Confirm adequate controls are set up and their use validated
– A CD274 knock-out C092 cell line was generated as a positive control, and the
knock-out validated using the Surveyor mismatch cleavage assay. This cell line
showed a drastic reduction in PD-L1 cell surface expression, showcasing a high
resolution for the discovery of PD-L1-regulating genes and pathways.
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– An OR14A16 knock-out C092 cell line was generated as a negative control, and
the knock-out validated using the Surveyor mismatch cleavage assay. This cell
line did not show any difference in PD-L1 cell surface expression compared to
the parental wild-type cell line, confirming the negligible impact of the CRISPR-
Cas9 screening process on PD-L1 expression.
• Verify that the screening conditions are appropriate for hit discovery
– Low number of zero gRNA counts, where the majority of gRNAs lost were
sample-specific confirmed that appropriate maintenance of library complexity
was achieved.
– High correlation between control replicates, verified dropout of essential genes
and a high ROC curve AUC value demonstrates a robust and high-performing
screen.
– CD274 (encoding PD-L1) was the top hit in both the original screen and pooled
validation screens, further confirming the success of the screens.
– Small-scale validation using individual gRNA knock-down confirmed PD-L1
regulation of all nine tested genes in two cell lines, showcasing a high reprodu-
cibility of the original screen.
– The pooled validation screens using the 1000 gRNA library in eight cell lines
of three tissue types showed acceptable control sample correlations, albeit lower
than the original screen. The smaller screens yielded higher noise, which was
reflected in the lower number of hits identified in many of the conditions as-
sessed. Absence of hit validation in some conditions could therefore reflect an
insufficient detection ability.
• Identify the various intracellular pathways by which PD-L1 is presented on the cell
surface
– Three main categories of genes of general pathways involved in PD-L1 present-
ation on the cell surface of cancer cells were identified:
  Basal transcription factor genes: Five TAF genes encoding proteins which
make up the C lobe of the TFIID complex were identified in the original
screen, suggesting this part of the TFIID complex could be particularly im-
portant for transcriptional regulation of PD-L1. Some of these hits also
validated in additional melanoma and bladder cancer cell lines.
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  N-linked glycosylation genes: My screen confirmed the need of PD-L1 to
be properly glycosylated for cell surface display, where early glycosylation
processes mediated by ALG genes and the OST complex are particularly
important. Some of these hits also validated in additional melanoma and
bladder cancer cell lines.
  Intracellular transport genes: Hits from my screen show how PD-L1 trans-
itions from the ER to the cell surface through the Golgi, endosomes, lyso-
somes and autophagosomes, where it is regulated by complexes including
TRAPP, COG and HOPS. Genes associated with intracellular transport in-
cluding VPS genes were found in all eight validation screen cell lines, prov-
ing the importance of these generic processes for proper PD-L1 expression.
• Assess the novel hits and their potential druggability
– Epigenetic modulation of PD-L1 by BRD2, HDAC3 and TBL1XR1 were also
discovered in my screen. BRD2 only validated in the original C092 cell line,
whilst HDAC3 and TBL1XR1 was confirmed in two and one bladder cancer cell
lines, respectively, in addition to C092. HDAC and BET inhibitors might there-
fore be beneficial in conferring a reduced PD-L1 tumour expression to trigger
an immune response.
– CDKN2A was a hit in the original screen, and validated in the 647V cell line. The
role of cell cycle on PD-L1 expression is supported in literature, but the benefit
of reduced PD-L1 expression would most likely not overcome the detriment of
tumour suppressor silencing in a clinical setting.
– Several other novel genes were found, but from the validation screens SPNS1
was deemed most interesting to follow up.
• Present top candidate hits for follow-up validation
– SPNS1 was a novel hit which validated across five cell lines, and is postulated to
be involved in autophagy. It is commonly amplified or deleted in cancers, where
a high expression is linked to a worse prognosis. This candidate was selected







The overarching aim of my dissertation was to improve our understanding of melanoma as
a disease: from the genetic processes that govern tumour development, to the impairment
of host protection and how we can reverse such a dysfunctional state.
In the first part, I presented some of the most critical genetic aberrations found in primary
melanomas. I designed my own targeted capture bait library to find alterations in genes driv-
ing melanoma disease progression, and to understand their contribution to the disease. Large
cohorts of primary melanomas have not been comprehensively studied by genomic profiling
before, therefore my study can help us understand how cancers evolve and are regulated in
their earliest stages. Additionally, my study has the power to validate or contradict previous
findings, as well as present new insights and knowledge. The first results chapter, Chapter
2, presented the methods, showed the reliability of the data generated for this project and
how I dealt with caveats and limitations. In the following two chapters, Chapter 3 and 4, I
investigated key genetic alterations in human primary melanoma to an extent previous re-
search has not been able to, whilst using the unique characteristics of the Leeds melanoma
cohort.
In Chapter 5, the second part of my thesis, I identified regulators of tumour PD-L1 sur-
face expression using a CRISPR-Cas9 screening approach. First, I established the optimal
screening conditions and controls, followed by the demonstration of a successful genome-
wide CRISPR-Cas9 screen. I discussed the results, which covered general pathways con-
trolling PD-L1 expression, novel regulators and new plausible therapeutic angles. To valid-
ate my results, I simultaneously performed a smaller pooled validation screen across eight
cell lines of three cancer types, and could confirm many of the hits from the original screen,
as well as identify one top candidate (SPNS1) for follow-up experiments.
In the following sections, I will highlight and discuss some of the key findings presented
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throughout my thesis, and how this has improved our knowledge about the genetic landscape
and immune regulation of melanoma.
6.1 Novel genetic alterations in primary melanomas
In my dissertation, I showed that most primary melanomas have a high mutation burden,
replete with UV damage-associated C to T mutations. Mutations were frequently found in
driver genes such as BRAF, NRAS, NF1, TERT and CDKN2A, but I also discovered hotspot
variants in novel genes including PCDHA2, TPTE and AHCTF1. Based on positive selec-
tion, 15 melanoma driver genes were found comprising mainly well-established melanoma
driver genes. However, my analysis also validated less acclaimed prospective driver genes
FAM58A, RQCD1 and MSR1, as well as one novel candidate gene TPTE. In support of my
findings, a recent sophisticated method of driver gene discovery also identified TPTE as a
driver using pan-cancer or melanoma-specific TCGA data [837]. Interestingly, my analysis
also discovered a mutual exclusive mutation pattern which proposes that both PTEN para-
logues TPTE and TPTE2 might be involved in the same tumourigenic pathways as PTEN,
showcasing a possible functional redundancy. However, whilst all of the mutation calls
in this gene were high quality, there appears to be multiple copies of TPTE pseudogenes
across the genome, a feature known to potentially confound variant detection. In spite of
this, my data suggests a possible role for TPTE as a novel driver of melanoma development,
an observation that needs to be explored functionally and lies beyond the scope of my thesis.
A more comprehensive analysis of mutation patterns identified mutual exclusivity between
two key melanoma driver genes, BRAF and CDKN2A, respectively, and several other known
or novel genes. The pattern between BRAF and EGFR for example, could indicate altern-
ative activation of the MAPK pathway driving oncogenesis in some patients, a feature that
could be utilised for personalised treatment using already approved drugs. Another inter-
esting pattern was observed between CDKN2A and PRDM2, where the Rb-binding capab-
ility of PRDM2 provides further support of a reciprocal function between the two genes.
Additionally, experimental evidence showed that PRDM2 might be involved in cell cycle
regulation [584, 585]. It would be very interesting to further study this hypothesis using
knock-out models and senescence bypass assays.
Unsurprisingly, co-occurring gene pairs were not observed in my dataset. The high
mutation rate in melanomas increases the likelihood of any two genes being co-mutated
by chance. Although I found no such interactions in my dataset, I believe co-occurring
mutations in theory should exist, and is important to study. However, these associations
6.1 Novel genetic alterations in primary melanomas 167
might be far more complex to unravel. As an example, they might be visible only on a
pathway rather than gene level. Therefore, the discovery of such interactions through this
type of analysis will prove extremely challenging. Nevertheless, studies in other cancers
have shown that patients showing alterations in multiple driver genes tend to have inferior
survival [631]. But again, similar studies in melanoma will be more difficult, as any effect
could be clouded by the high background mutation rates.
Copy number profiles in primary melanomas mimicked those of metastatic melanomas,
with chromosome 1q, 6p, 7 and 8 being frequently amplified whilst 6q, 9 and 10 were more
often deleted. IRF4, located on chromosome 6p, was of particular interest. In addition
to being one of the most frequently amplified genes in my dataset, IRF4 associated with
lethality in melanoma cell lines by analysing the DepMap CRISPR-Cas9 screen dataset. I
therefore hypothesised that IRF4 amplification could be an oncogenic event in melanoma,
whereby the loss of IRF4 expression might cause tumour cell vulnerability. This hypothesis
was in part confirmed through experimental validation, as siRNA-mediated knock-down
of this gene in an IRF4high cell line resulted in apoptosis and cell death. My data therefore
suggest that a subset of melanomas might be dependent on IRF4 expression, which suggests
IRF4 could be an interesting therapeutic target.
Any type of analysis involving genetic alterations comes with several challenges. Study-
ing less known cancer genes is difficult because we cannot fully ascertain the functional
consequence of each mutation. Generally, loss of function mutations such as nonsense,
splice site and frameshift mutations target tumour suppressor genes, while recurrent mis-
sense mutations tend to cluster in oncogenes and activate them. However, this is not always
true, as for example hotspot missense mutations causing disruption of gene function in the
tumour suppressor gene CDKN2A are commonly found. Moreover, mutations of the same
type, but in different positions or with different amino acid substitutions could affect the
function of the gene in different ways and to varying degrees. As the impact of each muta-
tion is difficult to predict, analyses involving driver gene discovery or mutational pattern
assessment will be noisy and difficult to interpret. Comparably, large copy number events
spanning multiple genes makes it difficult to assess the pathogenicity involving any of those
genes in isolation, which further complicates the accuracy by which key drivers behind such
events can be assigned. Additionally, there might be a dosage effect as heterozygous and
less damaging alterations might not completely abrogate the function of a gene or pathway.
In those cases, the occurrence of a mutation in a second component of the same pathway
might be favourable for the tumour. All of these factors play a role when we try to identify
the most important events driving tumourigenesis, and there is still much to learn in this
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field.
Sun exposure is an important contributor to melanoma development. Another con-
sequence of UV-driven high mutation burden in tumours, is the preference towards specific
alterations in active ETS transcription factor binding sites. I showed that with the exception
of TERT and RPS27, all other top recurrent promoter variants in melanoma, including both
known and novel positions, overlapped with this UV damage-associated pattern. This em-
phasises how we cannot assign such events as pathogenic drivers purely based on recurrence.
These findings require additional functional proof of the link between such modifications
and melanoma development.
In summary, my work has comprehensively outlined the landscape of genetic alterations
in primary melanoma. The pathways that govern primary tumours largely reflect that of
metastatic melanomas, and my analyses have validated the importance of many known and
prospective driver genes. In addition to this, I have also presented novel genetic altera-
tions and how they might play a role in disease progression. Given these results, IRF4 and
EGFR are interesting candidates to further explore in the context of personalised melanoma
therapy. The role of the PTEN paralogues TPTE and TPTE2, as well as the potentially func-
tionally equivalent genetic alterations seen in CDKN2A and PRDM2 are other compelling
findings which warrant further investigation.
6.2 Melanoma heterogeneity
Heterogeneity across melanoma has resulted in the adoption of several classifications sys-
tems, including histopathological, mutational and UV-associated categories. Several of
these existing classifications share commonalities, and it would be beneficial to stratify pa-
tients based on a combination of such features. Therefore, I have comprehensively studied
the genomic composition of different primary melanomas, highlighting both similarities and
clear differences between tumours.
The genomic landscape across melanomas originating from different body sites are dis-
tinct, where specific features can be found for each group. Patients with acral and mucosal
melanomas had both a lower frequency of mutations and a difference in driver genes, com-
pared to non-acral cutaneous melanomas. BRAF hotspot mutations were not found in a
single mucosal melanoma case; instead, these tumours seemed to be more influenced by
amplifications in chromosome 8q (MYC) and 6p. BRAF and NRAS hotspot mutations were
present in acral melanomas, but acral tumours also harboured frequent amplifications tar-
geting MYC and cell cycle regulatory genes such as CCND1 and CDK4. Several candid-
6.2 Melanoma heterogeneity 169
ate melanoma driver genes, including PTEN, RAC1, RB1, DDX3X and PPP6C were not
found mutated in any cases of acral or mucosal melanoma, in my cohort nor in the re-
cently published large cohort of melanomas [91]. Another interesting observation was that
driver genes in the rarer melanoma subtypes tended to be affected by copy number changes
rather than mutations. This feature was consistent across the whole genome, with acral and
mucosal melanomas generally presenting more frequent copy number alterations. These
distinct differences in part reflect the varying level of sun exposure commonly received at
the respective body sites, but also a fundamental difference in melanocyte biology and the
surrounding tissue where the tumour originated.
The current simplified definition of mutational subtypes in melanoma involves four
groups which are distinguished by alterations in BRAF, RAS, NF1 or the lack of mutations in
the former genes, termed triple wild-type. Although BRAF status is used for companion dia-
gnostics (BRAF inhibitors), the subtypes themselves do not provide prognostic value. These
driver genes all activate the MAPK pathway, but there are differences between patients in
respective group. Patients with NF1 mutations were generally older and had accrued the
largest number of mutational events. Conversely, patients of the BRAF subtype were typ-
ically younger, presenting a primary tumour with lower mutation load, often originating
from a body site with intermittent exposure to sun. Interestingly, patients with NRAS hot-
spot mutations were found to share similarities in their copy number profiles with the acral
and mucosal subtypes, suggesting some overlap between these categorisation systems ex-
ist. Through my Sambar pathway-mutation analysis, I showed that the mutational events in
patients can be further explained beyond the existing four mutational categories. The triple
wild-type group show their own distinct pattern of mutations, yet the other subtypes were
spread across several classes, suggesting further genetic differences exist between these
patients. Unfortunately, my extended Sambar-derived mutational classes could not better
explain the genetic variation contributing to a difference in survival probability amongst pa-
tients. However, my analysis did show that further diversity in genetic composition beyond
the existing classification exist, and therefore patients might benefit from being assessed
using a modified stratification approach.
The site of primary melanoma can be used as a guideline to evaluate the level of sun ex-
posure received. This measure is based on the assumption that different body sites normally
would have varying degrees of sun protection, with the head having the highest degree of
exposure, followed by limbs, trunk and other sites which includes acral, mucosal and genital
tumours. Several studies have proposed a biological difference between tumours occurring
on chronically sun-exposed, intermittent or completely sun-shielded locations. Of the can-
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didate melanoma driver genes identified in my study of 524 primary melanomas, 11 out
of 15 genes were associated with either increased mutation load and/or increased altera-
tion frequencies in tumours arising on sun-exposed sites compared to more sun-shielded
areas. These genes might therefore be particularly important in the disease aetiology of
sun-associated melanoma. The mechanism driving the development of sun-shielded melan-
omas is not well understood, but is evidently different. Genes such as BRAF, NRAS and
MAP2K1 did not appear to show a preference towards sun-related metrics, indicating a dif-
ference in disease aetiology and progression in these tumours. It is possible that this reflects
the origin and trajectory of melanoma development, where genes such as BRAF and NRAS
are early founding events in some tumours, whilst other driver genes linked to UV damage
might promote melanomagenesis along a divergent path. Important melanoma genes such
as PTEN and KIT show other intriguing mutation patterns. PTEN-mutant tumours presen-
ted alteration patterns distinct from UV damage, yet never targeted melanomas of the triple
wild-type, acral or mucosal category. Amplifications of KIT on the other hand, occurred
selectively in mucosal, acral or cutaneous melanomas with signs of chronic sun damage,
tumours otherwise known to be genetically distinct. Additionally, the same gene could be
targeted by different genetic events in different types of melanomas, highlighting the im-
portant role such genes play in melanomagenesis. The contribution of sun exposure to the
pathogenesis of melanoma is multifaceted, suggesting although sun exposure can in part
explain the differences between some melanomas, it cannot be used exclusively for strati-
fication. Melanoma is a highly heterogeneous cancer, where likely the combination of many
variables including UV exposure, tissue of origin, mutation composition and the biological
pathways altered are needed to comprehensively explain the underlying characteristics of
each patient.
6.3 Immune evasion
With the advent of checkpoint inhibitors, a large focus has been placed on the power of har-
nessing the immune system to battle cancer. Mutation load, neoantigen load, copy number
load and cytolytic score have all successfully been used to predict response to immunother-
apy. However, I was curious to see if these effects would manifest also in a treatment-naive
cohort. Using several stratification methods, higher mutation load or cytolytic score showed
a trend towards favourable prognosis; however, cytolytic score alone or in combination with
mutation load were the only factors mildly significant in multivariate analyses. This led me
to hypothesise that most tumours keep the immune system in check through suppressive
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mechanisms, to an extent where not even a highly antigenic environment is enough to trig-
ger a response. This would explain why a strong trend towards favourable survival could
not be seen in treatment-naive high mutation load tumours. Luckily, this suppressed state
can be reversed with immunotherapy administration, whereby high mutation load tumours
in particular become visible and targeted through an awakened host anti-tumour response.
Checkpoint inhibitors, with the PD-1/PD-L1 blocking antibodies at the forefront, have
revolutionised melanoma care. However, these therapies do come with limitations such as
severe drug-related toxicities, high cost, low bioavailability and resistance mechanisms. Tar-
geting PD-L1, which is often upregulated in tumour cells, rather than PD-1, could provide
a more focused approach, and potentially reduce adverse events. Additionally, activation of
the immune system by minimising PD-L1 expression levels can be achieved using small-
molecule inhibitors interfering with the biological pathways involved in PD-L1 regulation,
rather than relying on antibodies to block its physical interaction with PD-1. By improving
our understanding of the processes PD-L1 undergoes to be displayed on the surface of a
tumour cell, we can envision probable tumour counteractive mechanisms as well as strive
to identify new drug targets. Using the powerful CRISPR-Cas9 screening technology, I
identified several pathways encompassing the “life cycle of PD-L1”. With these new data, I
learned that TAF proteins, part of the TFIID machinery, are important for the transcription
of CD274. PD-L1 is then further processed through a range of post-translational modific-
ations, including N-linked glycosylation, which is mediated by an array of ALG proteins
and the OST complex. PD-L1 subsequently continues its journey towards the cell surface,
where its expression is controlled by equilibrium mechanisms regulating protein turnover
and recycling. Expression levels of PD-L1 on the surface of tumour cells are therefore
carefully monitored through intracellular transport processes, where defects in such mech-
anisms alters the dose of PD-L1 on the cell surface. My data demonstrates how PD-L1
is regulated by several MTCs including TRAPP, COG and HOPS complexes whilst trans-
itioning through vesicles between the ER, Golgi, endosomes, lysosomes and the plasma
membrane. Autophagosomal regulation through SPNS1 was also a major finding, provid-
ing a novel therapeutic approach by simultaneously targeting PD-L1 expression as well as
autophagic processes.
Several of the pathways I discovered to modulate PD-L1 expression, although broad and
general, could still be explored in a clinical setting. Recent studies have found that N-linked
glycosylation of PD-L1 is necessary to avoid subsequent internalisation and degradation
by the proteasomal machinery, and treatment with glycosylation-altering drugs have been
shown to diminish PD-1/PD-L1 binding, stimulate cytotoxic T cell activity and reduce tu-
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mour size in mouse models [783]. Furthermore, some genes associated with the regulation
of the above-mentioned PD-L1 controlling pathways are overexpressed in melanoma and
other tumours, and can promote tumour progression [746, 798]. Targeting these genes and
pathways could therefore in addition to controlling tumour growth, activate host anti-cancer
immunity through downregulation of PD-L1.
Melanomas typically harbour an abundance of genetic alterations, where certain on-
cogenic events can have a secondary tumourigenic effect in promoting immune evasion,
including through the regulation of PD-L1 expression. In addition, drug treatments have
also been found to alter PD-L1 expression levels and skew the immune architecture. We
should therefore remember to view the tumour and immune system as a dynamic network
which co-evolves with time, and this makes it particularly challenging to identify strong
predictive biomarkers. Nevertheless, it would be valuable to study genetic aberrations also
in the context of immune regulation, in order for us to learn more about how these events
shape the tumour microenvironment. As melanomas show different mechanisms of disease
development, drug susceptibility and immunogenicity, the ambition is to be able to predict
outcome and mechanisms of drug resistance from the genetic footprint of any individual
tumour.
6.4 Concluding remarks
It is important to emphasise that many genes do not regulate any one pathway in isola-
tion. In reality, there is an intricate network of intertwined interactions operating, and it
is likely that this interplay facilitates tumour progression rather than any one gene or path-
way alone. Oncogenic processes are often initiated through the stimulation of receptor
tyrosine kinases, which connects to several important cascades including both the MAPK
and PI3K/AKT pathways. Additionally, recognised essential melanoma driver genes such
as NRAS and CDKN2A regulate multiple pathways, and could shape the mutational compos-
ition in a different way compared to patients which have alterations in other driver genes. As
an example, the acquisition of BRAF mutations is an early event in melanoma progression;
however, this activation is not enough for melanoma development, and a second alteration
targeting e.g. PTEN could be required for oncogenesis. As activating mutations in BRAF
and NRAS normally would not be present simultaneously, the sequential mutations a tumour
would acquire could differ depending on whether a tumour first acquired a BRAF or NRAS
mutation. As an example, NRAS-mutant melanomas were more genetically similar in their
copy number profiles to rarer subtypes of melanomas, compared to other tumours of the cu-
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taneous category. Similarly, tumours with a high mutation burden show a particular driver
gene composition. The formation of sporadic tumours rather than naevi-progressed have
been reported to be more frequent on skin highly subjected to UV radiation [27, 49, 63],
adding further support to the existence of fundamentally different melanoma disease groups
which requires further investigation.
Applying the same rationale on a general level, past events would therefore shape the
final genetic heterogeneity seen in melanomas. However, it appears the simplest model
of this genetic diversity, studying the BRAF, NRAS, NF1 and WT mutational subtypes in
melanoma, does not completely stratify patients based on their mutational composition, nor
do these groups provide prognostic value. Studying mutations on a pathway-level is more
informative than looking at single genes alone; however, the cross-talk and multifaceted
role of important genes adds complexity to these types of analyses. Furthermore, on a
mutation level, not only will inevitable sporadic passenger events cause difficulty in accurate
interpretation of the data, but incomplete alterations of gene functions by some mutations
would also add to this uncertainty. It is therefore intriguing to find across many of the
main pathways altered in primary melanoma, a clear pattern where mutations in any one
component obviates the need for additional alterations to take place. Only in few cases,
which is more pronounced with higher mutational load, do the same patients show co-
mutations of key members of the same pathway. This suggests, this model of studying
mutual exclusivity to discover novel pathway components which harbour pro-tumourigenic
alterations is plausible and useful despite the aforementioned limitations.
Unfortunately, my study failed to present strong evidence of particular genetic events
associated with a favourable patient outcome. The important task of identifying genetic
contributors to patient survival in melanoma is a challenge, as not only is it a heterogenous
disease, but driver events are easily overshadowed by the vast amount of unspecific muta-
tions evident of tumours prone to have a high alteration rate. This increase in background
noise, as well as the lack in directionality (activating versus damaging) and rank (how activ-
ating or damaging) in the model, could be important factors contributing to the negligence
of anticipating patient survival.
Melanoma remains one of the most curable malignancies when diagnosed at early stages.
However, we are currently unable to identify the prognostic factors associated with relapse,
and few studies on early stage primary melanomas have been performed. With my thesis,
I have presented the most comprehensive evaluation into the somatic alteration landscape
of primary melanomas to date, bringing valuable insight into the architecture of such tu-
mours. Additionally, I introduced novel genes and key processes controlling PD-L1 gene
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transcription, processing and presentation on the cell surface. These findings expand our
understanding of cellular regulation of PD-L1 expression, potentially identifying new dir-
ections for drug development. I hope this new knowledge will further our comprehension
of melanoma progression and diversity, as well as bringing forth novel insights and possible
treatment modalities.
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1 Genes: ABL1, ACAN, ACD, ACVR1B, ACVR2A, ADAM29, ADAMTS18, 
ADAR, AFF4, AHCTF1, AHNAK, AJUBA, AKAP9, AKT1, AKT2, AKT3, 
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CAMTA1, CASP8, CBFB, CBLB, CCDC28A, CCND1, CCND2, CD1D, 
CD274, CD48, CD58, CDC27, CDH1, CDH2, CDK12, CDK4, CDK6, 
CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDX2, 
CELA3B, CEP290, CHD3, CHD6, CHD9, CHEK2, CIC, CLCC1, CNOT3, 
CNTFR, COL11A1, COL1A1, COL2A1, COL6A3, COL9A2, CREB1, 
CREB3, CREBBP, CRLF2, CRTC3, CRYM, CSF2RA, CSF3R, CSMD1, 
CTCF, CTNNB1, CUX1, CXCL10, CXCL12, CXCR4, CYLD, DAXX, DCC, 
DDR2, DDX3X, DDX58, DICER1, DLG2, DNAH17, DNAJC11, DNMT3A, 
DOCK2, EBI3, ECT2L, EEF1A1, EGFR, EHHADH, EIF2AK3, EIF4G1, 
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DTH Less than 1/3 mutant alleles were >= 25 base quality 
 
RP Coverage was less than 8 and no mutant alleles were found in the 
first 2/3 of a read (shifted 0.08 from the start and extended 0.08 
more than 2/3 of the read length) 
 
MN More than 0.03 of mutant alleles that were >= 15 base quality 
found in the matched normal 
 
PT Mutant alleles all on one direction of read (1rd allowed on opposite 
strand) and in second half of the read. Second half of read 
contains the motif GGC[AT]G in sequenced orientation and the 
mean base read contains the motif GGC[AT]G in sequenced 
orientation and the mean base quality of all bases after the motif 
was less than 20 
 
MQ Mean mapping quality of the mutant allele reads was < 21 
 
SR Position falls within a simple repeat using the supplied bed file 
 
CR Position falls within a centromeric repeat using the supplied bed 
file 
 
PH Mutant reads were on one strand (permitted proportion on other 
strand: 0.04 
 
TI More than 10 percent of reads covering this position contained an 
indel according to mapping 
 
SRP More than 80 percent of reads contain the mutant allele at the 
same read position 
 
HSD Position falls within a high sequencing depth region using the 
supplied bed file 
 
AN Position could not be annotated against a transcript using the 
supplied bed file 
 
VUM Position has >= 3 mutant allele present in at least 1 percent 
unmatched normal samples in the unmatched VCF. 
 
SE Coverage is >= 10 on each strand but mutant allele is only present 
on one strand 
 
MNP Tumour sample mutant allele proportion - normal sample mutant 
allele proportion < 0.2 
 
DTH Less than 1/3 mutant alleles were >= 25 base quality 
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RP Coverage was less than 8 and no mutant alleles were found in the 
first 2/3 of a read (shifted 0.08 from the start and extended 0.08 
more than 2/3 of the read length) 
 
MN More than 0.03 of mutant alleles that were >= 15 base quality 
found in the matched normal 
 
PT Mutant alleles all on one direction of read (1rd allowed on opposite 
strand) and in second half of the read. Second half of read 
contains the motif GGC[AT]G in sequenced orientation and the 
mean base read contains the motif GGC[AT]G in sequenced 
orientation and the mean base quality of all bases after the motif 
was less than 20 
 
MQ Mean mapping quality of the mutant allele reads was < 21 
 
SR Position falls within a simple repeat using the supplied bed file 
 
CR Position falls within a centromeric repeat using the supplied bed 
file 
 
PH Mutant reads were on one strand (permitted proportion on other 
strand: 0.04 
 
TI More than 10 percent of reads covering this position contained an 
indel according to mapping 
 
SRP More than 80 percent of reads contain the mutant allele at the 
same read position 
 
HSD Position falls within a high sequencing depth region using the 
supplied bed file 
 
AN Position could not be annotated against a transcript using the 
supplied bed file 
 
VUM Position has >= 3 mutant allele present in at least 1 percent 
unmatched normal samples in the unmatched VCF 
 
SE Coverage is >= 10 on each strand but mutant allele is only present 
on one strand 
 
MNP Tumour sample mutant allele proportion - normal sample mutant 
allele proportion < 0.2 
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A.4 Pindel filters
A.5 DISCOVER: Analysis of mutational patterns
Analysis of mutual exclusivity were done for all 524 melanoma patients, including SNPs
and indels in all genes of the panel with a minimum 5% mutation recurrence. To provide a
cleaner output, only nonsynonymous coding mutations and highly recurrent promoter
mutations were included. Furthermore, only known hotspot variants in BRAF, NRAS and
TERT were considered. A 5% FDR threshold was applied, followed by an additional filter
to address a weakness in the algorithm. The method was found to discover several
mutually exclusive gene pairs where a notable fraction of patients showed a substantial
number of co-occurring mutations in both genes. Therefore, such gene pairs were removed
by applying a filter that excluded gene pairs where either gene had  15% of all its
mutations in tumors showing co-occurring mutations with the second gene. By applying
this filter, the number of gene pairs were reduced from 78 to 8. Notably, genes with a high
alteration frequency such as BRAF had a tendency to show mutual exclusivity with an
unrealistically high number of other genes, but a large proportion of such hits were
successfully removed using the 15% overlap filter.
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A.7 Top promoter mutations across body sites
A.8 Top coding mutations across body sites 255
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A.9 Comparison of mutation load between BRAF
variants
A.10 Distribution of mutation load in Sambar subtyped
versus non-subtyped samples
Sambar subtyped = YES Sambar subtyped = NO
























n = 195 (95%) n = 131 (89%) n = 13 (41%) n = 101 (73%) n = 10 (5%) n = 17 (11%) n = 19 (59%) n = 38 (27%)
A.11 Patterns of genetic alterations in RTKs 257
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A.12 Patterns of genetic alterations in TP53−associated
pathways in primary melanoma
A.13 The effect of neoantigen load on survival and its correlation with mutation
load 259
A.13 The effect of neoantigen load on survival and its
correlation with mutation load
A.14 The effect of copy number load on survival and its
correlation with mutation load
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A.15 Comparison of key clinical variables between
datasets
A.16 The effect of genetic alterations in B2M on survival 261
































No (n = 404)
Loss of heterozygosity (n = 97)
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Missense mutation (n = 1)
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Univariate survival analysis: Alteration in B2M
A.17 The effect of genetic alterations in IFN-g pathway
genes on survival
262 Supplementary data
A.18 MOI for C092 screen replicates and controls
A.19 Titration of virus and calculations of MOIs for the
CRISPR-Cas9 screen
A.20 Distribution of gRNA counts in control samples of the CRISPR-Cas9 screen 263
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CTR sample gRNA distribution (log2 normalised)
A.21 Sort statistics for the C092 screen
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A.22 Method to compute the ROC curve and AUC
calculations
1. Perform Mageck analysis comparing plasmid counts with counts in the control
samples (Section A.1)
2. Order the data frame to list genes in ascending order based on the Mageck negative
rank (neg.rank)
3. Annotate in a new column whether each gene is part of the Bagel core reference
genes of essential or non-essential genes [714]
4. At each position in the data frame, loop through the genes in ascending order and
assign a true positive (TP), true negative (TN), false positive (FP) and false negative
(FN) value based on:
(a) TP: sum of the total number of bagel essential genes identified
(b) TN: sum of the total number of bagel non-essential genes not yet identified
(c) FP: sum of the total number of bagel non-essential genes identified
(d) FN: sum of the total number of bagel essential genes not yet identified
5. Scale the negative rank to range from 0 to 1
6. Calculate the sensitivity, specificity and false positive rate (FPR) as follows:
(a) Sensitivity = T PT P+FN
(b) Speci f icity = T NT N+FP
(c) FPR = 1 Speci f icity
7. AUC is calculated using the R package kulife using the FPR and sensitivity values
8. ROC curve is generated the R package ggplot2 using the FPR and sensitivity values
A.23 STRING analysis of PD-L1 CRISPR-Cas9 screen hits 265
A.23 STRING analysis of PD-L1 CRISPR-Cas9 screen
hits
266 Supplementary data
A.24 MOIs in the pooled validation screen
A.25 Validation screen QC
A.26 Correlation between gRNA counts in control samples in the validation screen 267
A.26 Correlation between gRNA counts in control
samples in the validation screen
268 Supplementary data
A.27 Validation pattern across cell lines (FDR <10%)
A.28 Expression of SPNS1 in normal tissues 269
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A.29 Expression of SPNS1 in cancer tissues
Appendix B
Supplementary data in electronic format
The following supplementary files are provided in electronic format as well as on a CD.
B.1 Targeted capture bait design
This file contains the genomic location of all positions aimed to be captured using my bait
design, excluding probe group 7: HLA typing panel which has been published [433].
File name: targeted_panel_covered.bed
Link to file: https://drive.google.com/open?id=1HylHmk2wZzRJH4k9ds-VFfDsTZQJKv0A
B.2 ASCAT SNP distribution
This file shows the distribution of SNPs used by ASCAT, split by chromosome, as well as
the genomic location of all genes in my targeted capture bait panel.
File name: Panel_SNPs_and_genes_across_chromosomes_detailed.pdf
Link to file: https://drive.google.com/open?id=1LhfQOrpflMrUxhesZ71Q4SAEL8rBgzeC
B.3 Survival curves IFN-g pathway
This file contains melanoma-specific survival curves, where patients were stratified by the
presence or absence of mutation in IFN-g pathways genes as well as cytolytic score.
File name: Alt_IFNg_pathway_genes_by_mutation_load_and_cyt_score_KM.pdf
Link to file: https://drive.google.com/open?id=1ysEQ-yhEDhIY5fVqXNrumGegM_2C6hGz
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B.4 Pooled validation screen library design
This file contains information about the gRNAs in the pooled validation screen.
• Total_pooled_library: This sheet provides an overview of the library design
• Master_pooled_sgRNA_sequences: This sheet contains detailed information about the
gRNA sequences
• Gene_rationale: This sheet outlines the rationale for gene selection
File name: Validation_screen_suppl_info.xlsx
Link to file: https://drive.google.com/open?id=12Cczl5cshILvuj3tx2zm3GK6wt558Gpk
B.5 MOI figures for pooled validation screen
This file contains flow cytometry scatter plots showing the MOI of each replicate and cell
line used in the pooled validation screen.
File name: Val_screen_MOIs.png
Link to file: https://drive.google.com/open?id=1VINCsWKJB6GZRHLoOH65b-TYm_o2132k
B.6 Pooled validation screen statistics
This file contains statistics of read counts and library coverage for each sample in the
pooled validation screen.
File name: Stats_combined_PDL1_validation_screen_results.txt
Link to file: https://drive.google.com/open?id=1QWJOFzIYqrkRZnHkZCyFJTh-XtB24YwI
Appendix C
Collaborators and datasets
C.1 Collaborators contributing to my thesis
Martin Del Castillo Velasco-Herrera: Dr. Del Castillo Velasco-Herrera was a PhD
student in the group of Dr. David Adams, and is currently a postdoctoral fellow in
the group of Dr. Sam Behjati. He selected gRNAs against CD274 and OR14A16
from his design published in [710]. These were used in Chapter 5 of my thesis to
generate stable knock-out cell lines as controls for my screen.
Kerstin Haase: Dr. Haase is a postdoctoral fellow in the group of Dr. Peter van Loo, at
the Francis Crick Institute. She contributed to this thesis by running the ASCAT
software to generate copy number data for the Leeds melanoma cohort (Section.
2.2.5). She provided the purity, ploidy and copy number data on a segment level,
from which I generated gene level copy number estimates and did all further
analysis. She also provided the original code and data to generate whole genome
copy number overview figures, both for the Leeds melanoma cohort and the TCGA
SKCM dataset (Section. 4.3.3).
Victoria Harle: Dr. Harle is a postdoctoral fellow in the group of Dr. David Adams. She
helped out with one of the the small-scale validation experiments in LCLC103H at
day 14 (Section 5.5). She also carried out the assembly and production of the pooled
validation gRNA library used in Section 5.6 of my thesis. Additionally, she also
performed the lentiviral production of the pooled validation gRNA library,
Cas9-transductions for SKMEL25, UKEMEL118C, 5637, 647V and UBLC1 cell
lines and antibiotic and library titrations for all cell lines used in the validation
screen. Finally, the experimental work for the pooled validation screen were done
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collaboratively with Dr. Harle.
Vivek Iyer: Dr. Iyer was a principal scientist in the group of Dr. David Adams, and is now
leading the Human Genetics Informatics team at Sanger. He selected heterozygous
SNPs against the 28 genes selected for detailed copy number estimation of probe
group 4 (Section. 2.2.2). He also interpreted and performed the ABSOLUTE power
calculation to fit my dataset (Section. 2.3.2).
Marieke Kuijjer: Dr. Kuijjer is a group leader at the Centre for Molecular Medicine
Norway, University of Oslo. She developed the tool Sambar, and ran it for my
dataset (Section. 4.2.1). I prepared the input data, including the required mutation
matrix, from which Dr. Kuijjer ran the subtyping (Appendix. A.1), and returned the
output to me for further analysis.
Rashid Mamunur: Dr. Mamunur was a senior computational biologist in the group of Dr.
David Adams, and is currently employed by Cambridge Epigenetics. Dr. Mamunur
ran the cake pipeline to generate Mutect mutation calls, used to compare my
Caveman calls to in Section. 2.3.6. Dr. Mamunur also performed the DepMap
CRISPR gene dependency analysis whereby he discovered 35 genes which were
significantly associated with lethality in skin cancer cell lines (Section. 3.3.1). I
intersected these results with my analysis and identified a melanoma-associated
genetic vulnerability mediated by the IRF4 gene.
Ultan McDermott: Dr. McDermott was a group leader at Sanger, and is currently
employed by AstraZeneca as a Chief Scientist. He designed the targeted capture
baits for probe group 3 and 6, and a solid tumour gene panel from which I selected
254 genes to include in probe group 1 (Section. 2.2.2).
Julia Newton-Bishop: Prof. Newton-Bishop is a Clinician Scientist and Professor of
Dermatology at the University of Leeds, where she is leading the Melanoma
Research Group. Prof. Newton-Bishop and her team recruited, biopsied, and
followed up all the patients in the Leeds melanoma cohort (Section C.2). Jonathan
Laye, Mark Harland, Tracey Mell and Timothy Bishop were involved in the sample
processing to DNA extraction from tumour and normal samples (Section. 2.2.3).
Measures of sun sensitivity metrics used in Chapter 4 were generated by John
Davies. Mark Iles provided me with the SNP array data, used for the genotype
concordance analysis in Section. 2.3.4.
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Annette Paschen: Prof. Paschen is a group leader at Universitätsklinikum Essen. Sonia
Leonardelli in her team obtained flow cytometry PD-L1 expression data of the
patient-derived melanoma cell line UKEMEL118C, and sent the cell line. After I
confirmed its high PD-L1 expression, I decided to include this cell line in the pooled
validation screen in Chapter 5 of my thesis.
Marco Ranzani: Dr. Ranzani provided me with RNA-sequencing data in FPKM-format
of his in-house collection of melanoma cell lines, from which C092 was selected for
the screen (Section 5.3.1).
Kosuke Yusa: Prof. Yusa was a former group leader at Sanger, and is currently a
Professor at Kyoto University. He developed and gifted the human genome-wide
gRNA library human v.1.1, used in Section 5.4 of my thesis.
Sanger core facilities: The Sanger CGP and sequencing core facilities performed the
sample processing from second round of PCR to sequencing of my CRISPR-Cas9
screen samples (Section 5.4). Additionally, they performed all steps from DNA
extraction to sequencing of the samples part of the pooled validation screen (Section
5.6). The Sanger flow cytometry core facility helped with the sorting of samples for
my CRISPR-Cas9 screen (Section 5.4), and performed all sorting steps for the
pooled validation screen samples (Section 5.6).
Sanger pipelines teams: The pipelines teams at Sanger processed all DNA from the
Leeds melanoma cohort, including targeted capture pull-down, library generation,
sequencing and alignment (Section. 2.2.3).
C.2 Datasets used in my thesis
Leeds melanoma cohort: This is the main dataset used throughout part I of my thesis. It
originally comprises 2182 patients recruited from the Northern England or Yorkshire
region [838], from which 524 primary tumours were successfully sequenced as part
of my project. Generally throughout my thesis these 524 primary tumours are
referred to as the Leeds melanoma cohort. Additionally, transcriptomes from 700
primary tumours of this cohort were sequenced as part of another study [833], and
this data was used in Chapter 5 for the SPNS1 survival analysis. 318 tumours have
been profiled to yield both mutation data and transcriptomic data, which was used in
Section 4.8 of my thesis. This cohort and corresponding clinical data were collected
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by Prof. Julia Newton-Bishop’s group at Leeds University, and the patients have
been followed up for over 15 years.
TCGA SKCM: The TCGA SKCM dataset, also known as the Skin Cutaneous Melanoma
(TCGA, PanCancer Atlas) dataset is the largest and most widely used dataset
comprising comprehensive genetic information about melanoma. It has been used
throughout Part I of my thesis, as a comparison to my analysis of the Leeds
melanoma dataset.
TCGA Pan-cancer: The TCGA Pan-cancer cohort are a collective dataset comprising 33
major tumour types. This dataset was used in Chapter 5 of my thesis to compare
variants found in the Leeds melanoma cohort with those found in other cancer types
as well as melanoma.
TCGA BLCA and NSCLC Pan-Lung: These TCGA datasets were used in Chapter 4 of
my thesis, to look at alterations in the SPNS1 gene, using the cBioPortal platform
[480, 481]. They were also used for a survival analysis using the UCSC Xena
platform [834].
Primary melanocyte expression dataset: This unpublished dataset consisting of gene
expression data from primary melanocytes extracted from human foreskin, generated
by Dr. Kevin Brown, Senior Investigator at the NIH. This dataset was used to assess
IRF4 expression in melanocytes in Section 3.3.1 of my thesis.
Broad DepMap dataset: This is an extensive CRISPR-Cas9 dropout screen dataset,
where 342 cancer cell lines of varying tissue types have been studied. The data was
downloaded and reprocessed at Sanger by Dr. Francesco Iorio, to generate lethality
scores for each condition. This data was then used in Section 3.3.1 of my thesis.
